🏷

Classifications

Harrison's Part

ISDS Skeletal Nosology

👪

Inheritance

1

Autosomal dominant inheritance HP:0000006

Autosomal dominant with near-complete penetrance and wide, including intrafamilial, variability in expression. About one in ten affected people has no affected parent. Penetrance was 96% in the Washington kindred study (one unaffected obligate heterozygote among 26) and 100% in the Wicklund natural-history series, so the value is recorded as COMPLETE with the measured percentage beside it. Older claims of reduced penetrance in females were not borne out: the male excess in affected populations reflects more severe and more frequent complications in males, not transmission.

Autosomal dominant inheritance Penetrance: COMPLETE Penetrance %: 96 Expressivity: VARIABLE De novo rate: 10

Show evidence (6 references)

PMID:20301413 SUPPORT Other

"HMO is inherited in an autosomal dominant manner."

States the mode of inheritance.

PMID:20301413 SUPPORT Other

"Approximately 90% of individuals diagnosed with HMO have an affected parent; approximately 10% of individuals have the disorder as the result of a de novo pathogenic variant."

Source of the recorded de novo rate.

PMID:8027127 SUPPORT Human Clinical

"With the use of twenty-three pedigrees that demonstrated an adequate multigenerational history for determination of penetrance of the gene, we identified one unaffected individual among twenty-six obligate heterozygotes, a rate of penetrance of 96 per cent."

The measured penetrance figure recorded in penetrance_percentage.

+ 3 more references

◆

Subtypes

2

EXT1-related hereditary multiple osteochondromas (type 1) MONDO:0007585

~65% of mutation-positive cases EXT1 hgnc:3512

The commoner and, on average, more severe type. EXT1 variants account for roughly two thirds of cases with an identified variant, and in genotype-phenotype series EXT1 carriers have shorter stature, more deformity, worse function, and more of the sarcomas.

Show evidence (3 references)

PMID:19810120 SUPPORT Human Clinical

"EXT1 mutations are detected in +/-65% of cases, versus +/-35% EXT2 mutations in MO patient cohorts."

Source of the subtype frequency.

PMID:15446535 SUPPORT Human Clinical

"The sites of mutation affected the severity of disease with patients with EXT1 mutations having a significantly worse condition than those with EXT2 mutations in three of five parameters of severity (stature, deformity and functional parameters)."

The genotype-severity difference that distinguishes the two types clinically.

PMID:22258776 SUPPORT Human Clinical

"in contrast, a severe phenotype was associated with male sex (odds ratio = 2.431; 95% confidence interval, 1.544 to 3.826), EXT1 mutations (odds ratio = 6.817; 95% confidence interval, 1.003 to 46.348), and more than twenty affected skeletal sites (odds ratio = 2.413; 95% confidence interval,..."

Independent 529-patient series associating EXT1 with the severe phenotype; note the wide confidence interval.

EXT2-related hereditary multiple osteochondromas (type 2) MONDO:0007586

~35% of mutation-positive cases EXT2 hgnc:3513

The milder type on average, accounting for about a third of mutation-positive cases; EXT2 variants were a "protective" factor for a mild phenotype in the 529-patient series.

Show evidence (2 references)

PMID:19810120 SUPPORT Human Clinical

"EXT1 mutations are detected in +/-65% of cases, versus +/-35% EXT2 mutations in MO patient cohorts."

Source of the subtype frequency.

PMID:22258776 SUPPORT Human Clinical

"In our cohort of patients, variables such as female sex (odds ratio = 1.840; 95% confidence interval, 1.223 to 2.766), fewer than five skeletal sites with exostoses (odds ratio = 7.588; 95% confidence interval, 3.479 to 16.553), EXT2 mutations (odds ratio = 2.652; 95% confidence interval, 1.665..."

EXT2 genotype associated with the mild phenotype.

?

Discussions and Knowledge Gaps

5

Does every human osteochondroma require a somatic second hit in EXT1 or EXT2, or is regional heparan sulfate dosage below a threshold sufficient, with the second hit one route among several?

KNOWLEDGE GAP OPEN hmo_second_hit_versus_dosage

Attached to

pathophysiology#Somatic Second Hit in Growth-Plate Chondrocytes pathophysiology#Systemic Heparan Sulfate Insufficiency

The mouse data point both ways. Clonal or stochastic biallelic Ext1 loss in chondrocytes reproduces the disease and single heterozygotes do not, which argues for a required second hit; but compound Ext1/Ext2 heterozygotes form stereotypic long-bone exostoses with no second hit, and the same group showed incidence is inversely and continuously related to Ext expression. In human lesions loss of heterozygosity is found in a subset, homozygous deletion is confined to the cartilage cap, and the lesion is a mixture of mutant and wild-type cells, so the fraction of caps carrying a demonstrable second hit is well below one. Whether the remainder reflect undetected second hits, epigenetic silencing, or dosage alone is not known, and the answer determines whether HMO is a tumour-suppressor disease or a dosage-threshold disease with a tumour-suppressor-like presentation.

Proposed experiments

Single-cell genotyping and heparan sulfate quantification of human cartilage caps

hmo_cap_single_cell_genotyping

Genotype the EXT locus and measure heparan sulfate per cell across the cartilage cap, perichondrium and stalk of resected human osteochondromas from germline-confirmed patients, to establish what fraction of caps contain any biallelic-null cells, how those cells are distributed, and whether caps without a detectable second hit have heparan sulfate levels below those of caps with one.

Why does the germline heterozygous mouse, which carries the exact human genotype, fail to form the long-bone osteochondromas that define the human disease?

HUMAN MODEL MISMATCH OPEN hmo_heterozygous_mouse_resistance

Attached to

pathophysiology#Germline Heterozygous Loss-of-Function Variant in EXT1 or EXT2 pathophysiology#Osteochondroma Formation by Ectopic Endochondral Ossification

Ext1+/- and Ext2+/- mice are highly resistant to osteochondroma formation, especially in long bones, and form only occasional rib outgrowths, yet in humans the same genotype is essentially fully penetrant. The mismatch is mechanistically informative rather than a nuisance: it is what forced the field to the second-hit and dosage models. Candidate explanations include a lower somatic mutation rate over the much shorter murine growth period, a different threshold of heparan sulfate below which the perichondrial border fails, and species differences in growth-plate architecture and duration. None has been tested directly, and the answer matters for any attempt to use dosage or second-hit rate as a prognostic variable in patients.

Proposed experiments

Measure spontaneous second-hit frequency in heterozygous mouse and human growth plates

hmo_heterozygote_second_hit_rate

Use lineage-traced reporter alleles at the Ext locus in Ext1+/- mice, and deep sequencing of microdissected physeal cartilage from heterozygous patients undergoing surgery, to estimate the rate of spontaneous loss of the wild-type allele per cell per unit of growth in each species, and test whether the difference in rate accounts for the difference in lesion penetrance.

What determines which cartilage cap transforms to secondary peripheral chondrosarcoma, and is the EXT1 excess of sarcomas real?

KNOWLEDGE GAP OPEN hmo_malignant_transformation_determinants

Attached to

pathophysiology#Malignant Transformation of the Cartilage Cap

Transformation is a few per cent over a lifetime, mostly low grade, mostly pelvic and mostly adult, and the risk factors are unresolved: one prospective genotype-phenotype study found seven sarcomas in EXT1 carriers against one in EXT2, while a larger 529-patient series found no association with genotype, sex, severity or lesion count. Nothing in the mouse models transforms, so there is no experimental system for the step. The molecular events downstream of the heparan-sulfate-deficient cap that convert it are curated in the Chondrosarcoma entry (Chondrosarcoma:pathophysiology#Secondary Peripheral Malignant Transformation); this discussion records the gap on the HMO side, which is the absence of any predictor better than cap thickness and post-maturity growth.

Proposed experiments

Registry-based genotype-stratified transformation risk model

hmo_registry_transformation_risk_model

Use a large longitudinal registry with confirmed genotypes to estimate transformation incidence by gene, variant class, sex, lesion count and site with adequate power, and test whether cap thickness at skeletal maturity predicts later transformation, which would turn a warning sign into a surveillance criterion.

Are PTPN11 loss-of-function variants in osteochondroma-only probands evidence of a third HMO gene, or of misclassified metachondromatosis?

OPEN QUESTION OPEN hmo_ptpn11_overlap

Attached to

genetic#

A 2024 cohort of 244 unrelated probands found PTPN11 loss-of-function variants in five probands with osteochondromas and no enchondromas, and EXT1/EXT2 variants in two with enchondromas, and proposed a phenotypic and genetic overlap between HMO and metachondromatosis. This entry does not add PTPN11 as a causal gene: enchondromas can be missed on conventional imaging, metachondromatosis lesions regress and point toward joints, and five cases do not establish a locus. The finding does mean that an EXT-negative patient should have PTPN11 sequenced, and it is recorded here so that it is not re-nominated as new.

Show evidence (2 references)

PMID:40225915 SUPPORT Human Clinical

"Specifically, we identified five cases with OCs and no ECs as well as four cases with MC carrying LoF variants in the PTPN11 gene and two additional cases with ECs harboring variants in the EXT1/2 genes."

The observation behind the open question.

PMID:40225915 SUPPORT Human Clinical

"It is essential to determine whether MO and MC represent distinct diseases or if they encompass a broader clinical spectrum."

The authors themselves leave the question open.

Why did a drug that prevents 91% of osteochondromas in Ext1-deficient mice show no efficacy signal in children, and is the question closed?

HUMAN MODEL MISMATCH OPEN hmo_palovarotene_translation

Attached to

pathophysiology#Loss of Perichondrial Border Function and Ectopic Chondrogenesis treatments#Palovarotene (investigational; MO-Ped trial terminated)

Palovarotene is the only mechanism-directed drug to reach a randomised trial in HMO, and the trial was negative on the truncated data. The mouse result is robust and mechanistically coherent, so the discrepancy is informative: possibilities include that the mouse model's stochastic Cre-driven lesions are more retinoid-sensitive than second-hit human lesions, that the human dose was limited by physeal toxicity to below the effective range, and that twelve months in 30 children is simply too little to see an effect on annualised lesion rate. The trial's own authors say interpretation was limited by reduced treatment duration and a smaller than expected cohort, so the question is not closed, but any successor must first solve the growth-plate safety problem that stopped this one.

Show evidence (2 references)

PMID:41188357 SUPPORT Human Clinical

"No significant differences in the annualized rate of new OCs, or change from baseline in volume of OCs or OC cartilage, were observed between treatment groups."

The null efficacy result.

PMID:29120519 SUPPORT Model Organism

"Four-week daily treatment with PVO starting at postnatal day (P) 14 reduced the number of osteochondromas that develop in these mice by up to 91% in a dose-dependent manner."

The preclinical result the trial failed to reproduce.

⚙

Pathophysiology

10

Germline Heterozygous Loss-of-Function Variant in EXT1 or EXT2

The initiating lesion. A heterozygous germline variant inactivates one allele of EXT1 (about 65% of mutation-positive cases) or EXT2 (about 35%). Three quarters or more are nonsense, frameshift or splice-site changes that truncate the protein; large deletions and the rarer missense variants that do abolish activity make up the rest. The mutation spectrum is the spectrum of a tumour suppressor: it was loss of function, not gain, from the first mutation reports onward, and EXT1 was cloned from the Langer-Giedion region of 8q24 by walking to the breakpoints of two patients' translocations. This node is the germline first hit; the somatic second hit is curated separately.

EXT1 hgnc:3512 EXT2 hgnc:3513

Genetic context EXT1 hgnc:3512 EXT2 hgnc:3513 variant_origin: GERMLINE allelic_hit_role: FIRST_HIT allelic_event: NONSENSE_VARIANT allelic_event: FRAMESHIFT_VARIANT allelic_event: SPLICE_SITE_VARIANT allelic_event: DELETION allelic_event: MISSENSE_VARIANT zygosity: HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Heterozygous germline inactivation of one EXT1 or EXT2 allele; mostly truncating. Some reported missense variants retain full heparan sulfate synthesis in functional assays and may be benign polymorphisms, so a missense call needs functional support before it is treated as pathogenic.

Downstream

Reduced EXT1-EXT2 Heparan Sulfate Copolymerase Activity One inactive allele halves the supply of a subunit of the EXT1-EXT2 complex, and the complex is the active enzyme.

Somatic Second Hit in Growth-Plate Chondrocytes The germline lesion is the first hit of a two-hit process; it makes a single somatic event in one chondrocyte sufficient to abolish heparan sulfate synthesis in that cell's descendants.

Show evidence (5 references)

PMID:9463333 SUPPORT Human Clinical

"Most of the mutations in EXT1 and EXT2 cause premature termination of the EXT proteins, whereas missense mutations are rare. The development is thus mainly due to loss of function of the EXT genes, consistent with the hypothesis that the EXT genes have a tumor- suppressor function."

The mutation-spectrum analysis that established loss of function as the mechanism. Quoted verbatim including the source's spacing in "tumor- suppressor".

PMID:19810120 SUPPORT Human Clinical

"Inactivating mutations (nonsense, frame shift, and splice-site mutations) represent the majority of MO causing mutations (75-80%)."

Quantifies the truncating share of the spectrum across 895 variants.

PMID:7550340 SUPPORT Human Clinical

"Furthermore, the gene harbours frameshift mutations in affected members of two EXT1 families."

The original EXT1 identification, with frameshift alleles in affected family members.

+ 2 more references

Reduced EXT1-EXT2 Heparan Sulfate Copolymerase Activity

EXT1 and EXT2 are type II transmembrane glycosyltransferases that form a hetero-oligomeric complex in the Golgi and alternately add glucuronic acid and N-acetylglucosamine to elongate heparan sulfate chains. Neither is much of an enzyme alone: the complex has substantially higher glycosyltransferase activity than either subunit, EXT2 has no significant activity without EXT1, and the complex is what accumulates in the Golgi. That is why a mutation in either gene produces the same disease, and why aetiologic missense variants that keep the protein in the endoplasmic reticulum fail to alter cell-surface heparan sulfate.

heparan sulfate GlcNAc transferase (EXT1/EXT2 copolymerase) GO:0050508 ↓ DECREASED heparan sulfate GlcA transferase (EXT1/EXT2 copolymerase) GO:0050509 ↓ DECREASED

Golgi apparatus GO:0005794

Downstream

Systemic Heparan Sulfate Insufficiency Less copolymerase means shorter and fewer heparan sulfate chains on proteoglycans throughout the body.

Show evidence (3 references)

PMID:9756849 SUPPORT In Vitro

"Thus at least two members of the EXT family of tumor suppressors encode glycosyltransferases involved in the chain elongation step of HS biosynthesis."

Identifies the enzymatic function of both genes as heparan sulfate chain elongation.

PMID:10639137 SUPPORT In Vitro

"Remarkably, the Golgi-localized EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone, which suggests that the complex represents the biologically relevant form of the enzyme(s)."

Establishes the complex, not either subunit, as the active enzyme, and its Golgi location.

PMID:9620772 SUPPORT In Vitro

"Two EXT1 variants containing aetiologic missense mutations failed to alter cell-surface glycosaminoglycans, despite retaining their ER-localization."

Disease missense variants lose the ability to generate cell-surface heparan sulfate.

Systemic Heparan Sulfate Insufficiency

Heterozygosity is enough to be measurable. The heparan sulfate to chondroitin sulfate ratio in patients' blood is about half that of controls, with the chain structure itself largely preserved: it is the amount, not the sulfation pattern, that is short. Compound Ext1/Ext2-heterozygous mice show the same thing in chondrocytes, endothelial cells and fibroblasts, which make shortened heparan sulfate chains and respond less to heparan-sulfate-dependent factors such as FGF-18. This node is the dosage arm of the mechanism: it operates in every cell, it is what the compound-heterozygous mouse shows to be sufficient for exostoses, and it sets the threshold that a somatic second hit pushes a clone over.

heparan sulfate proteoglycan biosynthesis GO:0015012 ↓ DECREASED

Animal models

Compound Ext1+/-;Ext2+/- heterozygous mouse (Zak 2011) Mouse recapitulates Shortened heparan sulfate chains and reduced growth-factor responsiveness in multiple cell types.

Downstream

Disrupted Heparan-Sulfate-Dependent Morphogen Signaling The dosage route: even without a second hit, a sufficiently reduced heparan sulfate level in the growth plate disturbs morphogen handling, which is why compound-heterozygous mice form long-bone exostoses.

Show evidence (3 references)

PMID:23514715 SUPPORT Human Clinical

"However, interestingly, although both the amounts of HS and chondroitin sulfate (CS) varied depending on the different individuals, the amounts of HS in both the plasma and cellular fractions of HME patient samples were decreased and the ratios of HS to CS (HS/CS) of HME patient samples were..."

Direct human measurement of the systemic deficiency in heterozygous patients.

PMID:23514715 SUPPORT Human Clinical

"We found that HS structures of HME patients were almost similar to those of controls in both plasma and cellular fractions."

Establishes that it is chain quantity, not structure, that is reduced.

PMID:21310272 SUPPORT Model Organism

"Ext1(+/-)Ext2(+/-) exostoses contained very low levels of immuno-detectable heparan sulfate, and Ext1(+/-)Ext2(+/-) chondrocytes, endothelial cells and fibroblasts in vitro produced shortened heparan sulfate chains compared to controls and responded less vigorously to exogenous factors such as FGF-18."

Shows the dosage-dependent shortening of chains and its functional consequence for growth-factor responsiveness.

Somatic Second Hit in Growth-Plate Chondrocytes

In a subset of growth-plate chondrocytes the remaining wild-type EXT allele is lost somatically, producing a clone with essentially no heparan sulfate. Human osteochondroma tissue shows loss of heterozygosity at the EXT locus, and in sporadic lesions homozygous EXT1 deletions are confined to the cartilage cap and absent from the perichondrium and bony stalk. The decisive experiment was the mouse: Ext1- or Ext2-heterozygous animals, which carry the human germline genotype, are nearly resistant to long-bone osteochondromas, whereas clonal or stochastic inactivation of the second allele in chondrocytes reproduces the disease. What the mouse also showed is that the resulting lesion is not a pure mutant clone: the osteochondroma is a mixture of mutant and wild-type chondrocytes, recruited by their null neighbours, and lacks most neoplastic properties. The second hit initiates the lesion; it does not build it alone.

proliferating growth-plate chondrocyte CL:1000217

Genetic context EXT1 hgnc:3512 EXT2 hgnc:3513 variant_origin: SOMATIC allelic_hit_role: SECOND_HIT allelic_event: LOSS_OF_HETEROZYGOSITY allelic_event: BIALLELIC_INACTIVATION zygosity: HOMOZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Somatic loss of the wild-type allele in a chondrocyte clone, on the germline heterozygous background; demonstrated in a subset of human lesions and sufficient in mice.

Animal models

Clonal chondrocyte Ext1 inactivation mouse (Jones 2010) Mouse recapitulates Engineered biallelic Ext1 loss in a clone of physeal chondrocytes on a wild-type-competent background.

Stochastic chondrocyte-specific Ext1 knockout mouse (Matsumoto 2010) Mouse partially recapitulates Shows that Ext1 loss in a small fraction of chondrocytes suffices, but also that the resulting lesion is a mixed mutant/wild-type mass rather than a clone, which complicates a strict two-hit tumour-suppressor reading.

Downstream

Disrupted Heparan-Sulfate-Dependent Morphogen Signaling A heparan-sulfate-null clone in the physis cannot bind or present the morphogens that pattern it; the disturbance is focal, which is why the lesions are focal.

Show evidence (4 references)

PMID:20080592 SUPPORT Model Organism

"We also confirm homozygous disruption of Ext1 in osteochondroma chondrocytes and their origin in proliferating physeal chondrocytes. These results explain prior modeling failures with the necessity for somatic LOH in a developmentally regulated cell type."

Names the cell of origin and states that somatic loss of heterozygosity is necessary, which is the whole of this node.

PMID:20534475 SUPPORT Model Organism

"Hampering elucidation of the pathogenic mechanism of MHE, both Ext1(+/-) and Ext2(+/-) heterozygous mutant mice, which mimic the genetic status of human MHE, are highly resistant to osteochondroma formation, especially in long bones."

The germline genotype alone is insufficient in the mouse, which is the argument for a second hit.

PMID:20534475 SUPPORT Model Organism

"Surprisingly, however, genotyping and fate mapping analyses reveal that chondrocytes constituting osteochondromas are mixtures of mutant and wild-type cells."

The lesion is mosaic, not clonal: null cells recruit wild-type neighbours, which is why the second hit initiates rather than composes the osteochondroma.

+ 1 more reference

Disrupted Heparan-Sulfate-Dependent Morphogen Signaling

Heparan sulfate is the matrix that governs where growth-plate morphogens act. With less of it, Indian hedgehog spreads further from the prehypertrophic chondrocytes that make it, so the range of Ihh signalling and the PTHrP feedback it drives are expanded; bone morphogenetic proteins are no longer held in the matrix and cells become more responsive to them; and fibroblast growth factors, which need heparan sulfate as a co-receptor and normally restrain chondrogenesis, signal less. The net direction is pro-chondrogenic. Note the distinction from constitutive hedgehog activation: the ligand and receptor are normal here, and what changes is the diffusion field. The Ext2-heterozygous mouse in fact showed cartilage disorganisation that was not attributable to a hedgehog defect, so the BMP and FGF arms are not secondary to the hedgehog one.

Indian hedgehog signaling range in the growth plate GO:0007224 ↑ INCREASED BMP signaling in perichondrial and growth-plate cells GO:0030509 ↑ INCREASED FGF receptor signaling in chondrocytes GO:0008543 ↓ DECREASED

epiphyseal growth plate UBERON:0002516

Downstream

Loss of Perichondrial Border Function and Ectopic Chondrogenesis Unrestrained pro-chondrogenic signalling at the physeal margin changes the fate of perichondrial progenitors and lateral chondrocytes.

Show evidence (5 references)

PMID:15177029 SUPPORT Model Organism

"In contrast, we show that reduced HS synthesis in mice carrying a hypomorphic mutation in Ext1 results in an elevated range of Indian hedgehog (Ihh) signaling during embryonic chondrocyte differentiation."

The direct demonstration that reduced heparan sulfate expands the Ihh signalling range.

PMID:15177029 SUPPORT Model Organism

"Second, HS negatively regulates the range of Hedgehog signaling in a concentration-dependent manner."

States the mechanism as a range constraint rather than a receptor-level activation.

PMID:23458899 SUPPORT In Vitro

"Interference with HS function reduced the physical association and interactions of BMP2 with HS and increased the cell responsiveness to endogenous and exogenous BMP proteins."

The BMP arm: loss of heparan sulfate frees BMP2 and increases cellular responsiveness to it.

+ 2 more references

Loss of Perichondrial Border Function and Ectopic Chondrogenesis

The perichondrium normally walls the growth plate laterally and keeps chondrogenesis inside it; the groove of Ranvier at the physeal margin is rich in progenitors. When heparan sulfate is lost in perichondrium and the lateral chondrocytes flanking the epiphysis, that border fails: ectopic cartilage forms, cells at the chondro-perichondrial boundary change phenotype, and cartilage nodules lose their peripheral definition and fuse. Chondrocytes and progenitors escape sideways from the physis and proliferate ectopically at the metaphyseal periphery. This is the node a RAR-gamma agonist acts on: palovarotene restores the chondrogenic fate decision of Ext1-deficient perichondrial progenitors in mice.

perichondrial progenitor cell CL:4033025 chondrocyte CL:0000138

ectopic chondrocyte differentiation GO:0002062 ↑ INCREASED

perichondrium UBERON:0002222

Downstream

Osteochondroma Formation by Ectopic Endochondral Ossification The escaped cartilage matures through the endochondral programme and becomes a bony outgrowth with its own cartilage cap.

Show evidence (3 references)

PMID:23458899 SUPPORT Model Organism

"Indeed, conditional Ext1 ablation in perichondrium and lateral chondrocytes flanking the epiphyseal region of mouse embryo long bone anlagen - a region encompassing the groove of Ranvier - caused ectopic cartilage formation."

The direct demonstration that Ext1 loss at the perichondrial border produces ectopic cartilage.

PMID:28445472 SUPPORT Model Organism

"Osteochondroma formation was preceded by phenotypic alteration of cells at the chondro-perichondrial boundary and was accompanied by ectopic expression of major cartilage matrix genes -collagen 2 and collagen X- within the growing ectopic masses."

Places the phenotypic change at the boundary before the lesion forms, and shows the ectopic mass is cartilage.

PMID:29120519 SUPPORT Model Organism

"We also found that PVO attenuates BMP signaling in Fsp1Cre ;Ext1flox/flox mice and that aberrant chondrogenic fate determination of Ext1-deficient perichondrial progenitor cells in these mice is restored by PVO."

Names the aberrant chondrogenic fate of perichondrial progenitors as the cellular event, by showing what reverses it.

Osteochondroma Formation by Ectopic Endochondral Ossification

The lesion. Ectopic cartilage at the metaphyseal margin ossifies by endochondral ossification, so the osteochondroma has a cortex and a marrow cavity continuous with the parent bone and a hyaline cartilage cap that acts as its own growth plate. Lesions arise wherever bone forms from cartilage, most often at the metaphyses of long bones and around the knee, with the cranial base recently shown to be affected too; membranous bones of the face are spared. They enlarge and multiply during childhood and stop when the physes close, which is why growth or new pain in an adult is a warning sign rather than the expected course.

ectopic endochondral ossification GO:0001958 ⚠ ABNORMAL

metaphysis of long bones UBERON:0001438 long bone UBERON:0002495

Animal models

Clonal chondrocyte Ext1 inactivation mouse (Jones 2010) Mouse recapitulates Multiple metaphyseal osteochondromas of the human type.

Stochastic chondrocyte-specific Ext1 knockout mouse (Matsumoto 2010) Mouse recapitulates Osteochondromas in a pattern and frequency almost identical to human disease.

Ext2 heterozygous knockout mouse (Stickens 2005) Mouse partially recapitulates Sporadic rib exostoses in about a third of animals; no stereotypic long-bone lesions.

Compound Ext1+/-;Ext2+/- heterozygous mouse (Zak 2011) Mouse partially recapitulates Stereotypic growth-plate-like long-bone exostoses from dosage reduction alone.

Downstream

Multiple osteochondromas The clinical sign is the lesion itself.

Cranial base osteochondroma-like outgrowths The same process at the synchondrosis growth plates of the skull base.

Growth-Plate Tethering and Disturbed Longitudinal Bone Growth Lesions at the physis divert and tether growth, and the underlying heparan sulfate deficit disorganises the growth plate itself.

Mechanical Impingement by Osteochondromas A bony mass next to a joint, tendon, nerve or vessel presses on it.

Malignant Transformation of the Cartilage Cap The cartilage cap is the tissue that transforms; no cap, no secondary peripheral chondrosarcoma.

Show evidence (4 references)

PMID:20080592 SUPPORT Model Organism

"We report a mouse model of multiple osteochondromas (MO), an autosomal dominant disease in humans, also known as multiple hereditary exostoses (MHE or HME) and characterized by the formation of cartilage-capped osseous growths projecting from the metaphyses of endochondral bones."

Defines the lesion as a cartilage-capped osseous growth from the metaphysis of an endochondral bone.

PMID:18271966 SUPPORT Human Clinical

"Osteochondromas develop and increase in size in the first decade of life, ceasing to grow when the growth plates close at puberty."

The growth-plate-linked timing of lesion growth.

PMID:18271966 SUPPORT Human Clinical

"The majority are asymptomatic and located in bones that develop from cartilage, especially the long bones of the extremities, predominantly around the knee. The facial bones are not affected."

The endochondral distribution of lesions, with sparing of membranous facial bone.

+ 1 more reference

Growth-Plate Tethering and Disturbed Longitudinal Bone Growth

Lesions sitting at the physis tether the bone, divert growth into the outgrowth, and shorten and angulate the segment; where two bones grow in parallel, as in the forearm and the leg, the shorter one bows the other and dislocates the joint between them. The heparan sulfate deficit also disorganises the growth plate directly, so the growth disturbance is not purely mechanical. The result is short stature, the characteristic forearm deformity, limb-length inequality and valgus at the knee and ankle, all progressive during growth and fixed after it. Deformity is a strong discriminator of severity and is worse with EXT1.

longitudinal endochondral bone growth GO:0003416 ↓ DECREASED

epiphyseal growth plate UBERON:0002516

Animal models

Ext2 heterozygous knockout mouse (Stickens 2005) Mouse partially recapitulates Growth-plate disorganisation and premature hypertrophy in every heterozygote, without the lesions.

Downstream

Short stature Reduced longitudinal growth across many physes.

Forearm deformity Ulnar shortening with radial bowing and radial head subluxation.

Limb length discrepancy Asymmetric tethering of paired lower-limb physes.

Genu valgum Angular deformity from asymmetric growth at the knee.

Ankle valgus deformity Distal fibular shortening tilting the ankle mortise.

Show evidence (3 references)

PMID:32592948 SUPPORT Human Clinical

"Throughout follow-up, 80.4% of patients developed new osteochondromas, 57.6% developed new deformities, 23.4% developed new functional limitation(s)."

Quantifies the accrual of deformity during skeletal growth in 158 children.

PMID:20534475 SUPPORT Model Organism

"We show that these mice develop multiple osteochondromas and characteristic bone deformities in a pattern and a frequency that are almost identical to those of human MHE, suggesting a role for Ext1 LOH in MHE."

The deformities travel with the lesions in the mosaic mouse, supporting the tethering mechanism.

PMID:16236767 SUPPORT Model Organism

"Significantly, all of the mice showed multiple abnormalities in cartilage differentiation, including disorganization of chondrocytes in long bones and premature hypertrophy in costochondral cartilage."

Growth-plate disorganisation from haploinsufficiency alone, which is the non-mechanical contribution to the growth disturbance.

Mechanical Impingement by Osteochondromas

A bony mass at a metaphysis presses on whatever lies beside it: tendons and bursae, joint capsules, peripheral nerves and vessels, and in spinal lesions the cord. This is the source of most symptoms in the disease and of most surgery. Pain is near-universal in adults and fatigue, which is at least as prevalent, tracks psychological factors and pain rather than lesion burden.

Downstream

Pain Pressure on soft tissue, bursitis, and impingement.

Limitation of joint mobility Juxta-articular lesions block the arc of motion.

Peripheral nerve compression Lesions adjacent to nerves, classically the peroneal nerve at the fibular neck.

Spinal cord compression Intraspinal growth of a vertebral lesion.

Premature osteoarthritis Juxta-articular lesions and malalignment accelerate joint degeneration.

Fatigue Fatigue is associated with pain and psychological factors rather than directly with the lesions; the edge is indirect by design.

Show evidence (2 references)

PMID:20301413 SUPPORT Other

"Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."

Enumerates the mechanical consequences.

PMID:9463333 SUPPORT Human Clinical

"Besides suffering complications caused by the pressure of these exostoses on the surrounding tissues, EXT patients are at an increased risk for malignant chondrosarcoma, which may develop from an exostosis."

Names pressure on surrounding tissue as the mechanism of complications.

Malignant Transformation of the Cartilage Cap

The cartilage cap of an osteochondroma can transform into a secondary peripheral chondrosarcoma, usually low grade and usually in adulthood (median 34 years in the Rizzoli series, but from age 13), most often in the pelvis and lower limb. Lifetime risk is a few per cent, ascertainment dependent, and higher in EXT1 carriers. Growth of a lesion after skeletal maturity, new pain, and a cap thicker than about 2 cm in an adult are the warning signs. This entry stops at the transformation threshold: the tumour's own biology, grading and surgical management are curated in the Chondrosarcoma entry, whose "Secondary Peripheral" subtype and "EXT1/EXT2 Heparan Sulfate Polymerization Failure" node are the continuation of this chain.

cartilage cap chondrocyte CL:0000138

Downstream

Secondary peripheral chondrosarcoma The malignant phenotype; continued in the Chondrosarcoma entry.

Show evidence (5 references)

PMID:38351015 SUPPORT Human Clinical

"The age at diagnosis of SPC ranges from 13 to 63, with median age at diagnosis of 34 years. The site most frequently affected by malignant degeneration was the pelvis (46 patients, 44%) with higher incidence in male patients (32 males vs.14 females)."

Age and site distribution of transformation in 105 cases.

PMID:38351015 SUPPORT Human Clinical

"Histological information - available for 103 patients - showed: 59 patients with grade 1; 40 patients had a grade 2 and 4 patients had a grade 3."

Most transformed lesions are low grade.

PMID:18271966 SUPPORT Human Clinical

"The most important complication is malignant transformation of osteochondroma towards secondary peripheral chondrosarcoma, which is estimated to occur in 0.5-5%."

The population-level estimate of lifetime risk.

+ 2 more references

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Head and Neck 1

Cranial base osteochondroma-like outgrowths FREQUENT Abnormal skull base morphology HP:0002693

Show evidence (1 reference)

PMID:28445472 SUPPORT Human Clinical

"Interestingly, nearly half of the patients displayed moderate defects or osteochondroma-like outgrowths in the cranial base and specifically in the clivus."

Nearly half of 50 consecutive patients, which maps to the FREQUENT band.

Limbs 2

Forearm deformity FREQUENT Abnormal forearm morphology HP:0002973

Show evidence (2 references)

PMID:8027127 SUPPORT Human Clinical

"In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity..."

39% with obvious forearm deformity, which maps to FREQUENT.

PMID:20301413 SUPPORT Other

"forearm deformity may be treated with excision of the osteochondromas, corrective osteotomies, and/or ulnar-lengthening procedures"

GeneReviews names forearm deformity as a treated manifestation, with ulnar lengthening implying the short ulna.

Genu valgum OCCASIONAL HP:0002857

Show evidence (2 references)

PMID:8027127 SUPPORT Human Clinical

"In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity..."

8% with angular deformity of the knee, which maps to OCCASIONAL.

PMID:20301413 SUPPORT Other

"angular misalignment of the lower limbs may be treated with hemiepiphysiodeses (or osteotomies) at the distal femur, proximal tibia, or distal tibia"

GeneReviews names lower-limb angular misalignment and its sites.

Musculoskeletal 4

Multiple osteochondromas OBLIGATE Multiple exostoses HP:0002762

Show evidence (4 references)

PMID:20301413 SUPPORT Other

"Hereditary multiple osteochondromas (HMO) (also known as multiple hereditary exostoses [MHE]) is characterized by growths of multiple osteochondromas, benign cartilage-capped bone tumors that grow outward from the metaphyses of long bones."

The defining feature, which is why the frequency is OBLIGATE.

PMID:20301413 SUPPORT Other

"The median age of diagnosis is three years; nearly all affected individuals are diagnosed by age 12 years."

Onset and age-related ascertainment.

PMID:18271966 SUPPORT Human Clinical

"Multiple osteochondromas (MO) is characterised by development of two or more cartilage capped bony outgrowths (osteochondromas) of the long bones."

The diagnostic threshold of two or more lesions.

+ 1 more reference

Limitation of joint mobility HP:0001376

Show evidence (2 references)

PMID:20301413 SUPPORT Other

"Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."

GeneReviews lists restricted joint motion.

PMID:32592948 SUPPORT Human Clinical

"Throughout follow-up, 80.4% of patients developed new osteochondromas, 57.6% developed new deformities, 23.4% developed new functional limitation(s)."

Incidence of new functional limitation during growth; not used as a prevalence band because it counts new events over follow-up.

Premature osteoarthritis HP:0002758

Show evidence (1 reference)

PMID:20301413 SUPPORT Other

"Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."

GeneReviews lists premature osteoarthrosis.

Secondary peripheral chondrosarcoma HP:0006765

Show evidence (4 references)

PMID:20301413 SUPPORT Other

"The risk for malignant transformation to osteochondrosarcoma increases with age, although the lifetime risk for malignant transformation is low (~2%-10%)."

GeneReviews' lifetime risk range and its age dependence.

PMID:7702095 SUPPORT Human Clinical

"Only 2.8% of the total affected population had experienced exostosis-related malignancy, an estimate which is considerably less than earlier reports would suggest."

A population-oriented estimate at the low end.

PMID:22258776 SUPPORT Human Clinical

"Malignant transformation was observed in 5% of patients, and no evidence of association between chondrosarcoma onset and EXT mutation, sex, severity of disease, or number of lesions was detected."

A referral-cohort estimate at the upper end of the range.

+ 1 more reference

Nervous System 2

Peripheral nerve compression HP:0003406

Show evidence (1 reference)

PMID:20301413 SUPPORT Other

"Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."

GeneReviews lists compression of peripheral nerves.

Spinal cord compression HP:0002176

Show evidence (1 reference)

PMID:20301413 SUPPORT Other

"Some recommend a screening spine MRI in childhood to identify spinal lesions that may cause pressure on the spinal cord and would warrant close clinical follow up with excision of lesions that cause spinal cord impingement and/or symptoms; others recommend against screening spine MRI except in..."

Establishes spinal cord impingement by spinal lesions as a recognised complication, and the unresolved screening question.

Constitutional 2

Pain VERY_FREQUENT HP:0012531

Show evidence (1 reference)

PMID:39018287 SUPPORT Human Clinical

"Pain was reported by 87.8% (NRS = 3.19±2.6) and fatigue by 90.4% (NRS = 4.1±2.6) of patients with MO."

87.8% of adults, which maps to VERY_FREQUENT.

Fatigue VERY_FREQUENT HP:0012378

Show evidence (2 references)

PMID:39018287 SUPPORT Human Clinical

"Pain was reported by 87.8% (NRS = 3.19±2.6) and fatigue by 90.4% (NRS = 4.1±2.6) of patients with MO."

90.4% of adults, which maps to VERY_FREQUENT.

PMID:39018287 SUPPORT Human Clinical

"Fatigue scores for MO (CIS = 84.1±15.3) were significantly higher (p<0.001) compared to reference scores of healthy subjects and patients with RA."

Fatigue exceeds both healthy and rheumatoid-arthritis reference values.

Growth 2

Short stature HP:0004322

Show evidence (2 references)

PMID:20301413 SUPPORT Other

"Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."

GeneReviews lists shortened stature among the associations.

PMID:15446535 SUPPORT Human Clinical

"The sites of mutation affected the severity of disease with patients with EXT1 mutations having a significantly worse condition than those with EXT2 mutations in three of five parameters of severity (stature, deformity and functional parameters)."

Stature is one of the measured severity parameters, and it is worse with EXT1.

Limb length discrepancy OCCASIONAL Lower limb asymmetry HP:0100559

Show evidence (2 references)

PMID:8027127 SUPPORT Human Clinical

"In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity..."

10% with limb-length inequality, which maps to OCCASIONAL.

PMID:20301413 SUPPORT Other

"leg length inequalities may be treated with epiphysiodesis (growth plate arrest) of the longer leg"

GeneReviews names leg-length inequality as a managed manifestation.

Other 1

Ankle valgus deformity VERY_RARE

Show evidence (2 references)

PMID:8027127 SUPPORT Human Clinical

"In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity..."

2% with ankle deformity, which maps to VERY_RARE.

PMID:20301413 SUPPORT Other

"early treatment of ankle deformity may prevent or decrease later deterioration of function"

GeneReviews names ankle deformity as a managed manifestation.

🧬

Genetic Associations

2

EXT1 (Causative)

Gene: EXT1 hgnc:3512 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (3 references)

PMID:7550340 SUPPORT Human Clinical

"In a majority of families, the genetic defect (EXT1) is linked to the Langer-Giedion syndrome chromosomal region in 8q24.1. From this region we have cloned and characterized a cDNA which spans chromosomal breakpoints previously identified in two multiple exostoses patients."

The positional cloning of EXT1 and its relation to the Langer-Giedion region.

PMID:19810120 SUPPORT Human Clinical

"EXT1 is located at 8q24.11-q24.13, and comprises 11 exons, whereas the 16 exon EXT2 is located at 11p12-p11. To date, an EXT1 or EXT2 mutation is detected in 70-95% of affected individuals."

Gene location and the combined diagnostic yield of the two genes.

PMID:18271966 SUPPORT Human Clinical

"In almost 90% of MO patients germline mutations in the tumour suppressor genes EXT1 or EXT2 are found."

Independent statement of the combined detection rate.

EXT2 (Causative)

Gene: EXT2 hgnc:3513 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (3 references)

PMID:8782816 SUPPORT Human Clinical

"Here, we report the isolation and characterization of the EXT2 gene. This gene shows striking sequence similarity to the EXT1 gene, and we have identified a four base deletion segregating with the phenotype."

The original EXT2 identification.

PMID:10639137 SUPPORT In Vitro

"Here, by testing a cell line with a specific defect in EXT1 in in vivo and in vitro assays, we show that EXT2 does not harbor significant glycosyltransferase activity in the absence of EXT1."

EXT2 acts only within the complex, explaining why its loss phenocopies EXT1 loss.

PMID:19810120 SUPPORT Human Clinical

"EXT1 mutations are detected in +/-65% of cases, versus +/-35% EXT2 mutations in MO patient cohorts."

The EXT2 share of mutation-positive cases.

💊

Medical Actions

6

Surgical Excision of Symptomatic Osteochondromas

Action: excision of osteochondroma including cartilage cap and perichondrium Ontology label: Surgical Procedure NCIT:C15329

Platform: Surgery

The mainstay. Asymptomatic lesions are observed; lesions that cause pain, impingement, restricted motion, neurovascular compromise or cosmetic concern are excised, and the excision must include the cartilage cap and overlying perichondrium, because a retained cap regrows. Removed lesions should be examined histologically for malignant change. This treats the mass effect of an existing lesion; nothing prevents new ones from forming while the physes are open.

Mechanism Target:

INHIBITS Mechanical Impingement by Osteochondromas — Removing the mass removes the pressure it exerts.

Show evidence (1 reference)

PMID:20301413 SUPPORT Other

"Painful lesions in the absence of bone deformity may be treated with surgical excision that includes the cartilage cap and overlying perichondrium to prevent recurrence"

Excision for painful lesions, with the cap-and-perichondrium requirement that prevents regrowth.

Show evidence (2 references)

PMID:20301413 SUPPORT Other

"Painful lesions in the absence of bone deformity may be treated with surgical excision that includes the cartilage cap and overlying perichondrium to prevent recurrence"

GeneReviews management guidance.

PMID:18271966 SUPPORT Other

"Management includes removal of osteochondromas when they give complaints. Removed osteochondromas should be examined for malignant transformation towards secondary peripheral chondrosarcoma."

Symptom-driven excision and histological review of the specimen.

Corrective Osteotomy, Guided Growth and Limb Lengthening

Action: corrective osteotomy, hemiepiphysiodesis and limb lengthening Ontology label: Orthopedic Surgical Procedure NCIT:C16186

Platform: Surgery

Reconstruction of growth-related deformity: excision of the culprit lesions with corrective osteotomy and ulnar lengthening for the forearm; hemiepiphysiodesis (guided growth) or osteotomy at the distal femur, proximal tibia or distal tibia for angular malalignment; epiphysiodesis of the longer leg for limb-length inequality; and early correction of ankle valgus. Evidence that forearm reconstruction improves long-term function is weak, so indications are individualised rather than radiographic.

Mechanism Target:

MODULATES Growth-Plate Tethering and Disturbed Longitudinal Bone Growth — Redirects or arrests growth at chosen physes to correct angulation and length inequality; it does not restore normal growth-plate biology.

Show evidence (1 reference)

PMID:20301413 SUPPORT Other

"angular misalignment of the lower limbs may be treated with hemiepiphysiodeses (or osteotomies) at the distal femur, proximal tibia, or distal tibia"

Guided growth and osteotomy for angular deformity.

Show evidence (2 references)

PMID:20301413 SUPPORT Other

"forearm deformity may be treated with excision of the osteochondromas, corrective osteotomies, and/or ulnar-lengthening procedures"

The forearm reconstruction options.

PMID:20301413 SUPPORT Other

"leg length inequalities may be treated with epiphysiodesis (growth plate arrest) of the longer leg"

Epiphysiodesis for length inequality.

Clinical and Imaging Surveillance for Malignant Transformation

Action: surveillance imaging for malignant transformation of osteochondromas Ontology label: Cancer Screening NCIT:C15406

Platform: Other

Monitoring lesion size in adults, with prompt MRI and sarcoma referral for growth after skeletal maturity, new pain, or a thick cartilage cap. Widely recommended but without an accepted schedule or cost-benefit evidence; the yield argument rests on the sarcoma risk being comparable to that in screened populations for other cancers. Bound to the NCIT cancer-screening action because that is what surveillance of an at-risk population for malignant transformation is.

Show evidence (3 references)

PMID:20301413 SUPPORT Other

"Monitoring of the size of osteochondromas in adults may aid in early identification of malignant transformation, but no cost-benefit analyses are available to support routine surveillance."

The recommendation and its evidence gap, stated together.

PMID:18271966 SUPPORT Other

"Patients should be well instructed and regular follow-up for early detection of malignancy seems justified."

The review's surveillance recommendation.

PMID:15446535 SUPPORT Human Clinical

"The sarcoma risk in EXT1 carriers is similar to the risk of breast cancer in an older population subjected to breast-screening, suggesting that a role for regular screening in patients with hereditary multiple exostoses is justifiable."

The risk-comparison argument for surveillance, strongest in EXT1 carriers.

En Bloc Resection of Secondary Peripheral Chondrosarcoma

Action: en bloc resection of secondary peripheral chondrosarcoma Ontology label: Surgical Procedure NCIT:C15329

Platform: Surgery

A transformed lesion is resected en bloc with its pseudocapsule and tumour-free margins, preferably in a bone tumour centre; grade 2-3 histology and partial resection predict worse disease-free survival. Recorded here only as the exit from this entry's chain; the oncological management is curated in the Chondrosarcoma entry.

Mechanism Target:

INHIBITS Malignant Transformation of the Cartilage Cap — Removes the transformed cap and its margin before local or distant spread.

Show evidence (1 reference)

PMID:38351015 SUPPORT Human Clinical

"Outcome in disease-free survival highlights that a worse course of the disease was associated with histological grade 2 or 3, and partial resection surgery."

Completeness of resection is what determines outcome.

Show evidence (2 references)

PMID:20301413 SUPPORT Other

"sarcomatous degeneration is treated by surgical resection"

GeneReviews management guidance.

PMID:18271966 SUPPORT Other

"For secondary peripheral chondrosarcoma, en-bloc resection of the lesion and its pseudocapsule with tumour-free margins, preferably in a bone tumour referral centre, should be performed."

The surgical standard for the transformed lesion.

Palovarotene (investigational; MO-Ped trial terminated)

Action: Pharmacotherapy NCIT:C15986

Agent: palovarotene CHEBI:188559

Platform: Small molecule

A selective retinoic acid receptor gamma agonist that, in Ext1-deficient mice, cut osteochondroma formation by up to 91%, attenuated BMP signalling, and restored the chondrogenic fate decision of perichondrial progenitors; a later mouse study showed it also arrests growth of pre-existing lesions via Stat3. The phase 2 MO-Ped trial (NCT03442985) randomised 193 children to placebo or two doses, was placed on partial clinical hold over concern about premature physeal closure and then terminated. In the 30 patients with 12-month imaging there was no difference in the annualised rate of new osteochondromas or in lesion volume, and the sponsor concluded the benefit-risk profile was not favourable. Recorded as an experimental treatment with a negative human result, not as a therapy; there is no approved disease-modifying drug for HMO.

Mechanism Target:

INHIBITS Loss of Perichondrial Border Function and Ectopic Chondrogenesis — RAR-gamma agonism suppresses chondrogenesis and BMP signalling in perichondrial progenitors; demonstrated in mice, not confirmed in the terminated human trial.

Show evidence (1 reference)

PMID:29120519 SUPPORT INDIRECT Model Organism

"We also found that PVO attenuates BMP signaling in Fsp1Cre ;Ext1flox/flox mice and that aberrant chondrogenic fate determination of Ext1-deficient perichondrial progenitor cells in these mice is restored by PVO."

INDIRECT because the mechanism-level effect is shown in mice only.

Show evidence (5 references)

PMID:29120519 SUPPORT INDIRECT Model Organism

"Four-week daily treatment with PVO starting at postnatal day (P) 14 reduced the number of osteochondromas that develop in these mice by up to 91% in a dose-dependent manner."

The preclinical efficacy that motivated the trial.

PMID:39062860 SUPPORT INDIRECT Model Organism

"These findings suggest that palovarotene treatment is effective against pre-existing osteochondromas and that the Stat3 pathway is involved in the antitumor actions of palovarotene."

Preclinical activity against established lesions, again mouse only.

PMID:41188357 REFUTE Human Clinical

"Overall, palovarotene showed no clear efficacy signal in MHE, resulting in a non-favorable benefit-risk profile."

The human trial result, recorded as REFUTE of efficacy.

+ 2 more references

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Platform: Other

Autosomal dominant transmission with a 50% risk to each child, near-complete penetrance, variable severity that cannot be predicted from genotype, and the possibility of prenatal or preimplantation testing once the familial variant is known.

Show evidence (1 reference)

PMID:20301413 SUPPORT Other

"Each child of an individual with HMO has a 50% chance of inheriting an HMO-causing pathogenic variant. If the HMO-causing pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible."

The counselling content.

🔬

Biochemical Markers

1

Blood heparan sulfate to chondroitin sulfate ratio (DECREASED)

Context: A research biomarker, not a clinical test. In a single prospective series the amount of heparan sulfate in both plasma and the cellular fraction of blood was reduced and the heparan sulfate to chondroitin sulfate (HS/CS) ratio was about half that of healthy controls, with heparan sulfate chain structure preserved. The authors proposed the ratio as a diagnostic biomarker; it has not been validated against molecular testing in an independent cohort and is not part of any diagnostic pathway. The ratio is a value computed over two measurements, so the bound term is the analyte that falls (heparan sulfate) and the ratio identity is carried in the name, per the design-decision entry on composite indices.

Pathograph Readouts

Readout Of Systemic Heparan Sulfate Insufficiency Negative Diagnostic

A lower blood HS/CS ratio reports a greater systemic shortfall in heparan sulfate synthesis from the heterozygous EXT1/EXT2 defect; the ratio is halved in patients, in line with a dosage effect.

Show evidence (1 reference)

PMID:23514715 SUPPORT Human Clinical

"However, interestingly, although both the amounts of HS and chondroitin sulfate (CS) varied depending on the different individuals, the amounts of HS in both the plasma and cellular fractions of HME patient samples were decreased and the ratios of HS to CS (HS/CS) of HME patient samples were..."

The measured reduction in blood heparan sulfate and in the HS/CS ratio is the readout of the systemic heparan sulfate insufficiency node.

Show evidence (2 references)

PMID:23514715 SUPPORT Human Clinical

"The results suggest that HME patients' blood exhibited reduced HS amounts and HS/CS ratios, which could be used as a diagnostic biomarker for HME."

The authors' proposal of the reduced HS/CS ratio as a diagnostic biomarker; the wording is a suggestion from one series, which is why the marker is recorded as a research candidate.

PMID:23514715 SUPPORT Human Clinical

"We found that HS structures of HME patients were almost similar to those of controls in both plasma and cellular fractions."

Chain structure is preserved, so the biomarker is a quantity, not a sulfation-pattern signature.

🔬

Diagnosis

4

Clinical and radiographic diagnosis (two or more osteochondromas)

The diagnosis is clinical and radiographic. It is established in a proband by characteristic radiographic findings of multiple osteochondromas (and/or by a heterozygous EXT1 or EXT2 pathogenic variant, below). The working criterion is two or more cartilage-capped bony outgrowths whose cortex and medulla are continuous with the parent bone, on physical examination, family history and plain radiographs; where an affected relative is already established, the diagnosis can be made clinically without molecular testing. Histology of an excised lesion supplements but is not required.

plain radiography of the skeleton with physical examination NCIT:C137876

Results: Two or more osteochondromas, pedunculated or sessile, at the metaphyses of long bones or on flat bones, with cortical and medullary continuity with the underlying bone.

Show evidence (5 references)

PMID:20301413 SUPPORT Other

"The diagnosis of HMO is established in a proband with characteristic radiographic findings of multiple osteochondromas and/or a heterozygous pathogenic variant in EXT1 or EXT2 identified on molecular genetic testing."

The GeneReviews statement of how the diagnosis is established.

PMID:18271966 SUPPORT Human Clinical

"Multiple osteochondromas (MO) is characterised by development of two or more cartilage capped bony outgrowths (osteochondromas) of the long bones."

The two-lesion criterion that the clinical diagnosis rests on.

PMID:18271966 SUPPORT Human Clinical

"The diagnosis is based on radiological and clinical documentation, supplemented with, if available, histological evaluation of osteochondromas."

Radiology and clinical documentation carry the diagnosis; histology is supplementary.

+ 2 more references

Cross-sectional imaging for complex anatomy and cartilage-cap assessment

Plain radiography is first line. CT is used for lesions in complex anatomy (pelvis, scapula, ribs, spine) where radiographs cannot define the base and extent. MRI is the modality for the hyaline cartilage cap (T2-weighted sequences), the marrow, adjacent soft tissue and neurovascular structures, and for suspected spinal or malignant complications; ultrasound can measure the cap of a superficial lesion. The imaging ladder (radiography, then CT for complex sites, MRI for the cap, ultrasound for superficial caps) follows the Falcon deep-research report's synthesis of the radiology reviews; the cited sources quote the MRI role directly. Whether children should have a screening spine MRI is unsettled.

magnetic resonance imaging of the cartilage cap (with CT and ultrasound as adjuncts) NCIT:C16809

Results: Defines lesion base and extent at complex sites (CT), and measures cartilage-cap thickness and shows marrow, soft-tissue and neurovascular relationships (MRI); a spine MRI may show asymptomatic canal lesions.

Show evidence (3 references)

PMID:18271966 SUPPORT Human Clinical

"To evaluate possible malignant transformation in case of complaints or growth of the lesion after puberty, the size of the cartilaginous cap can be well established with T2- weighted magnetic resonance (MR) imaging [64]."

MRI as the modality for cartilage-cap measurement; quoted with the source PDF's line breaks.

PMID:20301413 SUPPORT Other

"Some recommend a screening spine MRI in childhood to identify spinal lesions that may cause pressure on the spinal cord and would warrant close clinical follow up with excision of lesions that cause spinal cord impingement and/or symptoms; others recommend against screening spine MRI except in..."

The disputed role of screening spine MRI.

PMID:40225915 SUPPORT Human Clinical

"The diagnosis of MO typically involves identifying multiple benign bone tumors known as osteochondromas (OCs) through imaging studies and physical examinations."

Imaging plus physical examination as the basis of lesion identification.

Evaluation of suspected malignant transformation (cartilage-cap thickness)

The red flags for secondary peripheral chondrosarcoma are growth of a lesion after skeletal maturity, new or increasing pain in an adult, and a thick cartilage cap on MRI. Thresholds in the literature range from over 1 cm (Bovée 2008 abstract) through 1.5-2 cm to the WHO 2020 histological criterion of more than 2 cm; a cap thicker than about 2 cm in an adult is the commonly used trigger. The Falcon deep-research report gives a higher threshold of about 3 cm for children, which is not quoted from a cached source. Imaging alone may not separate an osteochondroma from a low-grade chondrosarcoma, so a suspicious lesion goes to a sarcoma team for expert radiology and pathology.

MRI measurement of cartilage-cap thickness in a growing or painful lesion NCIT:C16809

Results: Cartilage cap thicker than about 2 cm in an adult, growth after skeletal maturity, a lobulated surface, soft-tissue nodules or invasion of the stalk raise suspicion of secondary peripheral chondrosarcoma.

Show evidence (4 references)

PMID:38351015 SUPPORT Human Clinical

"An increase in size of a lesion after puberty and the presence of pain in adults are signs that raise suspicion of a Secondary Peripheral Chondrosarcoma (SPC). In addition, the most reliable feature to suspect a SPC is the cartilaginous cap thickness (exceeding 1.5–2 cm)"

The clinical red flags and the cap-thickness threshold as stated by the Rizzoli series.

PMID:38351015 SUPPORT Human Clinical

"The most important feature was the thickness of the cartilaginous cap > 2 cm; a lobular pattern with nodules in the surrounding soft tissue, separated by the mail mass, and the invasion of the stalk of the osteochondroma were also in favor of malignancy."

The 2 cm cap criterion and the ancillary features used for grade 1 peripheral chondrosarcoma under the WHO 2020 classification; quoted verbatim including the source's spelling.

PMID:38351015 SUPPORT Human Clinical

"Moreover, the imaging or the histology per se may not be distinguish an osteochondroma from low-grade peripheral chondrosarcoma because the diagnosis needs specialized bone tumor pathologists as well as a multidisciplinary approach"

Why a suspicious lesion is referred to a specialist team; quoted verbatim including the source's grammar.

+ 1 more reference

EXT1 and EXT2 sequencing followed by deletion/duplication analysis

Molecular confirmation identifies a heterozygous pathogenic variant in EXT1 or EXT2. Sequence analysis of all coding exons and flanking splice regions of both genes is performed first; if negative, exon-level deletion/duplication analysis (typically MLPA) follows, since gross deletions account for a meaningful share of pathogenic alleles. Together these find a variant in about 90% of clinically diagnosed patients. In a sequencing-negative proband, or one with enchondromas or hand and foot lesions, PTPN11 should be added, because loss-of-function PTPN11 variants (the metachondromatosis gene) were found in about 4% of a large cohort referred with a diagnosis of multiple osteochondromas. Testing of relatives, and prenatal or preimplantation testing, become possible once the familial variant is known.

EXT1 and EXT2 sequence analysis with deletion/duplication (MLPA) testing NCIT:C15709

Results: A heterozygous pathogenic or likely pathogenic EXT1 or EXT2 variant (nonsense, frameshift, splice-site, missense or exon-level deletion) confirms the diagnosis; a PTPN11 loss-of-function variant points to metachondromatosis or the overlap spectrum.

Show evidence (6 references)

PMID:20301413 SUPPORT Other

"The diagnosis of HMO is established in a proband with characteristic radiographic findings of multiple osteochondromas and/or a heterozygous pathogenic variant in EXT1 or EXT2 identified on molecular genetic testing."

Molecular genetic testing as the alternative route to an established diagnosis.

PMID:40225915 SUPPORT Human Clinical

"DNA analysis of the coding region and copy number variations (CNVs) in EXT1/2 genes is currently the gold standard for diagnosing MO"

Sequence plus copy-number analysis of both genes as the molecular standard.

PMID:38351015 SUPPORT Human Clinical

"in case of negative results, both genes were evaluated by MLPA (Multiple Ligation-dependent Probe Amplification) analysis for the presence of exon or multi-exons deletion/amplification"

The sequencing-then-MLPA order as run in the Rizzoli laboratory.

+ 3 more references

📊

Prevalence

2

State of Washington, USA (kindred database)

Point Prevalence 2.0 per 100,000 1–9 per 100,000

"The over-all prevalence was at least one in 50,000" (Schmale 1994), from 46 kindreds with 113 affected members; a minimum estimate, since mildly affected people are under-ascertained. 1 in 50,000 = 2.0 per 100,000.

Show evidence (1 reference)

PMID:8027127 SUPPORT Human Clinical

"The over-all prevalence was at least one in 50,000."

The source of the recorded rate.

General population (European and North American estimates)

Point Prevalence 2.0 per 100,000 1–9 per 100,000

"The prevalence is estimated at 1:50,000" (Bovée 2008), the figure carried through the review literature and derived from the Washington study; the apparent male excess (1.5:1) reflects ascertainment of more severe disease rather than sex-dependent transmission.

Show evidence (1 reference)

PMID:18271966 SUPPORT Human Clinical

"The prevalence is estimated at 1:50,000, and it seems to be higher in males (male-to-female ratio 1.5:1)."

The review estimate and the sex ratio it reports.

🔀

Differential Diagnoses

6

Conditions with similar clinical presentations that must be differentiated from Hereditary Multiple Osteochondromas:

Solitary osteochondroma

Overlapping Features A single osteochondroma is the common, non-hereditary lesion (about 85% of all osteochondromas); it arises from somatic biallelic EXT1 loss confined to the cartilage cap and carries no germline variant. A second lesion, a positive family history or a germline EXT1/EXT2 variant moves the diagnosis to the hereditary disorder.

Distinguishing Features

One lesion only, no family history
No germline EXT1 or EXT2 variant; somatic homozygous EXT1 deletion restricted to the cartilage cap

Show evidence (3 references)

PMID:17341731 SUPPORT Human Clinical

"However, 85% of all osteochondromas present as solitary (nonhereditary) lesions in which somatic mutations in EXT1 are extremely rare, but loss of heterozygosity and clonal rearrangement of 8q24 (the chromosomal locus of EXT1) are common."

The solitary lesion as the majority, non-hereditary form.

PMID:17341731 SUPPORT Human Clinical

"FISH analysis of the cartilage cap, perichondrium, and bony stalk showed that these homozygous EXT1 deletions were present only in the cartilage cap of osteochondroma."

Somatic, cap-restricted biallelic EXT1 loss in the sporadic lesion, as opposed to a germline variant.

PMID:40225915 SUPPORT Human Clinical

"the presence of two or more OCs is sufficient for the diagnosis of MO according to clinical criteria"

The lesion count is what separates the two.

Metachondromatosis Not Yet Curated MONDO:0007979

Overlapping Features Autosomal dominant PTPN11 loss-of-function disorder with both osteochondromas and enchondromas. Its osteochondromas favour the hands and feet, point toward the adjacent growth plate rather than away from it, do not cause the shortening and deformity seen here, and may regress spontaneously. The boundary is not sharp: PTPN11 loss-of-function variants were found in about 4% of probands referred with a diagnosis of multiple osteochondromas, several without enchondromas, so the two may form a spectrum.

Distinguishing Features

Enchondromas present; osteochondromas mainly in hands and feet, pointing toward the growth plate
Lesions do not shorten or deform bones and may regress spontaneously
PTPN11 loss-of-function variant rather than EXT1/EXT2

Show evidence (4 references)

PMID:18271966 SUPPORT Human Clinical

"point toward the adjacent growth plate, while in MO the osteochondromas are mainly located in the long or other tubular bones and point away from the epiphysis"

The radiographic orientation that separates metachondromatosis lesions from those of this disorder.

PMID:18271966 SUPPORT Human Clinical

"in patients with MC the lesions do not result in shortening or deformity of affected bones as in MO, and may spontaneously decrease in size or resolve completely, both clinically and radiologically"

The natural-history difference.

PMID:40225915 SUPPORT Human Clinical

"Metachondromatosis (OMIM#156250) (MC) is a rare genetic disease characterized by the presence of obligatory enchondromas (ECs) and nonobligatory OCs, caused by LoF variants in the PTPN11 gene"

The defining features and gene of the differential.

+ 1 more reference

Dysplasia epiphysealis hemimelica (Trevor disease) Not Yet Curated MONDO:0007489

Overlapping Features A non-hereditary developmental cartilaginous overgrowth of one or more epiphyses, usually on one side (medial more than lateral) of a single lower limb. Like osteochondromas the lesions are diagnosed in childhood and stop growing at skeletal maturity, but they are epiphyseal rather than metaphyseal, unilateral, not inherited, and malignant transformation has not been reported.

Distinguishing Features

Epiphyseal, not metaphyseal, overgrowth; hemimelic distribution in one limb
No genetic transmission; no reported malignant transformation

Show evidence (4 references)

PMID:18271966 SUPPORT Human Clinical

"MO should be distinguished from metachondromatosis, dysplasia epiphysealis hemimelica and Ollier disease."

The review names it in the differential.

PMID:18271966 SUPPORT Human Clinical

"Similar to osteochondroma, DEH is usually diagnosed prior to the age of 15 years, more often in boys than in girls, and growth of these lesions end at puberty as the growth plates close"

The shared timing that makes it a differential.

PMID:18271966 SUPPORT Human Clinical

"In contrast to MO, malignant transforma- tion has not been reported so far"

No reported malignant transformation, unlike this disorder; quoted with the source PDF's line break.

+ 1 more reference

Ollier disease Not Yet Curated MONDO:0008145

Overlapping Features Non-hereditary enchondromatosis: multiple cartilage tumours inside the medullary cavity, with a predilection for the short tubular bones of the hands and feet and a unilateral predominance, rather than surface exostoses with cortical continuity.

Distinguishing Features

Intramedullary enchondromas rather than surface osteochondromas
Short tubular bones of hands and feet; unilateral predominance; not inherited

Show evidence (1 reference)

PMID:18271966 SUPPORT Human Clinical

"(Ollier disease and Maffucci syndrome), in which multiple cartilage tumours are found in the medulla of bone, with a predilection for the short tubular bones and a unilateral predominance"

The location and distribution that separate enchondromatosis from this disorder.

Maffucci syndrome Not Yet Curated MONDO:0013808

Overlapping Features Enchondromatosis with soft-tissue haemangiomas. As for Ollier disease the cartilage tumours are intramedullary and favour the hands and feet; the vascular lesions are the added distinguishing feature.

Distinguishing Features

Intramedullary enchondromas plus soft-tissue haemangiomas
Not inherited; no EXT1/EXT2 variant

Show evidence (1 reference)

PMID:18271966 SUPPORT Human Clinical

"(Ollier disease and Maffucci syndrome), in which multiple cartilage tumours are found in the medulla of bone, with a predilection for the short tubular bones and a unilateral predominance"

The review groups it with Ollier disease as enchondromatosis to be distinguished from this disorder.

Langer-Giedion syndrome (trichorhinophalangeal syndrome type II) Not Yet Curated MONDO:0007874

Overlapping Features A contiguous 8q23-q24 deletion that removes EXT1 together with TRPS1 (and RAD21), so the multiple exostoses of this disorder occur alongside the trichorhinophalangeal features (sparse hair, bulbous nose, cone-shaped epiphyses), ectodermal anomalies and, in some, intellectual disability. A child with osteochondromas plus dysmorphic features or developmental delay should have chromosomal microarray rather than EXT1/EXT2 sequencing alone.

Distinguishing Features

Facial dysmorphism, sparse hair, cone-shaped epiphyses and possible intellectual disability in addition to exostoses
Contiguous 8q23q24 deletion including TRPS1 and EXT1 on microarray, not an intragenic EXT1/EXT2 variant

Show evidence (3 references)

PMID:35290978 SUPPORT Human Clinical

"Langer-Giedion syndrome (LGS) is caused by a contiguous deletion at 8q23q24, characterized by exostoses, facial, ectodermal, and skeletal anomalies, and, occasionally, intellectual disability."

The contiguous-deletion basis and the added features that distinguish it.

PMID:35290978 SUPPORT Human Clinical

"Our findings suggest a 3.2-Mb critical region for a typical presentation of the syndrome, emphasizing the contribution of the TRPS1, RAD21, and EXT1 genes' haploinsufficiency, and facial dysmorphisms as well as bone anomalies as the most frequent features among patients with LGS."

EXT1 haploinsufficiency within the deleted region is what produces the exostoses.

PMID:7550340 SUPPORT Human Clinical

"In a majority of families, the genetic defect (EXT1) is linked to the Langer-Giedion syndrome chromosomal region in 8q24.1."

The shared locus behind the overlap.

🔬

Clinical Trials

1

NCT03442985 PHASE_II TERMINATED

MO-Ped: a randomised, double-blind, placebo-controlled phase 2 trial of two doses of palovarotene in children with multiple osteochondromas, terminated after a partial clinical hold over premature physeal closure; no efficacy signal in the truncated dataset.

Show evidence (2 references)

clinicaltrials:NCT03442985 SUPPORT Other

"This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO)."

The registry summary of the trial design.

PMID:41188357 SUPPORT Human Clinical

"Due to concerns of premature physeal closure (PPC), a partial clinical hold was instituted, followed by trial termination."

Source of the TERMINATED status.

🐁

Animal Models

4

Clonal chondrocyte Ext1 inactivation mouse (Jones 2010)

The model that settled the second-hit question. Rather than the germline heterozygous genotype, which had failed to produce long-bone lesions, it models the chimeric tissue genotype of somatic loss of heterozygosity by inactivating both Ext1 alleles in a scattered subset of chondrocytes. The mice develop multiple metaphyseal osteochondromas, the lesion chondrocytes are Ext1-null, and they derive from proliferating physeal chondrocytes.

Species

Mouse

Genotype

Ext1 conditional (head-to-head loxP) with tamoxifen-inducible Cre in chondrocytes, producing mosaic homozygous Ext1 loss

Publication

PMID:20080592

Pathograph links

Somatic Second Hit in Growth-Plate Chondrocytes recapitulates fidelity: high observes: cellular Engineered biallelic Ext1 loss in a clone of physeal chondrocytes on a wild-type-competent background.

Limitations: The second hit is induced by Cre at a chosen time and in a chosen cell type rather than arising stochastically on a germline heterozygous background, so the model shows sufficiency of clonal loss but not the natural rate or timing of second hits in patients.

Show evidence (1 reference)

PMID:20080592 SUPPORT Model Organism

"We also confirm homozygous disruption of Ext1 in osteochondroma chondrocytes and their origin in proliferating physeal chondrocytes. These results explain prior modeling failures with the necessity for somatic LOH in a developmentally regulated cell type."

The model demonstrates the cell of origin and the necessity of somatic loss of heterozygosity.

Osteochondroma Formation by Ectopic Endochondral Ossification recapitulates fidelity: high observes: tissue Multiple metaphyseal osteochondromas of the human type.

Show evidence (1 reference)

PMID:20080592 SUPPORT Model Organism

"These mice faithfully recapitulate the human phenotype of multiple metaphyseal osteochondromas."

The authors' own statement of phenotype fidelity.

Stochastic chondrocyte-specific Ext1 knockout mouse (Matsumoto 2010)

Independent mosaic model in which Ext1 is inactivated stochastically in a small fraction of chondrocytes. It reproduces the human pattern and frequency of osteochondromas and bone deformities, and it added the finding that lesions are mixtures of mutant and wild-type cells lacking most neoplastic properties. It is the model used for the palovarotene and BMP-antagonist preclinical work.

Species

Mouse

Genotype

Fsp1-Cre; Ext1flox/flox, stochastic chondrocyte-specific Ext1 inactivation

Publication

PMID:20534475

Pathograph links

Osteochondroma Formation by Ectopic Endochondral Ossification recapitulates fidelity: high observes: tissue Osteochondromas in a pattern and frequency almost identical to human disease.

Limitations: Lesions are induced by stochastic Cre activity rather than by somatic mutation on a germline heterozygous background, and the model does not reproduce the pain, adult complications or malignant transformation of the human disease.

Show evidence (1 reference)

PMID:20534475 SUPPORT Model Organism

"We show that these mice develop multiple osteochondromas and characteristic bone deformities in a pattern and a frequency that are almost identical to those of human MHE, suggesting a role for Ext1 LOH in MHE."

Phenotype fidelity as stated by the authors.

Somatic Second Hit in Growth-Plate Chondrocytes partially recapitulates fidelity: moderate observes: cellular Shows that Ext1 loss in a small fraction of chondrocytes suffices, but also that the resulting lesion is a mixed mutant/wild-type mass rather than a clone, which complicates a strict two-hit tumour-suppressor reading.

Limitations: The lesion is not clonal and lacks neoplastic properties, so the model supports the second hit as an initiating event but argues against osteochondroma as a true clonal neoplasm; the human lesion may differ, since human caps can carry homozygous EXT1 deletion.

Show evidence (2 references)

PMID:20534475 SUPPORT Model Organism

"Together, our results suggest that inactivation of Ext1 in a small fraction of chondrocytes is sufficient for the development of osteochondromas and other skeletal defects associated with MHE."

Sufficiency of focal inactivation.

+ 1 more reference

Ext2 heterozygous knockout mouse (Stickens 2005)

The germline-genotype model. Heterozygotes carry exactly the genotype of a patient, yet only about a third form any exostosis and those are on the ribs; long bones are largely spared. All of them nonetheless show disorganised growth-plate cartilage and premature hypertrophy, which the authors could not attribute to a hedgehog defect. Homozygous loss arrests the embryo at gastrulation.

Species

Mouse

Genotype

Ext2+/- (targeted null allele); Ext2-/- is embryonic lethal at gastrulation

Publication

PMID:16236767

Pathograph links

Osteochondroma Formation by Ectopic Endochondral Ossification partially recapitulates fidelity: low observes: tissue Sporadic rib exostoses in about a third of animals; no stereotypic long-bone lesions.

Limitations: Despite carrying the human germline genotype, the heterozygote is highly resistant to the long-bone osteochondromas that define the human disease, which is the model failure that motivated the second-hit models.

Show evidence (1 reference)

PMID:16236767 SUPPORT Model Organism

"Heterozygotes had a normal lifespan and were fertile; however, analysis of their skeletons showed that about one-third of the animals formed one or more ectopic bone growths (exostoses)."

The partial, low-penetrance lesion phenotype.

Growth-Plate Tethering and Disturbed Longitudinal Bone Growth partially recapitulates fidelity: moderate observes: tissue Growth-plate disorganisation and premature hypertrophy in every heterozygote, without the lesions.

Limitations: The cartilage changes occur without osteochondromas, so the model isolates the haploinsufficiency contribution to growth-plate disturbance but cannot show the mechanical tethering component.

Show evidence (1 reference)

PMID:16236767 SUPPORT Model Organism

"Significantly, all of the mice showed multiple abnormalities in cartilage differentiation, including disorganization of chondrocytes in long bones and premature hypertrophy in costochondral cartilage."

Fully penetrant growth-plate disorganisation from haploinsufficiency.

Compound Ext1+/-;Ext2+/- heterozygous mouse (Zak 2011)

The dosage model. Halving both subunits of the copolymerase, without any second hit, roughly doubles the number of outgrowths relative to a single heterozygote and, unlike either single heterozygote, produces stereotypic growth-plate-like exostoses along the long bones. The lesions contain very little heparan sulfate and the cells make shortened chains. It shows that exostosis incidence is inversely related to Ext dosage and that complete loss is not required.

Species

Mouse

Genotype

Ext1+/-; Ext2+/- compound heterozygote

Publication

PMID:21310272

Pathograph links

Systemic Heparan Sulfate Insufficiency recapitulates fidelity: moderate observes: molecular Shortened heparan sulfate chains and reduced growth-factor responsiveness in multiple cell types.

Show evidence (1 reference)

PMID:21310272 SUPPORT Model Organism

"Ext1(+/-)Ext2(+/-) exostoses contained very low levels of immuno-detectable heparan sulfate, and Ext1(+/-)Ext2(+/-) chondrocytes, endothelial cells and fibroblasts in vitro produced shortened heparan sulfate chains compared to controls and responded less vigorously to exogenous factors such as FGF-18."

The molecular readout of dosage-dependent deficiency.

Osteochondroma Formation by Ectopic Endochondral Ossification partially recapitulates fidelity: moderate observes: tissue Stereotypic growth-plate-like long-bone exostoses from dosage reduction alone.

Limitations: Patients are heterozygous at one locus, not both, so the model achieves by compound dosage what the human disease achieves focally; it shows a sufficient condition rather than the human route.

Show evidence (1 reference)

PMID:21310272 SUPPORT Model Organism

"However, compound heterozygous mice had nearly twice as many outgrowths and, more importantly, displayed stereotypic growth plate-like exostoses along their long bones."

The dosage-driven long-bone lesion phenotype.

{ }

Source YAML

click to show

name: Hereditary Multiple Osteochondromas
creation_date: "2026-09-04T23:23:40Z"
category: Mendelian
disease_term:
  preferred_term: Hereditary Multiple Osteochondromas
  term:
    id: MONDO:0005508
    label: hereditary multiple osteochondromas
synonyms:
- HMO
- Hereditary multiple exostoses
- HME
- Multiple hereditary exostoses
- MHE
- Multiple osteochondromas
- MO
- Multiple cartilaginous exostoses
- Osteochondromatosis
- Diaphyseal aclasis
- EXT
description: >-
  Hereditary multiple osteochondromas (HMO), long known as hereditary multiple
  exostoses, is an autosomal dominant skeletal disorder in which multiple
  cartilage-capped bony outgrowths, osteochondromas, form at the metaphyses of
  the growing skeleton. A germline loss-of-function variant in EXT1 or EXT2
  halves the activity of the Golgi copolymerase that elongates heparan sulfate
  chains on proteoglycans. Heparan sulfate is what holds morphogens in place in
  the growth plate: it binds Indian hedgehog and constrains its range, it
  restrains bone morphogenetic proteins, and it presents fibroblast growth
  factors to their receptors. When it is deficient, and especially when a
  somatic second hit removes the remaining EXT allele from a clone of
  growth-plate chondrocytes, the perichondrium loses its border function,
  chondrocytes escape sideways from the physis, and the ectopic cartilage
  ossifies by the same endochondral programme as the bone it grew from,
  producing an outgrowth with cortex and marrow continuous with the parent
  bone.

  The clinical picture follows from where and when the lesions grow. They are
  rarely present at birth, appear in early childhood with a median age at
  diagnosis of three years, multiply and enlarge while the growth plates are
  open, and stop growing at skeletal maturity. Because they sit next to the
  physes, they tether and distort longitudinal growth: short stature, the
  characteristic forearm deformity with a short bowed ulna, limb-length
  inequality, and valgus at the knee and ankle. Because they are masses, they
  impinge: pain, restricted joint motion, bursitis, peripheral nerve and vessel
  compression, and, rarely, spinal cord compression. And because each carries
  a cartilage cap, a small fraction, on the order of a few per cent over a
  lifetime and higher with EXT1 than EXT2, transform to secondary peripheral
  chondrosarcoma, usually in adulthood; a cap thicker than about 2 cm in an
  adult is the warning sign.

  The entry is organised around that chain, from germline lesion through
  enzyme, heparan sulfate, second hit and morphogen gradients to the lesion and
  its three consequences: growth disturbance, mechanical impingement, and
  malignant transformation. The malignant branch is curated only to its
  threshold; the biology of the chondrosarcoma itself belongs to the
  Chondrosarcoma entry.
parents:
- Genetic Skeletal Disorders
- Hereditary Tumor Predisposition Syndromes
notes: >-
  Scope and lump/split. This entry is the disease-level concept
  MONDO:0005508 and carries the two OMIM-defined genetic types as
  `has_subtypes`: EXT1-related (MONDO:0007585, exostoses, multiple, type 1) and
  EXT2-related (MONDO:0007586, type 2). The two are curated together because the
  mechanism is identical at every node, the genes encode the two halves of one
  enzyme complex, and the phenotypes differ only in degree. The historical
  "EXT3" locus on 19p (MONDO:0010846, exostoses, multiple, type III) was mapped
  by linkage and never resolved to a gene; it is mentioned here and not entered
  as a subtype. The Langer-Giedion syndrome (trichorhinophalangeal syndrome
  type II), a contiguous-gene deletion of 8q24 removing EXT1 together with
  TRPS1, produces multiple osteochondromas as one feature of a broader syndrome
  and is a separate entry, not a subtype of this one. Metachondromatosis
  (PTPN11) is a differential diagnosis rather than a subtype; the 2024 cohort
  finding of PTPN11 loss-of-function variants in a few osteochondroma-only
  probands is recorded as an open question, not as a third causal gene.

  Module conformance deliberately not declared. The obvious candidate,
  `hedgehog_pathway_activation`, scopes itself to ligand-independent,
  constitutive SMO-GLI activation in neoplasms driven by PTCH1/PTCH2/SUFU loss
  or SMO gain, and defines the SMO-inhibitor mechanism of action. HMO is a
  different kind of hedgehog disturbance: the ligand is still Indian hedgehog,
  the receptor machinery is intact, and what changes is the diffusion range of
  the ligand because heparan sulfate no longer holds it near its source. The
  Ext2-heterozygous mouse in fact showed cartilage changes that were not
  attributable to a hedgehog defect at all, and BMP and FGF handling are
  disturbed in the same lesions. Conforming to a constitutive-SMO module would
  therefore assert a mechanism the entry does not claim and would wrongly
  suggest SMO antagonism as the drug pattern. The malignant branch is likewise
  not conformed to the Chondrosarcoma entry's nodes: that entry already
  carries an "EXT1/EXT2 Heparan Sulfate Polymerization Failure" node and a
  "Secondary Peripheral Malignant Transformation" node, so this entry stops at
  the transformation threshold and points across in prose and in a discussion
  rather than re-modelling chondrosarcoma biology.

  Evidence-source conventions. GeneReviews sentences are graded OTHER. Bovée's
  2008 Orphanet review is graded HUMAN_CLINICAL where the quoted sentence
  reports a human clinical or epidemiological fact and OTHER where it states a
  management recommendation. The Sgariglia 2013 perichondrium paper mixes
  conditional-knockout mouse work with explant and micromass culture, so its
  sentences are graded individually: the conditional-ablation and summary
  sentences MODEL_ORGANISM, the BMP2-binding sentence IN_VITRO. The Hameetman
  2007 homozygous-deletion finding concerns sporadic, nonhereditary
  osteochondromas and is cited with directness INDIRECT for the second-hit
  node. The gene-level `genetic` blocks do not repeat the inheritance object;
  the disease-level `inheritance` block is the single source for mode of
  inheritance, penetrance and de novo rate. The surveillance treatment is
  bound to NCIT Cancer Screening because the generic Surveillance, Patient
  Observation, Follow-Up and Patient Monitoring terms are not clinical
  interventions under NCIT:C25218 and fail the TreatmentActionTerm enum.

  Provenance. Built from an Edison Falcon deep-research report
  (research/Hereditary_Multiple_Osteochondromas-deep-research-falcon.md;
  reference validation 18/18 resolved, no unresolved terms, one obsolete NCIT
  term which is not used). The report cites by DOI and author-year key; every
  source used here was resolved to its PubMed record by title search and
  fetched by PMID, and all snippets are verified against the cached abstracts.
  Several of the report's suggested CURIEs were wrong on inspection and were
  not used: HP:0000934 is chondrocalcinosis, not multiple exostoses
  (HP:0002762 is); HP:0002970 is genu varum, not valgum (HP:0002857);
  CHEBI:177944 is a flavanone, not palovarotene (CHEBI:188559); and the
  proposed NCIT procedure codes named unrelated procedures. The classic
  primary papers (Ahn 1995, Stickens 1996, Wuyts 1998, McCormick 1998 and 2000,
  Lind 1998, Koziel 2004, Hameetman 2007, Jones 2010, Matsumoto 2010, Zak
  2011, Sgariglia 2013, Schmale 1994, Wicklund 1995, Porter 2004, Pedrini
  2011, Jennes 2009) were located directly on PubMed.
references:
- reference: PMID:20301413
  title: Hereditary Multiple Osteochondromas.
  tags:
  - GeneReviews
- reference: PMID:18271966
  title: Multiple osteochondromas.
- reference: PMID:19810120
  title: "Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)."
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      A Mendelian skeletal dysplasia with no inflammatory component; Harrison's
      would treat it under genetic disease rather than rheumatology.
    evidence:
    - reference: PMID:20301413
      reference_title: Hereditary Multiple Osteochondromas.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HMO is inherited in an autosomal dominant manner."
      explanation: >-
        GeneReviews frames the disorder as a Mendelian, autosomal dominant
        condition, which places it in the genetics Part.
  isds_skeletal_category:
  - classification_value: disorganized_development_of_skeletal_components
    notes: >-
      ISDS Nosology of Genetic Skeletal Disorders, 2023 revision (Unger et al.,
      PMID:36779427), group 30 "Disorganized development of skeletal
      components"; the EXT1- and EXT2-related multiple osteochondromas
      (multiple cartilaginous exostoses) entries are listed in that group.
      Assigned once, at the disease level, for both genetic types.
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: COMPLETE
  penetrance_percentage: "96"
  expressivity: VARIABLE
  de_novo_rate: "10"
  description: >-
    Autosomal dominant with near-complete penetrance and wide, including
    intrafamilial, variability in expression. About one in ten affected people
    has no affected parent. Penetrance was 96% in the Washington kindred study
    (one unaffected obligate heterozygote among 26) and 100% in the Wicklund
    natural-history series, so the value is recorded as COMPLETE with the
    measured percentage beside it. Older claims of reduced penetrance in
    females were not borne out: the male excess in affected populations
    reflects more severe and more frequent complications in males, not
    transmission.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HMO is inherited in an autosomal dominant manner."
    explanation: States the mode of inheritance.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Approximately 90% of individuals diagnosed with HMO have an affected parent; approximately 10% of individuals have the disorder as the result of a de novo pathogenic variant."
    explanation: Source of the recorded de novo rate.
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With the use of twenty-three pedigrees that demonstrated an adequate multigenerational history for determination of penetrance of the gene, we identified one unaffected individual among twenty-six obligate heterozygotes, a rate of penetrance of 96 per cent."
    explanation: The measured penetrance figure recorded in penetrance_percentage.
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was no evidence for a substantial reduction of penetrance in female subjects."
    explanation: >-
      Refutes the older suggestion of sex-dependent penetrance, which is why
      no sex qualifier is recorded.
  - reference: PMID:7702095
    reference_title: Natural history study of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The excess of males appears to be related to males having more severe and more frequent complications of EXT than having any primary genetic origin."
    explanation: >-
      Explains the male excess in ascertained series as an expressivity effect
      rather than a transmission effect.
  - reference: PMID:15446535
    reference_title: Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The severity of the disease did not differ significantly with gender and was very variable within any given family."
    explanation: Supports variable expressivity including within families.
has_subtypes:
- name: EXT1
  display_name: EXT1-related hereditary multiple osteochondromas (type 1)
  classification: molecular
  subtype_term:
    preferred_term: exostoses, multiple, type 1
    term:
      id: MONDO:0007585
      label: exostoses, multiple, type 1
  genes:
  - preferred_term: EXT1
    term:
      id: hgnc:3512
      label: EXT1
  subtype_frequency: "~65% of mutation-positive cases"
  description: >-
    The commoner and, on average, more severe type. EXT1 variants account for
    roughly two thirds of cases with an identified variant, and in
    genotype-phenotype series EXT1 carriers have shorter stature, more
    deformity, worse function, and more of the sarcomas.
  evidence:
  - reference: PMID:19810120
    reference_title: "Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EXT1 mutations are detected in +/-65% of cases, versus +/-35% EXT2 mutations in MO patient cohorts."
    explanation: Source of the subtype frequency.
  - reference: PMID:15446535
    reference_title: Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The sites of mutation affected the severity of disease with patients with EXT1 mutations having a significantly worse condition than those with EXT2 mutations in three of five parameters of severity (stature, deformity and functional parameters)."
    explanation: The genotype-severity difference that distinguishes the two types clinically.
  - reference: PMID:22258776
    reference_title: 'Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factors.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in contrast, a severe phenotype was associated with male sex (odds ratio = 2.431; 95% confidence interval, 1.544 to 3.826), EXT1 mutations (odds ratio = 6.817; 95% confidence interval, 1.003 to 46.348), and more than twenty affected skeletal sites (odds ratio = 2.413; 95% confidence interval, 1.144 to 5.091)."
    explanation: >-
      Independent 529-patient series associating EXT1 with the severe
      phenotype; note the wide confidence interval.
- name: EXT2
  display_name: EXT2-related hereditary multiple osteochondromas (type 2)
  classification: molecular
  subtype_term:
    preferred_term: exostoses, multiple, type 2
    term:
      id: MONDO:0007586
      label: exostoses, multiple, type 2
  genes:
  - preferred_term: EXT2
    term:
      id: hgnc:3513
      label: EXT2
  subtype_frequency: "~35% of mutation-positive cases"
  description: >-
    The milder type on average, accounting for about a third of
    mutation-positive cases; EXT2 variants were a "protective" factor for a
    mild phenotype in the 529-patient series.
  evidence:
  - reference: PMID:19810120
    reference_title: "Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EXT1 mutations are detected in +/-65% of cases, versus +/-35% EXT2 mutations in MO patient cohorts."
    explanation: Source of the subtype frequency.
  - reference: PMID:22258776
    reference_title: 'Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factors.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In our cohort of patients, variables such as female sex (odds ratio = 1.840; 95% confidence interval, 1.223 to 2.766), fewer than five skeletal sites with exostoses (odds ratio = 7.588; 95% confidence interval, 3.479 to 16.553), EXT2 mutations (odds ratio = 2.652; 95% confidence interval, 1.665 to 4.223), and absence of EXT1/2 mutations (odds ratio = 1.975; 95% confidence interval, 1.051 to 3.713) described patients with a mild phenotype"
    explanation: EXT2 genotype associated with the mild phenotype.
pathophysiology:
- name: Germline Heterozygous Loss-of-Function Variant in EXT1 or EXT2
  biological_scale: MOLECULAR
  description: >-
    The initiating lesion. A heterozygous germline variant inactivates one
    allele of EXT1 (about 65% of mutation-positive cases) or EXT2 (about 35%).
    Three quarters or more are nonsense, frameshift or splice-site changes that
    truncate the protein; large deletions and the rarer missense variants that
    do abolish activity make up the rest. The mutation spectrum is the
    spectrum of a tumour suppressor: it was loss of function, not gain, from
    the first mutation reports onward, and EXT1 was cloned from the
    Langer-Giedion region of 8q24 by walking to the breakpoints of two
    patients' translocations. This node is the germline first hit; the somatic
    second hit is curated separately.
  genes:
  - preferred_term: EXT1
    term:
      id: hgnc:3512
      label: EXT1
  - preferred_term: EXT2
    term:
      id: hgnc:3513
      label: EXT2
  genetic_context:
    genes:
    - preferred_term: EXT1
      term:
        id: hgnc:3512
        label: EXT1
    - preferred_term: EXT2
      term:
        id: hgnc:3513
        label: EXT2
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    allelic_hit_role: FIRST_HIT
    allelic_events:
    - NONSENSE_VARIANT
    - FRAMESHIFT_VARIANT
    - SPLICE_SITE_VARIANT
    - DELETION
    - MISSENSE_VARIANT
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Heterozygous germline inactivation of one EXT1 or EXT2 allele; mostly
      truncating. Some reported missense variants retain full heparan sulfate
      synthesis in functional assays and may be benign polymorphisms, so a
      missense call needs functional support before it is treated as
      pathogenic.
  evidence:
  - reference: PMID:9463333
    reference_title: Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most of the mutations in EXT1 and EXT2 cause premature termination of the EXT proteins, whereas missense mutations are rare. The development is thus mainly due to loss of function of the EXT genes, consistent with the hypothesis that the EXT genes have a tumor- suppressor function."
    explanation: >-
      The mutation-spectrum analysis that established loss of function as the
      mechanism. Quoted verbatim including the source's spacing in
      "tumor- suppressor".
  - reference: PMID:19810120
    reference_title: "Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Inactivating mutations (nonsense, frame shift, and splice-site mutations) represent the majority of MO causing mutations (75-80%)."
    explanation: Quantifies the truncating share of the spectrum across 895 variants.
  - reference: PMID:7550340
    reference_title: Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, the gene harbours frameshift mutations in affected members of two EXT1 families."
    explanation: The original EXT1 identification, with frameshift alleles in affected family members.
  - reference: PMID:8782816
    reference_title: The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report the isolation and characterization of the EXT2 gene. This gene shows striking sequence similarity to the EXT1 gene, and we have identified a four base deletion segregating with the phenotype."
    explanation: The original EXT2 identification, with a segregating frameshift deletion.
  - reference: PMID:11391482
    reference_title: "Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our results show that EXT1 mutants bearing six of these missense mutations (D164H, R280G/S, and R340S/H/L) are also defective in HS expression, but surprisingly, four (Q27K, N316S, A486V, and P496L) are phenotypically indistinguishable from wild-type EXT1."
    explanation: >-
      Functional assay showing that only some reported missense variants
      abolish heparan sulfate synthesis, which is the caution recorded in
      genetic_context.
  downstream:
  - target: Reduced EXT1-EXT2 Heparan Sulfate Copolymerase Activity
    causal_link_type: DIRECT
    description: >-
      One inactive allele halves the supply of a subunit of the EXT1-EXT2
      complex, and the complex is the active enzyme.
    evidence:
    - reference: PMID:10639137
      reference_title: The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "These findings provide a rationale to explain how inherited mutations in either of the two EXT genes can cause loss of activity, resulting in hereditary multiple exostoses."
      explanation: >-
        States the causal step explicitly: a mutation in either gene reduces
        the activity of the shared complex.
  - target: Somatic Second Hit in Growth-Plate Chondrocytes
    causal_link_type: DIRECT
    description: >-
      The germline lesion is the first hit of a two-hit process; it makes a
      single somatic event in one chondrocyte sufficient to abolish heparan
      sulfate synthesis in that cell's descendants.
    evidence:
    - reference: PMID:20080592
      reference_title: A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Rather than model the germ-line genotype, we modeled the chimeric tissue genotype of somatic loss of heterozygosity (LOH), by conditionally inactivating Ext1 via head-to-head loxP sites and temporally controlled Cre-recombinase in chondrocytes."
      explanation: >-
        The experimental design that treats the germline genotype as the
        background on which somatic loss of heterozygosity acts.
- name: Reduced EXT1-EXT2 Heparan Sulfate Copolymerase Activity
  biological_scale: MOLECULAR
  description: >-
    EXT1 and EXT2 are type II transmembrane glycosyltransferases that form a
    hetero-oligomeric complex in the Golgi and alternately add glucuronic acid
    and N-acetylglucosamine to elongate heparan sulfate chains. Neither is
    much of an enzyme alone: the complex has substantially higher
    glycosyltransferase activity than either subunit, EXT2 has no significant
    activity without EXT1, and the complex is what accumulates in the Golgi.
    That is why a mutation in either gene produces the same disease, and why
    aetiologic missense variants that keep the protein in the endoplasmic
    reticulum fail to alter cell-surface heparan sulfate.
  molecular_functions:
  - preferred_term: heparan sulfate GlcNAc transferase (EXT1/EXT2 copolymerase)
    modifier: DECREASED
    term:
      id: GO:0050508
      label: glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity
  - preferred_term: heparan sulfate GlcA transferase (EXT1/EXT2 copolymerase)
    modifier: DECREASED
    term:
      id: GO:0050509
      label: N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity
  cellular_components:
  - preferred_term: Golgi apparatus
    term:
      id: GO:0005794
      label: Golgi apparatus
  evidence:
  - reference: PMID:9756849
    reference_title: The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Thus at least two members of the EXT family of tumor suppressors encode glycosyltransferases involved in the chain elongation step of HS biosynthesis."
    explanation: Identifies the enzymatic function of both genes as heparan sulfate chain elongation.
  - reference: PMID:10639137
    reference_title: The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Remarkably, the Golgi-localized EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone, which suggests that the complex represents the biologically relevant form of the enzyme(s)."
    explanation: Establishes the complex, not either subunit, as the active enzyme, and its Golgi location.
  - reference: PMID:9620772
    reference_title: The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Two EXT1 variants containing aetiologic missense mutations failed to alter cell-surface glycosaminoglycans, despite retaining their ER-localization."
    explanation: Disease missense variants lose the ability to generate cell-surface heparan sulfate.
  downstream:
  - target: Systemic Heparan Sulfate Insufficiency
    causal_link_type: DIRECT
    description: >-
      Less copolymerase means shorter and fewer heparan sulfate chains on
      proteoglycans throughout the body.
    evidence:
    - reference: PMID:23514715
      reference_title: "Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The results suggest that HME patients' blood exhibited reduced HS amounts and HS/CS ratios, which could be used as a diagnostic biomarker for HME."
      explanation: The halved ratio in heterozygous patients is the systemic readout of reduced enzyme activity.
- name: Systemic Heparan Sulfate Insufficiency
  biological_scale: MOLECULAR
  description: >-
    Heterozygosity is enough to be measurable. The heparan sulfate to
    chondroitin sulfate ratio in patients' blood is about half that of
    controls, with the chain structure itself largely preserved: it is the
    amount, not the sulfation pattern, that is short. Compound
    Ext1/Ext2-heterozygous mice show the same thing in chondrocytes,
    endothelial cells and fibroblasts, which make shortened heparan sulfate
    chains and respond less to heparan-sulfate-dependent factors such as
    FGF-18. This node is the dosage arm of the mechanism: it operates in every
    cell, it is what the compound-heterozygous mouse shows to be sufficient
    for exostoses, and it sets the threshold that a somatic second hit pushes
    a clone over.
  biological_processes:
  - preferred_term: heparan sulfate proteoglycan biosynthesis
    modifier: DECREASED
    term:
      id: GO:0015012
      label: heparan sulfate proteoglycan biosynthetic process
  evidence:
  - reference: PMID:23514715
    reference_title: "Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, interestingly, although both the amounts of HS and chondroitin sulfate (CS) varied depending on the different individuals, the amounts of HS in both the plasma and cellular fractions of HME patient samples were decreased and the ratios of HS to CS (HS/CS) of HME patient samples were almost half those of healthy individuals."
    explanation: Direct human measurement of the systemic deficiency in heterozygous patients.
  - reference: PMID:23514715
    reference_title: "Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that HS structures of HME patients were almost similar to those of controls in both plasma and cellular fractions."
    explanation: Establishes that it is chain quantity, not structure, that is reduced.
  - reference: PMID:21310272
    reference_title: Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Ext1(+/-)Ext2(+/-) exostoses contained very low levels of immuno-detectable heparan sulfate, and Ext1(+/-)Ext2(+/-) chondrocytes, endothelial cells and fibroblasts in vitro produced shortened heparan sulfate chains compared to controls and responded less vigorously to exogenous factors such as FGF-18."
    explanation: Shows the dosage-dependent shortening of chains and its functional consequence for growth-factor responsiveness.
  downstream:
  - target: Disrupted Heparan-Sulfate-Dependent Morphogen Signaling
    causal_link_type: DIRECT
    description: >-
      The dosage route: even without a second hit, a sufficiently reduced
      heparan sulfate level in the growth plate disturbs morphogen handling,
      which is why compound-heterozygous mice form long-bone exostoses.
    evidence:
    - reference: PMID:21310272
      reference_title: Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The study indicates that formation of stereotypic exostoses requires a significant, but not complete, loss of Ext expression and that exostosis incidence and phenotype are intimately sensitive to, and inversely related to, Ext expression."
      explanation: Establishes the inverse dose-response between Ext expression and exostosis formation without requiring complete loss.
- name: Somatic Second Hit in Growth-Plate Chondrocytes
  biological_scale: CELLULAR
  description: >-
    In a subset of growth-plate chondrocytes the remaining wild-type EXT
    allele is lost somatically, producing a clone with essentially no heparan
    sulfate. Human osteochondroma tissue shows loss of heterozygosity at the
    EXT locus, and in sporadic lesions homozygous EXT1 deletions are confined
    to the cartilage cap and absent from the perichondrium and bony stalk. The
    decisive experiment was the mouse: Ext1- or Ext2-heterozygous animals,
    which carry the human germline genotype, are nearly resistant to
    long-bone osteochondromas, whereas clonal or stochastic inactivation of
    the second allele in chondrocytes reproduces the disease. What the mouse
    also showed is that the resulting lesion is not a pure mutant clone: the
    osteochondroma is a mixture of mutant and wild-type chondrocytes,
    recruited by their null neighbours, and lacks most neoplastic properties.
    The second hit initiates the lesion; it does not build it alone.
  cell_types:
  - preferred_term: proliferating growth-plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  genetic_context:
    genes:
    - preferred_term: EXT1
      term:
        id: hgnc:3512
        label: EXT1
    - preferred_term: EXT2
      term:
        id: hgnc:3513
        label: EXT2
    variant_origin: SOMATIC
    zygosity: HOMOZYGOUS
    allelic_hit_role: SECOND_HIT
    allelic_events:
    - LOSS_OF_HETEROZYGOSITY
    - BIALLELIC_INACTIVATION
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Somatic loss of the wild-type allele in a chondrocyte clone, on the
      germline heterozygous background; demonstrated in a subset of human
      lesions and sufficient in mice.
  evidence:
  - reference: PMID:20080592
    reference_title: A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We also confirm homozygous disruption of Ext1 in osteochondroma chondrocytes and their origin in proliferating physeal chondrocytes. These results explain prior modeling failures with the necessity for somatic LOH in a developmentally regulated cell type."
    explanation: >-
      Names the cell of origin and states that somatic loss of heterozygosity
      is necessary, which is the whole of this node.
  - reference: PMID:20534475
    reference_title: A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Hampering elucidation of the pathogenic mechanism of MHE, both Ext1(+/-) and Ext2(+/-) heterozygous mutant mice, which mimic the genetic status of human MHE, are highly resistant to osteochondroma formation, especially in long bones."
    explanation: The germline genotype alone is insufficient in the mouse, which is the argument for a second hit.
  - reference: PMID:20534475
    reference_title: A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Surprisingly, however, genotyping and fate mapping analyses reveal that chondrocytes constituting osteochondromas are mixtures of mutant and wild-type cells."
    explanation: >-
      The lesion is mosaic, not clonal: null cells recruit wild-type
      neighbours, which is why the second hit initiates rather than composes
      the osteochondroma.
  - reference: PMID:17341731
    reference_title: "The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "FISH analysis of the cartilage cap, perichondrium, and bony stalk showed that these homozygous EXT1 deletions were present only in the cartilage cap of osteochondroma."
    explanation: >-
      INDIRECT because the lesions are sporadic, nonhereditary
      osteochondromas; it nonetheless shows in human tissue that biallelic EXT1
      loss is confined to the cartilage cap, the compartment this node places
      the second hit in.
  downstream:
  - target: Disrupted Heparan-Sulfate-Dependent Morphogen Signaling
    causal_link_type: DIRECT
    description: >-
      A heparan-sulfate-null clone in the physis cannot bind or present the
      morphogens that pattern it; the disturbance is focal, which is why the
      lesions are focal.
- name: Disrupted Heparan-Sulfate-Dependent Morphogen Signaling
  biological_scale: CELLULAR
  description: >-
    Heparan sulfate is the matrix that governs where growth-plate morphogens
    act. With less of it, Indian hedgehog spreads further from the
    prehypertrophic chondrocytes that make it, so the range of Ihh signalling
    and the PTHrP feedback it drives are expanded; bone morphogenetic proteins
    are no longer held in the matrix and cells become more responsive to
    them; and fibroblast growth factors, which need heparan sulfate as a
    co-receptor and normally restrain chondrogenesis, signal less. The net
    direction is pro-chondrogenic. Note the distinction from constitutive
    hedgehog activation: the ligand and receptor are normal here, and what
    changes is the diffusion field. The Ext2-heterozygous mouse in fact showed
    cartilage disorganisation that was not attributable to a hedgehog defect,
    so the BMP and FGF arms are not secondary to the hedgehog one.
  biological_processes:
  - preferred_term: Indian hedgehog signaling range in the growth plate
    modifier: INCREASED
    term:
      id: GO:0007224
      label: smoothened signaling pathway
  - preferred_term: BMP signaling in perichondrial and growth-plate cells
    modifier: INCREASED
    term:
      id: GO:0030509
      label: BMP signaling pathway
  - preferred_term: FGF receptor signaling in chondrocytes
    modifier: DECREASED
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
  locations:
  - preferred_term: epiphyseal growth plate
    term:
      id: UBERON:0002516
      label: epiphyseal plate
  evidence:
  - reference: PMID:15177029
    reference_title: Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In contrast, we show that reduced HS synthesis in mice carrying a hypomorphic mutation in Ext1 results in an elevated range of Indian hedgehog (Ihh) signaling during embryonic chondrocyte differentiation."
    explanation: The direct demonstration that reduced heparan sulfate expands the Ihh signalling range.
  - reference: PMID:15177029
    reference_title: Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Second, HS negatively regulates the range of Hedgehog signaling in a concentration-dependent manner."
    explanation: States the mechanism as a range constraint rather than a receptor-level activation.
  - reference: PMID:23458899
    reference_title: "Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple Exostoses."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Interference with HS function reduced the physical association and interactions of BMP2 with HS and increased the cell responsiveness to endogenous and exogenous BMP proteins."
    explanation: >-
      The BMP arm: loss of heparan sulfate frees BMP2 and increases cellular
      responsiveness to it.
  - reference: PMID:21310272
    reference_title: Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Ext1(+/-)Ext2(+/-) exostoses contained very low levels of immuno-detectable heparan sulfate, and Ext1(+/-)Ext2(+/-) chondrocytes, endothelial cells and fibroblasts in vitro produced shortened heparan sulfate chains compared to controls and responded less vigorously to exogenous factors such as FGF-18."
    explanation: >-
      The FGF arm: heparan-sulfate-deficient chondrocytes respond less to
      FGF-18.
  - reference: PMID:16236767
    reference_title: Mice deficient in Ext2 lack heparan sulfate and develop exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These changes were not attributable to a defect in hedgehog signaling, suggesting that they arise from deficiencies in other heparan sulfate-dependent pathways."
    explanation: >-
      The reason the node is written as multi-pathway morphogen disruption
      rather than a hedgehog module: in the heterozygous mouse the cartilage
      abnormalities were independent of hedgehog signalling.
  downstream:
  - target: Loss of Perichondrial Border Function and Ectopic Chondrogenesis
    causal_link_type: DIRECT
    description: >-
      Unrestrained pro-chondrogenic signalling at the physeal margin changes
      the fate of perichondrial progenitors and lateral chondrocytes.
    evidence:
    - reference: PMID:23458899
      reference_title: "Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple Exostoses."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In sum, Ext genes and HS are needed to establish and maintain perichondrium's phenotype and border function, restrain pro-chondrogenic signaling proteins including BMPs, and restrict chondrogenesis."
      explanation: Ties the signalling disturbance to the loss of border function and the excess chondrogenesis of the next node.
- name: Loss of Perichondrial Border Function and Ectopic Chondrogenesis
  biological_scale: TISSUE
  description: >-
    The perichondrium normally walls the growth plate laterally and keeps
    chondrogenesis inside it; the groove of Ranvier at the physeal margin is
    rich in progenitors. When heparan sulfate is lost in perichondrium and the
    lateral chondrocytes flanking the epiphysis, that border fails: ectopic
    cartilage forms, cells at the chondro-perichondrial boundary change
    phenotype, and cartilage nodules lose their peripheral definition and
    fuse. Chondrocytes and progenitors escape sideways from the physis and
    proliferate ectopically at the metaphyseal periphery. This is the node a
    RAR-gamma agonist acts on: palovarotene restores the chondrogenic fate
    decision of Ext1-deficient perichondrial progenitors in mice.
  cell_types:
  - preferred_term: perichondrial progenitor cell
    term:
      id: CL:4033025
      label: perichondrial fibroblast
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: ectopic chondrocyte differentiation
    modifier: INCREASED
    term:
      id: GO:0002062
      label: chondrocyte differentiation
  locations:
  - preferred_term: perichondrium
    term:
      id: UBERON:0002222
      label: perichondrium
  evidence:
  - reference: PMID:23458899
    reference_title: "Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple Exostoses."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Indeed, conditional Ext1 ablation in perichondrium and lateral chondrocytes flanking the epiphyseal region of mouse embryo long bone anlagen - a region encompassing the groove of Ranvier - caused ectopic cartilage formation."
    explanation: The direct demonstration that Ext1 loss at the perichondrial border produces ectopic cartilage.
  - reference: PMID:28445472
    reference_title: Unsuspected osteochondroma-like outgrowths in the cranial base of Hereditary Multiple Exostoses patients and modeling and treatment with a BMP antagonist in mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Osteochondroma formation was preceded by phenotypic alteration of cells at the chondro-perichondrial boundary and was accompanied by ectopic expression of major cartilage matrix genes -collagen 2 and collagen X- within the growing ectopic masses."
    explanation: Places the phenotypic change at the boundary before the lesion forms, and shows the ectopic mass is cartilage.
  - reference: PMID:29120519
    reference_title: Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We also found that PVO attenuates BMP signaling in Fsp1Cre ;Ext1flox/flox mice and that aberrant chondrogenic fate determination of Ext1-deficient perichondrial progenitor cells in these mice is restored by PVO."
    explanation: >-
      Names the aberrant chondrogenic fate of perichondrial progenitors as the
      cellular event, by showing what reverses it.
  downstream:
  - target: Osteochondroma Formation by Ectopic Endochondral Ossification
    causal_link_type: DIRECT
    description: >-
      The escaped cartilage matures through the endochondral programme and
      becomes a bony outgrowth with its own cartilage cap.
    evidence:
    - reference: PMID:28445472
      reference_title: Unsuspected osteochondroma-like outgrowths in the cranial base of Hereditary Multiple Exostoses patients and modeling and treatment with a BMP antagonist in mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Osteochondroma formation was preceded by phenotypic alteration of cells at the chondro-perichondrial boundary and was accompanied by ectopic expression of major cartilage matrix genes -collagen 2 and collagen X- within the growing ectopic masses."
      explanation: >-
        Collagen X is the hypertrophic-chondrocyte marker, so its ectopic
        expression in the growing mass is the endochondral programme running
        outside the physis.
- name: Osteochondroma Formation by Ectopic Endochondral Ossification
  biological_scale: TISSUE
  description: >-
    The lesion. Ectopic cartilage at the metaphyseal margin ossifies by
    endochondral ossification, so the osteochondroma has a cortex and a marrow
    cavity continuous with the parent bone and a hyaline cartilage cap that
    acts as its own growth plate. Lesions arise wherever bone forms from
    cartilage, most often at the metaphyses of long bones and around the knee,
    with the cranial base recently shown to be affected too; membranous bones
    of the face are spared. They enlarge and multiply during childhood and
    stop when the physes close, which is why growth or new pain in an adult
    is a warning sign rather than the expected course.
  biological_processes:
  - preferred_term: ectopic endochondral ossification
    modifier: ABNORMAL
    term:
      id: GO:0001958
      label: endochondral ossification
  locations:
  - preferred_term: metaphysis of long bones
    term:
      id: UBERON:0001438
      label: metaphysis
  - preferred_term: long bone
    term:
      id: UBERON:0002495
      label: long bone
  evidence:
  - reference: PMID:20080592
    reference_title: A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We report a mouse model of multiple osteochondromas (MO), an autosomal dominant disease in humans, also known as multiple hereditary exostoses (MHE or HME) and characterized by the formation of cartilage-capped osseous growths projecting from the metaphyses of endochondral bones."
    explanation: Defines the lesion as a cartilage-capped osseous growth from the metaphysis of an endochondral bone.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Osteochondromas develop and increase in size in the first decade of life, ceasing to grow when the growth plates close at puberty."
    explanation: The growth-plate-linked timing of lesion growth.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority are asymptomatic and located in bones that develop from cartilage, especially the long bones of the extremities, predominantly around the knee. The facial bones are not affected."
    explanation: The endochondral distribution of lesions, with sparing of membranous facial bone.
  - reference: PMID:28445472
    reference_title: Unsuspected osteochondroma-like outgrowths in the cranial base of Hereditary Multiple Exostoses patients and modeling and treatment with a BMP antagonist in mice.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, nearly half of the patients displayed moderate defects or osteochondroma-like outgrowths in the cranial base and specifically in the clivus."
    explanation: Extends the endochondral distribution to the synchondroses of the cranial base.
  downstream:
  - target: Multiple osteochondromas
    causal_link_type: DIRECT
    description: The clinical sign is the lesion itself.
  - target: Cranial base osteochondroma-like outgrowths
    causal_link_type: DIRECT
    description: The same process at the synchondrosis growth plates of the skull base.
  - target: Growth-Plate Tethering and Disturbed Longitudinal Bone Growth
    causal_link_type: DIRECT
    description: >-
      Lesions at the physis divert and tether growth, and the underlying
      heparan sulfate deficit disorganises the growth plate itself.
    evidence:
    - reference: PMID:32592948
      reference_title: The natural history of multiple osteochondromas in a large Italian cohort of pediatric patients.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The disorder frequently leads to diminished stature, deformities and functional limitations."
      explanation: The natural-history cohort states the growth and deformity consequence of the lesions.
  - target: Mechanical Impingement by Osteochondromas
    causal_link_type: DIRECT
    description: A bony mass next to a joint, tendon, nerve or vessel presses on it.
    evidence:
    - reference: PMID:20301413
      reference_title: Hereditary Multiple Osteochondromas.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."
      explanation: GeneReviews attributes the mechanical consequences directly to the osteochondromas.
  - target: Malignant Transformation of the Cartilage Cap
    causal_link_type: DIRECT
    description: >-
      The cartilage cap is the tissue that transforms; no cap, no secondary
      peripheral chondrosarcoma.
    evidence:
    - reference: PMID:38351015
      reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most feared complication is the secondary peripheral chondrosarcoma, a malignant cartilaginous neoplasm that arises from the chondroid cap of pre-existent osteochondromas."
      explanation: Locates the origin of the malignancy in the cap of a pre-existing lesion.
- name: Growth-Plate Tethering and Disturbed Longitudinal Bone Growth
  biological_scale: TISSUE
  description: >-
    Lesions sitting at the physis tether the bone, divert growth into the
    outgrowth, and shorten and angulate the segment; where two bones grow in
    parallel, as in the forearm and the leg, the shorter one bows the other
    and dislocates the joint between them. The heparan sulfate deficit also
    disorganises the growth plate directly, so the growth disturbance is not
    purely mechanical. The result is short stature, the characteristic
    forearm deformity, limb-length inequality and valgus at the knee and
    ankle, all progressive during growth and fixed after it. Deformity is a
    strong discriminator of severity and is worse with EXT1.
  biological_processes:
  - preferred_term: longitudinal endochondral bone growth
    modifier: DECREASED
    term:
      id: GO:0003416
      label: endochondral bone growth
  locations:
  - preferred_term: epiphyseal growth plate
    term:
      id: UBERON:0002516
      label: epiphyseal plate
  evidence:
  - reference: PMID:32592948
    reference_title: The natural history of multiple osteochondromas in a large Italian cohort of pediatric patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Throughout follow-up, 80.4% of patients developed new osteochondromas, 57.6% developed new deformities, 23.4% developed new functional limitation(s)."
    explanation: Quantifies the accrual of deformity during skeletal growth in 158 children.
  - reference: PMID:20534475
    reference_title: A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We show that these mice develop multiple osteochondromas and characteristic bone deformities in a pattern and a frequency that are almost identical to those of human MHE, suggesting a role for Ext1 LOH in MHE."
    explanation: The deformities travel with the lesions in the mosaic mouse, supporting the tethering mechanism.
  - reference: PMID:16236767
    reference_title: Mice deficient in Ext2 lack heparan sulfate and develop exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Significantly, all of the mice showed multiple abnormalities in cartilage differentiation, including disorganization of chondrocytes in long bones and premature hypertrophy in costochondral cartilage."
    explanation: >-
      Growth-plate disorganisation from haploinsufficiency alone, which is the
      non-mechanical contribution to the growth disturbance.
  downstream:
  - target: Short stature
    causal_link_type: DIRECT
    description: Reduced longitudinal growth across many physes.
  - target: Forearm deformity
    causal_link_type: DIRECT
    description: Ulnar shortening with radial bowing and radial head subluxation.
  - target: Limb length discrepancy
    causal_link_type: DIRECT
    description: Asymmetric tethering of paired lower-limb physes.
  - target: Genu valgum
    causal_link_type: DIRECT
    description: Angular deformity from asymmetric growth at the knee.
  - target: Ankle valgus deformity
    causal_link_type: DIRECT
    description: Distal fibular shortening tilting the ankle mortise.
- name: Mechanical Impingement by Osteochondromas
  biological_scale: TISSUE
  description: >-
    A bony mass at a metaphysis presses on whatever lies beside it: tendons
    and bursae, joint capsules, peripheral nerves and vessels, and in spinal
    lesions the cord. This is the source of most symptoms in the disease and
    of most surgery. Pain is near-universal in adults and fatigue, which is at
    least as prevalent, tracks psychological factors and pain rather than
    lesion burden.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."
    explanation: Enumerates the mechanical consequences.
  - reference: PMID:9463333
    reference_title: Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Besides suffering complications caused by the pressure of these exostoses on the surrounding tissues, EXT patients are at an increased risk for malignant chondrosarcoma, which may develop from an exostosis."
    explanation: Names pressure on surrounding tissue as the mechanism of complications.
  downstream:
  - target: Pain
    causal_link_type: DIRECT
    description: Pressure on soft tissue, bursitis, and impingement.
  - target: Limitation of joint mobility
    causal_link_type: DIRECT
    description: Juxta-articular lesions block the arc of motion.
  - target: Peripheral nerve compression
    causal_link_type: DIRECT
    description: Lesions adjacent to nerves, classically the peroneal nerve at the fibular neck.
  - target: Spinal cord compression
    causal_link_type: DIRECT
    description: Intraspinal growth of a vertebral lesion.
  - target: Premature osteoarthritis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Juxta-articular lesions and malalignment accelerate joint degeneration.
  - target: Fatigue
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Fatigue is associated with pain and psychological factors rather than
      directly with the lesions; the edge is indirect by design.
- name: Malignant Transformation of the Cartilage Cap
  biological_scale: TISSUE
  description: >-
    The cartilage cap of an osteochondroma can transform into a secondary
    peripheral chondrosarcoma, usually low grade and usually in adulthood
    (median 34 years in the Rizzoli series, but from age 13), most often in
    the pelvis and lower limb. Lifetime risk is a few per cent, ascertainment
    dependent, and higher in EXT1 carriers. Growth of a lesion after skeletal
    maturity, new pain, and a cap thicker than about 2 cm in an adult are the
    warning signs. This entry stops at the transformation threshold: the
    tumour's own biology, grading and surgical management are curated in the
    Chondrosarcoma entry, whose "Secondary Peripheral" subtype and
    "EXT1/EXT2 Heparan Sulfate Polymerization Failure" node are the
    continuation of this chain.
  cell_types:
  - preferred_term: cartilage cap chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  evidence:
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The age at diagnosis of SPC ranges from 13 to 63, with median age at diagnosis of 34 years. The site most frequently affected by malignant degeneration was the pelvis (46 patients, 44%) with higher incidence in male patients (32 males vs.14 females)."
    explanation: Age and site distribution of transformation in 105 cases.
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Histological information - available for 103 patients - showed: 59 patients with grade 1; 40 patients had a grade 2 and 4 patients had a grade 3."
    explanation: Most transformed lesions are low grade.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most important complication is malignant transformation of osteochondroma towards secondary peripheral chondrosarcoma, which is estimated to occur in 0.5-5%."
    explanation: The population-level estimate of lifetime risk.
  - reference: PMID:15446535
    reference_title: Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A single sarcoma developed in an EXT2 mutation carrier, compared with seven in EXT1 mutation carriers."
    explanation: The genotype skew in sarcoma risk.
  - reference: PMID:22258776
    reference_title: 'Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factors.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant transformation was observed in 5% of patients, and no evidence of association between chondrosarcoma onset and EXT mutation, sex, severity of disease, or number of lesions was detected."
    explanation: >-
      REFUTE of the EXT1 risk skew specifically: the larger 529-patient series
      found no genotype association with transformation, so the EXT1 excess is
      recorded as reported by one study and contradicted by another.
  downstream:
  - target: Secondary peripheral chondrosarcoma
    causal_link_type: DIRECT
    description: The malignant phenotype; continued in the Chondrosarcoma entry.
phenotypes:
- name: Multiple osteochondromas
  category: Skeletal
  description: >-
    The defining feature: two or more cartilage-capped bony outgrowths, sessile
    or pedunculated, with cortex and marrow continuous with the parent bone,
    at the metaphyses of long bones and on flat bones formed by endochondral
    ossification. Rarely evident at birth; median age at diagnosis three
    years; essentially all affected people are diagnosed by twelve. Lesion
    count varies widely within and between families.
  phenotype_term:
    preferred_term: Multiple osteochondromas
    term:
      id: HP:0002762
      label: Multiple exostoses
  frequency: OBLIGATE
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hereditary multiple osteochondromas (HMO) (also known as multiple hereditary exostoses [MHE]) is characterized by growths of multiple osteochondromas, benign cartilage-capped bone tumors that grow outward from the metaphyses of long bones."
    explanation: The defining feature, which is why the frequency is OBLIGATE.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The median age of diagnosis is three years; nearly all affected individuals are diagnosed by age 12 years."
    explanation: Onset and age-related ascertainment.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multiple osteochondromas (MO) is characterised by development of two or more cartilage capped bony outgrowths (osteochondromas) of the long bones."
    explanation: The diagnostic threshold of two or more lesions.
  - reference: PMID:7702095
    reference_title: Natural history study of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Penetrance was 100%. There was an excess of males within the entire affected population (104:76) and within identified probands (28:15)."
    explanation: >-
      Supports the obligate frequency band; the male excess in the same
      sentence is a cohort observation, not part of the penetrance claim.
- name: Cranial base osteochondroma-like outgrowths
  category: Skeletal
  description: >-
    Osteochondroma-like outgrowths and defects of the cranial base,
    specifically the clivus, found in nearly half of 50 consecutive patients
    whose cervical spine imaging included the skull base. The cranial base is
    formed by endochondral ossification at synchondroses, so this is the same
    lesion at an unexpected site; the membranous facial bones remain spared.
  phenotype_term:
    preferred_term: Cranial base osteochondroma-like outgrowth
    term:
      id: HP:0002693
      label: Abnormal skull base morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:28445472
    reference_title: Unsuspected osteochondroma-like outgrowths in the cranial base of Hereditary Multiple Exostoses patients and modeling and treatment with a BMP antagonist in mice.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, nearly half of the patients displayed moderate defects or osteochondroma-like outgrowths in the cranial base and specifically in the clivus."
    explanation: Nearly half of 50 consecutive patients, which maps to the FREQUENT band.
- name: Short stature
  category: Growth
  description: >-
    Mild to moderate disproportionate short stature from tethered growth at
    many physes. Worse with EXT1 than EXT2; the pediatric natural-history
    cohort found 13 years to be the cut-off after which stature grows slowly.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."
    explanation: GeneReviews lists shortened stature among the associations.
  - reference: PMID:15446535
    reference_title: Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The sites of mutation affected the severity of disease with patients with EXT1 mutations having a significantly worse condition than those with EXT2 mutations in three of five parameters of severity (stature, deformity and functional parameters)."
    explanation: Stature is one of the measured severity parameters, and it is worse with EXT1.
- name: Forearm deformity
  category: Skeletal
  description: >-
    The most characteristic deformity: a short, bowed ulna with distal ulnar
    lesions, compensatory radial bowing, ulnar deviation of the wrist and, in
    some, radial head dislocation. Present in about 39% of the Washington
    cohort. Bound to the parent forearm-morphology term because HPO codes the
    components (radial bowing, ulnar hypoplasia, dislocated radial head)
    separately rather than the composite.
  phenotype_term:
    preferred_term: Forearm deformity (short bowed ulna with radial bowing)
    term:
      id: HP:0002973
      label: Abnormal forearm morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity of the knee, and two (2 per cent) had a deformity of the ankle."
    explanation: 39% with obvious forearm deformity, which maps to FREQUENT.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "forearm deformity may be treated with excision of the osteochondromas, corrective osteotomies, and/or ulnar-lengthening procedures"
    explanation: GeneReviews names forearm deformity as a treated manifestation, with ulnar lengthening implying the short ulna.
- name: Limb length discrepancy
  category: Skeletal
  description: >-
    Inequality in limb length from asymmetric physeal involvement, in about
    one in ten; treated when significant by epiphysiodesis of the longer leg.
  phenotype_term:
    preferred_term: Limb length discrepancy
    term:
      id: HP:0100559
      label: Lower limb asymmetry
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity of the knee, and two (2 per cent) had a deformity of the ankle."
    explanation: 10% with limb-length inequality, which maps to OCCASIONAL.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "leg length inequalities may be treated with epiphysiodesis (growth plate arrest) of the longer leg"
    explanation: GeneReviews names leg-length inequality as a managed manifestation.
- name: Genu valgum
  category: Skeletal
  description: >-
    Angular (valgus) deformity at the knee from asymmetric growth of the
    distal femoral and proximal tibial physes, in about 8%; managed by
    hemiepiphysiodesis or osteotomy during growth.
  phenotype_term:
    preferred_term: Genu valgum
    term:
      id: HP:0002857
      label: Genu valgum
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity of the knee, and two (2 per cent) had a deformity of the ankle."
    explanation: 8% with angular deformity of the knee, which maps to OCCASIONAL.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "angular misalignment of the lower limbs may be treated with hemiepiphysiodeses (or osteotomies) at the distal femur, proximal tibia, or distal tibia"
    explanation: GeneReviews names lower-limb angular misalignment and its sites.
- name: Ankle valgus deformity
  category: Skeletal
  description: >-
    Valgus tilt of the ankle from distal fibular shortening and distal tibial
    lesions, in 2% of the Washington cohort; early treatment may prevent later
    deterioration of function. Left unbound: HPO has no ankle-valgus term, and
    the available valgus terms (talipes valgus, calcaneovalgus, pes valgus)
    name foot deformities rather than the tibiotalar tilt seen here.
  phenotype_term:
    preferred_term: Ankle valgus deformity
  frequency: VERY_RARE
  evidence:
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a cohort of eighty-four subjects for whom we had complete information, the clinical range of expression was wide: thirty-three (39 per cent) had an obvious deformity of the forearm, eight (10 per cent) had an inequality in the lengths of the limbs, seven (8 per cent) had an angular deformity of the knee, and two (2 per cent) had a deformity of the ankle."
    explanation: 2% with ankle deformity, which maps to VERY_RARE.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "early treatment of ankle deformity may prevent or decrease later deterioration of function"
    explanation: GeneReviews names ankle deformity as a managed manifestation.
- name: Limitation of joint mobility
  category: Musculoskeletal
  description: >-
    Restricted range of motion where a lesion sits against a joint capsule or
    tendon, or where deformity has altered joint mechanics; new functional
    limitations appeared in 23.4% of children over three years of follow-up.
  phenotype_term:
    preferred_term: Limitation of joint mobility
    term:
      id: HP:0001376
      label: Limitation of joint mobility
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."
    explanation: GeneReviews lists restricted joint motion.
  - reference: PMID:32592948
    reference_title: The natural history of multiple osteochondromas in a large Italian cohort of pediatric patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Throughout follow-up, 80.4% of patients developed new osteochondromas, 57.6% developed new deformities, 23.4% developed new functional limitation(s)."
    explanation: >-
      Incidence of new functional limitation during growth; not used as a
      prevalence band because it counts new events over follow-up.
- name: Premature osteoarthritis
  category: Musculoskeletal
  description: >-
    Early degenerative joint disease from juxta-articular lesions and
    malalignment, a source of adult morbidity after lesion growth has stopped.
  phenotype_term:
    preferred_term: Premature osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."
    explanation: GeneReviews lists premature osteoarthrosis.
- name: Peripheral nerve compression
  category: Neurological
  description: >-
    Focal neuropathy from a lesion pressing on an adjacent nerve, classically
    the common peroneal nerve at the fibular neck; vessels are displaced or
    compressed by the same mechanism.
  phenotype_term:
    preferred_term: Peripheral nerve compression by osteochondroma
    term:
      id: HP:0003406
      label: Peripheral nerve compression
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Osteochondromas can be associated with shortened stature, bony deformity, restricted joint motion, premature osteoarthrosis, and compression of peripheral nerves."
    explanation: GeneReviews lists compression of peripheral nerves.
- name: Spinal cord compression
  category: Neurological
  description: >-
    A rare but serious complication of vertebral osteochondromas growing into
    the canal. Whether asymptomatic children should have a screening spine MRI
    is unsettled; recommendations diverge and no prospective study shows
    benefit.
  phenotype_term:
    preferred_term: Spinal cord compression
    term:
      id: HP:0002176
      label: Spinal cord compression
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Some recommend a screening spine MRI in childhood to identify spinal lesions that may cause pressure on the spinal cord and would warrant close clinical follow up with excision of lesions that cause spinal cord impingement and/or symptoms; others recommend against screening spine MRI except in those with neurologic compromise or osteochondroma(s) of the ribs or pelvis."
    explanation: Establishes spinal cord impingement by spinal lesions as a recognised complication, and the unresolved screening question.
- name: Pain
  category: Symptom
  description: >-
    Chronic pain from mechanical pressure, bursitis, impingement and
    degenerative change, reported by 87.8% of 353 Dutch adults with a mean
    numeric rating of about 3 out of 10. Fear-avoidance beliefs and fatigue
    were its strongest correlates, which argues for multidisciplinary rather
    than surgery-only management.
  phenotype_term:
    preferred_term: Chronic musculoskeletal pain
    term:
      id: HP:0012531
      label: Pain
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:39018287
    reference_title: "Pain and fatigue in adult patients with multiple osteochondromas: The Netherlands."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pain was reported by 87.8% (NRS = 3.19±2.6) and fatigue by 90.4% (NRS = 4.1±2.6) of patients with MO."
    explanation: 87.8% of adults, which maps to VERY_FREQUENT.
- name: Fatigue
  category: Symptom
  description: >-
    Reported by 90.4% of adults, with Checklist Individual Strength scores
    above those of both healthy people and rheumatoid arthritis patients.
    Anxiety and depression were its strongest correlates; it is recorded as
    an indirect consequence of the disease rather than of lesion burden.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:39018287
    reference_title: "Pain and fatigue in adult patients with multiple osteochondromas: The Netherlands."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pain was reported by 87.8% (NRS = 3.19±2.6) and fatigue by 90.4% (NRS = 4.1±2.6) of patients with MO."
    explanation: 90.4% of adults, which maps to VERY_FREQUENT.
  - reference: PMID:39018287
    reference_title: "Pain and fatigue in adult patients with multiple osteochondromas: The Netherlands."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fatigue scores for MO (CIS = 84.1±15.3) were significantly higher (p<0.001) compared to reference scores of healthy subjects and patients with RA."
    explanation: Fatigue exceeds both healthy and rheumatoid-arthritis reference values.
- name: Secondary peripheral chondrosarcoma
  category: Neoplastic
  description: >-
    Malignant transformation of an osteochondroma cartilage cap, usually to a
    low-grade chondrosarcoma, most often in the pelvis and around the hip and
    shoulder, typically in the third and fourth decades but from adolescence.
    Estimates of lifetime risk range from about 1% to 5% in population-based
    or large-cohort series (2.8% in Wicklund, 5% in Pedrini, 0.5-5% pooled)
    and up to 10% in older referral-centre figures; no single band is
    assigned because the estimates straddle the VERY_RARE/OCCASIONAL boundary.
    Warning signs are growth after skeletal maturity, new pain, and a cap
    thicker than about 2 cm in an adult. The tumour itself is curated in the
    Chondrosarcoma entry.
  phenotype_term:
    preferred_term: Secondary peripheral chondrosarcoma
    term:
      id: HP:0006765
      label: Chondrosarcoma
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The risk for malignant transformation to osteochondrosarcoma increases with age, although the lifetime risk for malignant transformation is low (~2%-10%)."
    explanation: GeneReviews' lifetime risk range and its age dependence.
  - reference: PMID:7702095
    reference_title: Natural history study of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only 2.8% of the total affected population had experienced exostosis-related malignancy, an estimate which is considerably less than earlier reports would suggest."
    explanation: A population-oriented estimate at the low end.
  - reference: PMID:22258776
    reference_title: 'Genotype-phenotype correlation study in 529 patients with multiple hereditary exostoses: identification of "protective" and "risk" factors.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant transformation was observed in 5% of patients, and no evidence of association between chondrosarcoma onset and EXT mutation, sex, severity of disease, or number of lesions was detected."
    explanation: A referral-cohort estimate at the upper end of the range.
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In conclusion, the present study gives an overview of the secondary peripheral chondrosarcomas, confirming that this disease represents an impacting complication for multiple osteochondromas patients and suggests that malignant transformation can occur also in younger patient, in a not irrelevant number of cases."
    explanation: >-
      Transformation is not confined to adults. Quoted verbatim including the
      source's grammar.
biochemical:
- name: Blood heparan sulfate to chondroitin sulfate ratio
  presence: DECREASED
  context: >-
    A research biomarker, not a clinical test. In a single prospective series
    the amount of heparan sulfate in both plasma and the cellular fraction of
    blood was reduced and the heparan sulfate to chondroitin sulfate (HS/CS)
    ratio was about half that of healthy controls, with heparan sulfate chain
    structure preserved. The authors proposed the ratio as a diagnostic
    biomarker; it has not been validated against molecular testing in an
    independent cohort and is not part of any diagnostic pathway. The ratio
    is a value computed over two measurements, so the bound term is the
    analyte that falls (heparan sulfate) and the ratio identity is carried in
    the name, per the design-decision entry on composite indices.
  biomarker_term:
    preferred_term: heparan sulfate (as HS/CS ratio in blood)
    term:
      id: NCIT:C540
      label: Heparan Sulfate
  readouts:
  - target: Systemic Heparan Sulfate Insufficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      A lower blood HS/CS ratio reports a greater systemic shortfall in
      heparan sulfate synthesis from the heterozygous EXT1/EXT2 defect; the
      ratio is halved in patients, in line with a dosage effect.
    evidence:
    - reference: PMID:23514715
      reference_title: "Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "However, interestingly, although both the amounts of HS and chondroitin sulfate (CS) varied depending on the different individuals, the amounts of HS in both the plasma and cellular fractions of HME patient samples were decreased and the ratios of HS to CS (HS/CS) of HME patient samples were almost half those of healthy individuals."
      explanation: >-
        The measured reduction in blood heparan sulfate and in the HS/CS
        ratio is the readout of the systemic heparan sulfate insufficiency
        node.
  evidence:
  - reference: PMID:23514715
    reference_title: "Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The results suggest that HME patients' blood exhibited reduced HS amounts and HS/CS ratios, which could be used as a diagnostic biomarker for HME."
    explanation: >-
      The authors' proposal of the reduced HS/CS ratio as a diagnostic
      biomarker; the wording is a suggestion from one series, which is why
      the marker is recorded as a research candidate.
  - reference: PMID:23514715
    reference_title: "Glycosaminoglycans in the blood of hereditary multiple exostoses patients: Half reduction of heparan sulfate to chondroitin sulfate ratio and the possible diagnostic application."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that HS structures of HME patients were almost similar to those of controls in both plasma and cellular fractions."
    explanation: >-
      Chain structure is preserved, so the biomarker is a quantity, not a
      sulfation-pattern signature.
genetic:
- name: EXT1
  gene_term:
    preferred_term: EXT1
    term:
      id: hgnc:3512
      label: EXT1
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Exostosin-1, 8q24.11, eleven exons. Cloned in 1995 from the Langer-Giedion
    region by walking to two patients' translocation breakpoints. Accounts for
    about 65% of mutation-positive cases; the spectrum is dominated by
    nonsense, frameshift and splice-site alleles, with whole-exon and
    whole-gene deletions detectable by MLPA and a minority of functionally
    validated missense alleles. Several reported missense variants retain
    heparan sulfate synthesis in functional assays and are probably not
    pathogenic. Functional impact is loss of function (haploinsufficiency at the
    germline level, biallelic loss in lesion chondrocytes), recorded
    structurally in the initiating pathophysiology node's genetic_context. The
    contiguous 8q24 deletion that removes EXT1 together with TRPS1 causes
    Langer-Giedion syndrome and is out of scope here.
  evidence:
  - reference: PMID:7550340
    reference_title: Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a majority of families, the genetic defect (EXT1) is linked to the Langer-Giedion syndrome chromosomal region in 8q24.1. From this region we have cloned and characterized a cDNA which spans chromosomal breakpoints previously identified in two multiple exostoses patients."
    explanation: The positional cloning of EXT1 and its relation to the Langer-Giedion region.
  - reference: PMID:19810120
    reference_title: "Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EXT1 is located at 8q24.11-q24.13, and comprises 11 exons, whereas the 16 exon EXT2 is located at 11p12-p11. To date, an EXT1 or EXT2 mutation is detected in 70-95% of affected individuals."
    explanation: Gene location and the combined diagnostic yield of the two genes.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In almost 90% of MO patients germline mutations in the tumour suppressor genes EXT1 or EXT2 are found."
    explanation: Independent statement of the combined detection rate.
- name: EXT2
  gene_term:
    preferred_term: EXT2
    term:
      id: hgnc:3513
      label: EXT2
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Exostosin-2, 11p11-p12, sixteen exons; identified in 1996 by its homology
    to EXT1. Accounts for about 35% of mutation-positive cases, with the same
    truncating-dominated spectrum as EXT1. EXT2 has no significant
    glycosyltransferase activity on its own and acts within the EXT1-EXT2
    complex, which is why its loss produces the same disease. On average the
    milder genotype. Functional impact is loss of function, as for EXT1.
  evidence:
  - reference: PMID:8782816
    reference_title: The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report the isolation and characterization of the EXT2 gene. This gene shows striking sequence similarity to the EXT1 gene, and we have identified a four base deletion segregating with the phenotype."
    explanation: The original EXT2 identification.
  - reference: PMID:10639137
    reference_title: The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here, by testing a cell line with a specific defect in EXT1 in in vivo and in vitro assays, we show that EXT2 does not harbor significant glycosyltransferase activity in the absence of EXT1."
    explanation: EXT2 acts only within the complex, explaining why its loss phenocopies EXT1 loss.
  - reference: PMID:19810120
    reference_title: "Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EXT1 mutations are detected in +/-65% of cases, versus +/-35% EXT2 mutations in MO patient cohorts."
    explanation: The EXT2 share of mutation-positive cases.
prevalence:
- population: State of Washington, USA (kindred database)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.0
  notes: >-
    "The over-all prevalence was at least one in 50,000" (Schmale 1994), from
    46 kindreds with 113 affected members; a minimum estimate, since mildly
    affected people are under-ascertained. 1 in 50,000 = 2.0 per 100,000.
  evidence:
  - reference: PMID:8027127
    reference_title: The natural history of hereditary multiple exostoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The over-all prevalence was at least one in 50,000."
    explanation: The source of the recorded rate.
- population: General population (European and North American estimates)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.0
  notes: >-
    "The prevalence is estimated at 1:50,000" (Bovée 2008), the figure
    carried through the review literature and derived from the Washington
    study; the apparent male excess (1.5:1) reflects ascertainment of more
    severe disease rather than sex-dependent transmission.
  evidence:
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence is estimated at 1:50,000, and it seems to be higher in males (male-to-female ratio 1.5:1)."
    explanation: The review estimate and the sex ratio it reports.
treatments:
- name: Surgical Excision of Symptomatic Osteochondromas
  description: >-
    The mainstay. Asymptomatic lesions are observed; lesions that cause pain,
    impingement, restricted motion, neurovascular compromise or cosmetic
    concern are excised, and the excision must include the cartilage cap and
    overlying perichondrium, because a retained cap regrows. Removed lesions
    should be examined histologically for malignant change. This treats the
    mass effect of an existing lesion; nothing prevents new ones from forming
    while the physes are open.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: excision of osteochondroma including cartilage cap and perichondrium
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Mechanical Impingement by Osteochondromas
    treatment_effect: INHIBITS
    description: Removing the mass removes the pressure it exerts.
    evidence:
    - reference: PMID:20301413
      reference_title: Hereditary Multiple Osteochondromas.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Painful lesions in the absence of bone deformity may be treated with surgical excision that includes the cartilage cap and overlying perichondrium to prevent recurrence"
      explanation: Excision for painful lesions, with the cap-and-perichondrium requirement that prevents regrowth.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Painful lesions in the absence of bone deformity may be treated with surgical excision that includes the cartilage cap and overlying perichondrium to prevent recurrence"
    explanation: GeneReviews management guidance.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Management includes removal of osteochondromas when they give complaints. Removed osteochondromas should be examined for malignant transformation towards secondary peripheral chondrosarcoma."
    explanation: Symptom-driven excision and histological review of the specimen.
- name: Corrective Osteotomy, Guided Growth and Limb Lengthening
  description: >-
    Reconstruction of growth-related deformity: excision of the culprit
    lesions with corrective osteotomy and ulnar lengthening for the forearm;
    hemiepiphysiodesis (guided growth) or osteotomy at the distal femur,
    proximal tibia or distal tibia for angular malalignment; epiphysiodesis of
    the longer leg for limb-length inequality; and early correction of ankle
    valgus. Evidence that forearm reconstruction improves long-term function
    is weak, so indications are individualised rather than radiographic.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: corrective osteotomy, hemiepiphysiodesis and limb lengthening
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_mechanisms:
  - target: Growth-Plate Tethering and Disturbed Longitudinal Bone Growth
    treatment_effect: MODULATES
    description: >-
      Redirects or arrests growth at chosen physes to correct angulation and
      length inequality; it does not restore normal growth-plate biology.
    evidence:
    - reference: PMID:20301413
      reference_title: Hereditary Multiple Osteochondromas.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "angular misalignment of the lower limbs may be treated with hemiepiphysiodeses (or osteotomies) at the distal femur, proximal tibia, or distal tibia"
      explanation: Guided growth and osteotomy for angular deformity.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "forearm deformity may be treated with excision of the osteochondromas, corrective osteotomies, and/or ulnar-lengthening procedures"
    explanation: The forearm reconstruction options.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "leg length inequalities may be treated with epiphysiodesis (growth plate arrest) of the longer leg"
    explanation: Epiphysiodesis for length inequality.
- name: Clinical and Imaging Surveillance for Malignant Transformation
  description: >-
    Monitoring lesion size in adults, with prompt MRI and sarcoma referral
    for growth after skeletal maturity, new pain, or a thick cartilage cap.
    Widely recommended but without an accepted schedule or cost-benefit
    evidence; the yield argument rests on the sarcoma risk being comparable
    to that in screened populations for other cancers. Bound to the NCIT
    cancer-screening action because that is what surveillance of an
    at-risk population for malignant transformation is.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: surveillance imaging for malignant transformation of osteochondromas
    term:
      id: NCIT:C15406
      label: Cancer Screening
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Monitoring of the size of osteochondromas in adults may aid in early identification of malignant transformation, but no cost-benefit analyses are available to support routine surveillance."
    explanation: The recommendation and its evidence gap, stated together.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Patients should be well instructed and regular follow-up for early detection of malignancy seems justified."
    explanation: The review's surveillance recommendation.
  - reference: PMID:15446535
    reference_title: Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The sarcoma risk in EXT1 carriers is similar to the risk of breast cancer in an older population subjected to breast-screening, suggesting that a role for regular screening in patients with hereditary multiple exostoses is justifiable."
    explanation: The risk-comparison argument for surveillance, strongest in EXT1 carriers.
- name: En Bloc Resection of Secondary Peripheral Chondrosarcoma
  description: >-
    A transformed lesion is resected en bloc with its pseudocapsule and
    tumour-free margins, preferably in a bone tumour centre; grade 2-3
    histology and partial resection predict worse disease-free survival.
    Recorded here only as the exit from this entry's chain; the oncological
    management is curated in the Chondrosarcoma entry.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: en bloc resection of secondary peripheral chondrosarcoma
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Malignant Transformation of the Cartilage Cap
    treatment_effect: INHIBITS
    description: Removes the transformed cap and its margin before local or distant spread.
    evidence:
    - reference: PMID:38351015
      reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Outcome in disease-free survival highlights that a worse course of the disease was associated with histological grade 2 or 3, and partial resection surgery."
      explanation: Completeness of resection is what determines outcome.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "sarcomatous degeneration is treated by surgical resection"
    explanation: GeneReviews management guidance.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "For secondary peripheral chondrosarcoma, en-bloc resection of the lesion and its pseudocapsule with tumour-free margins, preferably in a bone tumour referral centre, should be performed."
    explanation: The surgical standard for the transformed lesion.
- name: Palovarotene (investigational; MO-Ped trial terminated)
  description: >-
    A selective retinoic acid receptor gamma agonist that, in Ext1-deficient
    mice, cut osteochondroma formation by up to 91%, attenuated BMP signalling,
    and restored the chondrogenic fate decision of perichondrial progenitors;
    a later mouse study showed it also arrests growth of pre-existing lesions
    via Stat3. The phase 2 MO-Ped trial (NCT03442985) randomised 193 children
    to placebo or two doses, was placed on partial clinical hold over concern
    about premature physeal closure and then terminated. In the 30 patients
    with 12-month imaging there was no difference in the annualised rate of
    new osteochondromas or in lesion volume, and the sponsor concluded the
    benefit-risk profile was not favourable. Recorded as an experimental
    treatment with a negative human result, not as a therapy; there is no
    approved disease-modifying drug for HMO.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: palovarotene
      term:
        id: CHEBI:188559
        label: palovarotene
  target_mechanisms:
  - target: Loss of Perichondrial Border Function and Ectopic Chondrogenesis
    treatment_effect: INHIBITS
    description: >-
      RAR-gamma agonism suppresses chondrogenesis and BMP signalling in
      perichondrial progenitors; demonstrated in mice, not confirmed in the
      terminated human trial.
    evidence:
    - reference: PMID:29120519
      reference_title: Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "We also found that PVO attenuates BMP signaling in Fsp1Cre ;Ext1flox/flox mice and that aberrant chondrogenic fate determination of Ext1-deficient perichondrial progenitor cells in these mice is restored by PVO."
      explanation: INDIRECT because the mechanism-level effect is shown in mice only.
  evidence:
  - reference: PMID:29120519
    reference_title: Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Four-week daily treatment with PVO starting at postnatal day (P) 14 reduced the number of osteochondromas that develop in these mice by up to 91% in a dose-dependent manner."
    explanation: The preclinical efficacy that motivated the trial.
  - reference: PMID:39062860
    reference_title: Analysis of the Actions of RARγ Agonists on Growing Osteochondromas in a Mouse Model.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "These findings suggest that palovarotene treatment is effective against pre-existing osteochondromas and that the Stat3 pathway is involved in the antitumor actions of palovarotene."
    explanation: Preclinical activity against established lesions, again mouse only.
  - reference: PMID:41188357
    reference_title: "Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, palovarotene showed no clear efficacy signal in MHE, resulting in a non-favorable benefit-risk profile."
    explanation: The human trial result, recorded as REFUTE of efficacy.
  - reference: PMID:41188357
    reference_title: "Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Due to concerns of premature physeal closure (PPC), a partial clinical hold was instituted, followed by trial termination."
    explanation: Why the trial stopped; the safety concern specific to a growing skeleton.
  - reference: PMID:41188357
    reference_title: "Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "Interpretation of results was limited by the reduced treatment duration and smaller than expected cohort."
    explanation: >-
      The trial's own caveat: the negative result is underpowered and
      truncated, so it does not settle the question either way.
- name: Genetic Counseling
  description: >-
    Autosomal dominant transmission with a 50% risk to each child, near-complete
    penetrance, variable severity that cannot be predicted from genotype, and
    the possibility of prenatal or preimplantation testing once the familial
    variant is known.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Each child of an individual with HMO has a 50% chance of inheriting an HMO-causing pathogenic variant. If the HMO-causing pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible."
    explanation: The counselling content.
diagnosis:
- name: Clinical and radiographic diagnosis (two or more osteochondromas)
  description: >-
    The diagnosis is clinical and radiographic. It is established in a proband
    by characteristic radiographic findings of multiple osteochondromas
    (and/or by a heterozygous EXT1 or EXT2 pathogenic variant, below). The
    working criterion is two or more cartilage-capped bony outgrowths whose
    cortex and medulla are continuous with the parent bone, on physical
    examination, family history and plain radiographs; where an affected
    relative is already established, the diagnosis can be made clinically
    without molecular testing. Histology of an excised lesion supplements
    but is not required.
  diagnosis_term:
    preferred_term: plain radiography of the skeleton with physical examination
    term:
      id: NCIT:C137876
      label: Bone Radiography
  results: >-
    Two or more osteochondromas, pedunculated or sessile, at the metaphyses of
    long bones or on flat bones, with cortical and medullary continuity with
    the underlying bone.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of HMO is established in a proband with characteristic radiographic findings of multiple osteochondromas and/or a heterozygous pathogenic variant in EXT1 or EXT2 identified on molecular genetic testing."
    explanation: The GeneReviews statement of how the diagnosis is established.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multiple osteochondromas (MO) is characterised by development of two or more cartilage capped bony outgrowths (osteochondromas) of the long bones."
    explanation: The two-lesion criterion that the clinical diagnosis rests on.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis is based on radiological and clinical documentation, supplemented with, if available, histological evaluation of osteochondromas."
    explanation: Radiology and clinical documentation carry the diagnosis; histology is supplementary.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The identification of OCs through imaging studies such as X-rays or MRIs typically eliminates the need for differential diagnoses, and the presence of two or more OCs is sufficient for the diagnosis of MO according to clinical criteria"
    explanation: A large cohort study restating the two-lesion clinical criterion and the imaging it rests on.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With the currently used methods it is possible to detect point mutations or gross deletions in almost 90% of MO patients"
    explanation: >-
      Molecular confirmation is available for most but not all clinically
      diagnosed patients, which is why the clinical-radiographic route
      remains sufficient on its own.
- name: Cross-sectional imaging for complex anatomy and cartilage-cap assessment
  description: >-
    Plain radiography is first line. CT is used for lesions in complex
    anatomy (pelvis, scapula, ribs, spine) where radiographs cannot define
    the base and extent. MRI is the modality for the hyaline cartilage cap
    (T2-weighted sequences), the marrow, adjacent soft tissue and
    neurovascular structures, and for suspected spinal or malignant
    complications; ultrasound can measure the cap of a superficial lesion.
    The imaging ladder (radiography, then CT for complex sites, MRI for the
    cap, ultrasound for superficial caps) follows the Falcon deep-research
    report's synthesis of the radiology reviews; the cited sources quote the
    MRI role directly. Whether children should have a screening spine MRI is
    unsettled.
  diagnosis_term:
    preferred_term: magnetic resonance imaging of the cartilage cap (with CT and ultrasound as adjuncts)
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  results: >-
    Defines lesion base and extent at complex sites (CT), and measures
    cartilage-cap thickness and shows marrow, soft-tissue and neurovascular
    relationships (MRI); a spine MRI may show asymptomatic canal lesions.
  evidence:
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      To evaluate possible malignant transformation in case of
      complaints or growth of the lesion after puberty, the size
      of the cartilaginous cap can be well established with T2-
      weighted magnetic resonance (MR) imaging [64].
    explanation: >-
      MRI as the modality for cartilage-cap measurement; quoted with the
      source PDF's line breaks.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Some recommend a screening spine MRI in childhood to identify spinal lesions that may cause pressure on the spinal cord and would warrant close clinical follow up with excision of lesions that cause spinal cord impingement and/or symptoms; others recommend against screening spine MRI except in those with neurologic compromise or osteochondroma(s) of the ribs or pelvis."
    explanation: The disputed role of screening spine MRI.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of MO typically involves identifying multiple benign bone tumors known as osteochondromas (OCs) through imaging studies and physical examinations."
    explanation: Imaging plus physical examination as the basis of lesion identification.
- name: Evaluation of suspected malignant transformation (cartilage-cap thickness)
  description: >-
    The red flags for secondary peripheral chondrosarcoma are growth of a
    lesion after skeletal maturity, new or increasing pain in an adult, and
    a thick cartilage cap on MRI. Thresholds in the literature range from
    over 1 cm (Bovée 2008 abstract) through 1.5-2 cm to the WHO 2020
    histological criterion of more than 2 cm; a cap thicker than about 2 cm
    in an adult is the commonly used trigger. The Falcon deep-research
    report gives a higher threshold of about 3 cm for children, which is not
    quoted from a cached source. Imaging alone may not separate an
    osteochondroma from a low-grade chondrosarcoma, so a suspicious lesion
    goes to a sarcoma team for expert radiology and pathology.
  diagnosis_term:
    preferred_term: MRI measurement of cartilage-cap thickness in a growing or painful lesion
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  results: >-
    Cartilage cap thicker than about 2 cm in an adult, growth after skeletal
    maturity, a lobulated surface, soft-tissue nodules or invasion of the
    stalk raise suspicion of secondary peripheral chondrosarcoma.
  evidence:
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An increase in size of a lesion after puberty and the presence of pain in adults are signs that raise suspicion of a Secondary Peripheral Chondrosarcoma (SPC). In addition, the most reliable feature to suspect a SPC is the cartilaginous cap thickness (exceeding 1.5–2 cm)"
    explanation: The clinical red flags and the cap-thickness threshold as stated by the Rizzoli series.
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most important feature was the thickness of the cartilaginous cap > 2 cm; a lobular pattern with nodules in the surrounding soft tissue, separated by the mail mass, and the invasion of the stalk of the osteochondroma were also in favor of malignancy."
    explanation: >-
      The 2 cm cap criterion and the ancillary features used for grade 1
      peripheral chondrosarcoma under the WHO 2020 classification; quoted
      verbatim including the source's spelling.
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover, the imaging or the histology per se may not be distinguish an osteochondroma from low-grade peripheral chondrosarcoma because the diagnosis needs specialized bone tumor pathologists as well as a multidisciplinary approach"
    explanation: Why a suspicious lesion is referred to a specialist team; quoted verbatim including the source's grammar.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The suspicion of secondary chondrosarcoma is indicated by growth of the tumour after puberty, the presence of pain, or a thickness over 1 cm of the cartilaginous cap in adults."
    explanation: The lower end of the published cap-thickness thresholds, from the 2008 review.
- name: EXT1 and EXT2 sequencing followed by deletion/duplication analysis
  description: >-
    Molecular confirmation identifies a heterozygous pathogenic variant in
    EXT1 or EXT2. Sequence analysis of all coding exons and flanking
    splice regions of both genes is performed first; if negative,
    exon-level deletion/duplication analysis (typically MLPA) follows,
    since gross deletions account for a meaningful share of pathogenic
    alleles. Together these find a variant in about 90% of clinically
    diagnosed patients. In a sequencing-negative proband, or one with
    enchondromas or hand and foot lesions, PTPN11 should be added, because
    loss-of-function PTPN11 variants (the metachondromatosis gene) were
    found in about 4% of a large cohort referred with a diagnosis of
    multiple osteochondromas. Testing of relatives, and prenatal or
    preimplantation testing, become possible once the familial variant is
    known.
  diagnosis_term:
    preferred_term: EXT1 and EXT2 sequence analysis with deletion/duplication (MLPA) testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: >-
    A heterozygous pathogenic or likely pathogenic EXT1 or EXT2 variant
    (nonsense, frameshift, splice-site, missense or exon-level deletion)
    confirms the diagnosis; a PTPN11 loss-of-function variant points to
    metachondromatosis or the overlap spectrum.
  evidence:
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of HMO is established in a proband with characteristic radiographic findings of multiple osteochondromas and/or a heterozygous pathogenic variant in EXT1 or EXT2 identified on molecular genetic testing."
    explanation: Molecular genetic testing as the alternative route to an established diagnosis.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "DNA analysis of the coding region and copy number variations (CNVs) in EXT1/2 genes is currently the gold standard for diagnosing MO"
    explanation: Sequence plus copy-number analysis of both genes as the molecular standard.
  - reference: PMID:38351015
    reference_title: "Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in case of negative results, both genes were evaluated by MLPA (Multiple Ligation-dependent Probe Amplification) analysis for the presence of exon or multi-exons deletion/amplification"
    explanation: The sequencing-then-MLPA order as run in the Rizzoli laboratory.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "new techniques screening for larger deletions, such as MLPA, have dramatically decreased the proportion of MO patients without an EXT1 or EXT2 mutation to <15%"
    explanation: Why deletion analysis is part of the standard work-up.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings highlight the importance of expanding genetic testing beyond the EXT1 and EXT2 genes in MO cases, as other genes such as PTPN11 may also be causative."
    explanation: The basis for adding PTPN11 to the panel in EXT-negative probands.
  - reference: PMID:20301413
    reference_title: Hereditary Multiple Osteochondromas.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "If the HMO-causing pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible."
    explanation: Familial and reproductive testing once the variant is known.
differential_diagnoses:
- name: Solitary osteochondroma
  description: >-
    A single osteochondroma is the common, non-hereditary lesion (about 85%
    of all osteochondromas); it arises from somatic biallelic EXT1 loss
    confined to the cartilage cap and carries no germline variant. A second
    lesion, a positive family history or a germline EXT1/EXT2 variant moves
    the diagnosis to the hereditary disorder.
  distinguishing_features:
  - One lesion only, no family history
  - No germline EXT1 or EXT2 variant; somatic homozygous EXT1 deletion restricted to the cartilage cap
  evidence:
  - reference: PMID:17341731
    reference_title: "The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, 85% of all osteochondromas present as solitary (nonhereditary) lesions in which somatic mutations in EXT1 are extremely rare, but loss of heterozygosity and clonal rearrangement of 8q24 (the chromosomal locus of EXT1) are common."
    explanation: The solitary lesion as the majority, non-hereditary form.
  - reference: PMID:17341731
    reference_title: "The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FISH analysis of the cartilage cap, perichondrium, and bony stalk showed that these homozygous EXT1 deletions were present only in the cartilage cap of osteochondroma."
    explanation: Somatic, cap-restricted biallelic EXT1 loss in the sporadic lesion, as opposed to a germline variant.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the presence of two or more OCs is sufficient for the diagnosis of MO according to clinical criteria"
    explanation: The lesion count is what separates the two.
- name: Metachondromatosis
  description: >-
    Autosomal dominant PTPN11 loss-of-function disorder with both
    osteochondromas and enchondromas. Its osteochondromas favour the hands
    and feet, point toward the adjacent growth plate rather than away from
    it, do not cause the shortening and deformity seen here, and may regress
    spontaneously. The boundary is not sharp: PTPN11 loss-of-function
    variants were found in about 4% of probands referred with a diagnosis of
    multiple osteochondromas, several without enchondromas, so the two may
    form a spectrum.
  disease_term:
    preferred_term: metachondromatosis
    term:
      id: MONDO:0007979
      label: metachondromatosis
  distinguishing_features:
  - Enchondromas present; osteochondromas mainly in hands and feet, pointing toward the growth plate
  - Lesions do not shorten or deform bones and may regress spontaneously
  - PTPN11 loss-of-function variant rather than EXT1/EXT2
  evidence:
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "point toward the adjacent growth plate, while in MO the osteochondromas are mainly located in the long or other tubular bones and point away from the epiphysis"
    explanation: The radiographic orientation that separates metachondromatosis lesions from those of this disorder.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in patients with MC the lesions do not result in shortening or deformity of affected bones as in MO, and may spontaneously decrease in size or resolve completely, both clinically and radiologically"
    explanation: The natural-history difference.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Metachondromatosis (OMIM#156250) (MC) is a rare genetic disease characterized by the presence of obligatory enchondromas (ECs) and nonobligatory OCs, caused by LoF variants in the PTPN11 gene"
    explanation: The defining features and gene of the differential.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings suggest a potential overlap between the MO and MC both phenotypically and genetically."
    explanation: The overlap that makes this differential a spectrum question rather than a clean split.
- name: Dysplasia epiphysealis hemimelica (Trevor disease)
  description: >-
    A non-hereditary developmental cartilaginous overgrowth of one or more
    epiphyses, usually on one side (medial more than lateral) of a single
    lower limb. Like osteochondromas the lesions are diagnosed in childhood
    and stop growing at skeletal maturity, but they are epiphyseal rather
    than metaphyseal, unilateral, not inherited, and malignant transformation
    has not been reported.
  disease_term:
    preferred_term: dysplasia epiphysealis hemimelica
    term:
      id: MONDO:0007489
      label: dysplasia epiphysealis hemimelica
  distinguishing_features:
  - Epiphyseal, not metaphyseal, overgrowth; hemimelic distribution in one limb
  - No genetic transmission; no reported malignant transformation
  evidence:
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MO should be distinguished from metachondromatosis, dysplasia epiphysealis hemimelica and Ollier disease."
    explanation: The review names it in the differential.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Similar to osteochondroma, DEH is usually diagnosed prior to the age of 15 years, more often in boys than in girls, and growth of these lesions end at puberty as the growth plates close"
    explanation: The shared timing that makes it a differential.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      In contrast to MO, malignant transforma-
      tion has not been reported so far
    explanation: >-
      No reported malignant transformation, unlike this disorder; quoted
      with the source PDF's line break.
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and there does not appear to be any genetic transmission"
    explanation: Dysplasia epiphysealis hemimelica is not inherited, unlike this autosomal dominant disorder.
- name: Ollier disease
  description: >-
    Non-hereditary enchondromatosis: multiple cartilage tumours inside the
    medullary cavity, with a predilection for the short tubular bones of the
    hands and feet and a unilateral predominance, rather than surface
    exostoses with cortical continuity.
  disease_term:
    preferred_term: Ollier disease
    term:
      id: MONDO:0008145
      label: Ollier disease
  distinguishing_features:
  - Intramedullary enchondromas rather than surface osteochondromas
  - Short tubular bones of hands and feet; unilateral predominance; not inherited
  evidence:
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(Ollier disease and Maffucci syndrome), in which multiple cartilage tumours are found in the medulla of bone, with a predilection for the short tubular bones and a unilateral predominance"
    explanation: The location and distribution that separate enchondromatosis from this disorder.
- name: Maffucci syndrome
  description: >-
    Enchondromatosis with soft-tissue haemangiomas. As for Ollier disease the
    cartilage tumours are intramedullary and favour the hands and feet; the
    vascular lesions are the added distinguishing feature.
  disease_term:
    preferred_term: Maffucci syndrome
    term:
      id: MONDO:0013808
      label: Maffucci syndrome
  distinguishing_features:
  - Intramedullary enchondromas plus soft-tissue haemangiomas
  - Not inherited; no EXT1/EXT2 variant
  evidence:
  - reference: PMID:18271966
    reference_title: Multiple osteochondromas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "(Ollier disease and Maffucci syndrome), in which multiple cartilage tumours are found in the medulla of bone, with a predilection for the short tubular bones and a unilateral predominance"
    explanation: The review groups it with Ollier disease as enchondromatosis to be distinguished from this disorder.
- name: Langer-Giedion syndrome (trichorhinophalangeal syndrome type II)
  description: >-
    A contiguous 8q23-q24 deletion that removes EXT1 together with TRPS1
    (and RAD21), so the multiple exostoses of this disorder occur alongside
    the trichorhinophalangeal features (sparse hair, bulbous nose,
    cone-shaped epiphyses), ectodermal anomalies and, in some, intellectual
    disability. A child with osteochondromas plus dysmorphic features or
    developmental delay should have chromosomal microarray rather than
    EXT1/EXT2 sequencing alone.
  disease_term:
    preferred_term: Langer-Giedion syndrome
    term:
      id: MONDO:0007874
      label: trichorhinophalangeal syndrome type II
  distinguishing_features:
  - Facial dysmorphism, sparse hair, cone-shaped epiphyses and possible intellectual disability in addition to exostoses
  - Contiguous 8q23q24 deletion including TRPS1 and EXT1 on microarray, not an intragenic EXT1/EXT2 variant
  evidence:
  - reference: PMID:35290978
    reference_title: Minimal Critical Region and Genes for a Typical Presentation of Langer-Giedion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Langer-Giedion syndrome (LGS) is caused by a contiguous deletion at 8q23q24, characterized by exostoses, facial, ectodermal, and skeletal anomalies, and, occasionally, intellectual disability."
    explanation: The contiguous-deletion basis and the added features that distinguish it.
  - reference: PMID:35290978
    reference_title: Minimal Critical Region and Genes for a Typical Presentation of Langer-Giedion Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings suggest a 3.2-Mb critical region for a typical presentation of the syndrome, emphasizing the contribution of the TRPS1, RAD21, and EXT1 genes' haploinsufficiency, and facial dysmorphisms as well as bone anomalies as the most frequent features among patients with LGS."
    explanation: EXT1 haploinsufficiency within the deleted region is what produces the exostoses.
  - reference: PMID:7550340
    reference_title: Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In a majority of families, the genetic defect (EXT1) is linked to the Langer-Giedion syndrome chromosomal region in 8q24.1."
    explanation: The shared locus behind the overlap.
clinical_trials:
- name: NCT03442985
  phase: PHASE_II
  status: TERMINATED
  description: >-
    MO-Ped: a randomised, double-blind, placebo-controlled phase 2 trial of two
    doses of palovarotene in children with multiple osteochondromas, terminated
    after a partial clinical hold over premature physeal closure; no efficacy
    signal in the truncated dataset.
  evidence:
  - reference: clinicaltrials:NCT03442985
    reference_title: "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO)."
    explanation: The registry summary of the trial design.
  - reference: PMID:41188357
    reference_title: "Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Due to concerns of premature physeal closure (PPC), a partial clinical hold was instituted, followed by trial termination."
    explanation: Source of the TERMINATED status.
animal_models:
- name: Clonal chondrocyte Ext1 inactivation mouse (Jones 2010)
  species: Mouse
  genotype: Ext1 conditional (head-to-head loxP) with tamoxifen-inducible Cre in chondrocytes, producing mosaic homozygous Ext1 loss
  publication: PMID:20080592
  description: >-
    The model that settled the second-hit question. Rather than the germline
    heterozygous genotype, which had failed to produce long-bone lesions, it
    models the chimeric tissue genotype of somatic loss of heterozygosity by
    inactivating both Ext1 alleles in a scattered subset of chondrocytes. The
    mice develop multiple metaphyseal osteochondromas, the lesion chondrocytes
    are Ext1-null, and they derive from proliferating physeal chondrocytes.
  modeled_mechanisms:
  - target: Somatic Second Hit in Growth-Plate Chondrocytes
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: CELLULAR
    description: Engineered biallelic Ext1 loss in a clone of physeal chondrocytes on a wild-type-competent background.
    limitations: >-
      The second hit is induced by Cre at a chosen time and in a chosen cell
      type rather than arising stochastically on a germline heterozygous
      background, so the model shows sufficiency of clonal loss but not the
      natural rate or timing of second hits in patients.
    evidence:
    - reference: PMID:20080592
      reference_title: A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We also confirm homozygous disruption of Ext1 in osteochondroma chondrocytes and their origin in proliferating physeal chondrocytes. These results explain prior modeling failures with the necessity for somatic LOH in a developmentally regulated cell type."
      explanation: The model demonstrates the cell of origin and the necessity of somatic loss of heterozygosity.
  - target: Osteochondroma Formation by Ectopic Endochondral Ossification
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: TISSUE
    description: Multiple metaphyseal osteochondromas of the human type.
    evidence:
    - reference: PMID:20080592
      reference_title: A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These mice faithfully recapitulate the human phenotype of multiple metaphyseal osteochondromas."
      explanation: The authors' own statement of phenotype fidelity.
- name: Stochastic chondrocyte-specific Ext1 knockout mouse (Matsumoto 2010)
  species: Mouse
  genotype: Fsp1-Cre; Ext1flox/flox, stochastic chondrocyte-specific Ext1 inactivation
  publication: PMID:20534475
  description: >-
    Independent mosaic model in which Ext1 is inactivated stochastically in a
    small fraction of chondrocytes. It reproduces the human pattern and
    frequency of osteochondromas and bone deformities, and it added the
    finding that lesions are mixtures of mutant and wild-type cells lacking
    most neoplastic properties. It is the model used for the palovarotene and
    BMP-antagonist preclinical work.
  modeled_mechanisms:
  - target: Osteochondroma Formation by Ectopic Endochondral Ossification
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: TISSUE
    description: Osteochondromas in a pattern and frequency almost identical to human disease.
    limitations: >-
      Lesions are induced by stochastic Cre activity rather than by somatic
      mutation on a germline heterozygous background, and the model does not
      reproduce the pain, adult complications or malignant transformation of
      the human disease.
    evidence:
    - reference: PMID:20534475
      reference_title: A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We show that these mice develop multiple osteochondromas and characteristic bone deformities in a pattern and a frequency that are almost identical to those of human MHE, suggesting a role for Ext1 LOH in MHE."
      explanation: Phenotype fidelity as stated by the authors.
  - target: Somatic Second Hit in Growth-Plate Chondrocytes
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Shows that Ext1 loss in a small fraction of chondrocytes suffices, but
      also that the resulting lesion is a mixed mutant/wild-type mass rather
      than a clone, which complicates a strict two-hit tumour-suppressor
      reading.
    limitations: >-
      The lesion is not clonal and lacks neoplastic properties, so the model
      supports the second hit as an initiating event but argues against
      osteochondroma as a true clonal neoplasm; the human lesion may differ,
      since human caps can carry homozygous EXT1 deletion.
    evidence:
    - reference: PMID:20534475
      reference_title: A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Together, our results suggest that inactivation of Ext1 in a small fraction of chondrocytes is sufficient for the development of osteochondromas and other skeletal defects associated with MHE."
      explanation: Sufficiency of focal inactivation.
    - reference: PMID:20534475
      reference_title: A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Because the observed osteochondromas in our mouse model do not arise from clonal growth of chondrocytes, they cannot be considered true neoplasms."
      explanation: The non-clonal finding that limits the two-hit reading.
- name: Ext2 heterozygous knockout mouse (Stickens 2005)
  species: Mouse
  genotype: Ext2+/- (targeted null allele); Ext2-/- is embryonic lethal at gastrulation
  publication: PMID:16236767
  description: >-
    The germline-genotype model. Heterozygotes carry exactly the genotype of a
    patient, yet only about a third form any exostosis and those are on the
    ribs; long bones are largely spared. All of them nonetheless show
    disorganised growth-plate cartilage and premature hypertrophy, which the
    authors could not attribute to a hedgehog defect. Homozygous loss arrests
    the embryo at gastrulation.
  modeled_mechanisms:
  - target: Osteochondroma Formation by Ectopic Endochondral Ossification
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: TISSUE
    description: Sporadic rib exostoses in about a third of animals; no stereotypic long-bone lesions.
    limitations: >-
      Despite carrying the human germline genotype, the heterozygote is highly
      resistant to the long-bone osteochondromas that define the human
      disease, which is the model failure that motivated the second-hit
      models.
    evidence:
    - reference: PMID:16236767
      reference_title: Mice deficient in Ext2 lack heparan sulfate and develop exostoses.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Heterozygotes had a normal lifespan and were fertile; however, analysis of their skeletons showed that about one-third of the animals formed one or more ectopic bone growths (exostoses)."
      explanation: The partial, low-penetrance lesion phenotype.
  - target: Growth-Plate Tethering and Disturbed Longitudinal Bone Growth
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: Growth-plate disorganisation and premature hypertrophy in every heterozygote, without the lesions.
    limitations: >-
      The cartilage changes occur without osteochondromas, so the model
      isolates the haploinsufficiency contribution to growth-plate disturbance
      but cannot show the mechanical tethering component.
    evidence:
    - reference: PMID:16236767
      reference_title: Mice deficient in Ext2 lack heparan sulfate and develop exostoses.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Significantly, all of the mice showed multiple abnormalities in cartilage differentiation, including disorganization of chondrocytes in long bones and premature hypertrophy in costochondral cartilage."
      explanation: Fully penetrant growth-plate disorganisation from haploinsufficiency.
- name: Compound Ext1+/-;Ext2+/- heterozygous mouse (Zak 2011)
  species: Mouse
  genotype: Ext1+/-; Ext2+/- compound heterozygote
  publication: PMID:21310272
  description: >-
    The dosage model. Halving both subunits of the copolymerase, without any
    second hit, roughly doubles the number of outgrowths relative to a single
    heterozygote and, unlike either single heterozygote, produces stereotypic
    growth-plate-like exostoses along the long bones. The lesions contain very
    little heparan sulfate and the cells make shortened chains. It shows that
    exostosis incidence is inversely related to Ext dosage and that complete
    loss is not required.
  modeled_mechanisms:
  - target: Systemic Heparan Sulfate Insufficiency
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: MOLECULAR
    description: Shortened heparan sulfate chains and reduced growth-factor responsiveness in multiple cell types.
    evidence:
    - reference: PMID:21310272
      reference_title: Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Ext1(+/-)Ext2(+/-) exostoses contained very low levels of immuno-detectable heparan sulfate, and Ext1(+/-)Ext2(+/-) chondrocytes, endothelial cells and fibroblasts in vitro produced shortened heparan sulfate chains compared to controls and responded less vigorously to exogenous factors such as FGF-18."
      explanation: The molecular readout of dosage-dependent deficiency.
  - target: Osteochondroma Formation by Ectopic Endochondral Ossification
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: Stereotypic growth-plate-like long-bone exostoses from dosage reduction alone.
    limitations: >-
      Patients are heterozygous at one locus, not both, so the model achieves
      by compound dosage what the human disease achieves focally; it shows a
      sufficient condition rather than the human route.
    evidence:
    - reference: PMID:21310272
      reference_title: Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "However, compound heterozygous mice had nearly twice as many outgrowths and, more importantly, displayed stereotypic growth plate-like exostoses along their long bones."
      explanation: The dosage-driven long-bone lesion phenotype.
discussions:
- discussion_id: hmo_second_hit_versus_dosage
  prompt: >-
    Does every human osteochondroma require a somatic second hit in EXT1 or
    EXT2, or is regional heparan sulfate dosage below a threshold sufficient,
    with the second hit one route among several?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic Second Hit in Growth-Plate Chondrocytes
  - pathophysiology#Systemic Heparan Sulfate Insufficiency
  rationale: >-
    The mouse data point both ways. Clonal or stochastic biallelic Ext1 loss
    in chondrocytes reproduces the disease and single heterozygotes do not,
    which argues for a required second hit; but compound Ext1/Ext2
    heterozygotes form stereotypic long-bone exostoses with no second hit,
    and the same group showed incidence is inversely and continuously related
    to Ext expression. In human lesions loss of heterozygosity is found in a
    subset, homozygous deletion is confined to the cartilage cap, and the
    lesion is a mixture of mutant and wild-type cells, so the fraction of
    caps carrying a demonstrable second hit is well below one. Whether the
    remainder reflect undetected second hits, epigenetic silencing, or
    dosage alone is not known, and the answer determines whether HMO is a
    tumour-suppressor disease or a dosage-threshold disease with a
    tumour-suppressor-like presentation.
  proposed_experiments:
  - experiment_id: hmo_cap_single_cell_genotyping
    name: Single-cell genotyping and heparan sulfate quantification of human cartilage caps
    description: >-
      Genotype the EXT locus and measure heparan sulfate per cell across the
      cartilage cap, perichondrium and stalk of resected human osteochondromas
      from germline-confirmed patients, to establish what fraction of caps
      contain any biallelic-null cells, how those cells are distributed, and
      whether caps without a detectable second hit have heparan sulfate levels
      below those of caps with one.
- discussion_id: hmo_heterozygous_mouse_resistance
  prompt: >-
    Why does the germline heterozygous mouse, which carries the exact human
    genotype, fail to form the long-bone osteochondromas that define the
    human disease?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Germline Heterozygous Loss-of-Function Variant in EXT1 or EXT2
  - pathophysiology#Osteochondroma Formation by Ectopic Endochondral Ossification
  rationale: >-
    Ext1+/- and Ext2+/- mice are highly resistant to osteochondroma
    formation, especially in long bones, and form only occasional rib
    outgrowths, yet in humans the same genotype is essentially fully
    penetrant. The mismatch is mechanistically informative rather than a
    nuisance: it is what forced the field to the second-hit and dosage models.
    Candidate explanations include a lower somatic mutation rate over the
    much shorter murine growth period, a different threshold of heparan
    sulfate below which the perichondrial border fails, and species
    differences in growth-plate architecture and duration. None has been
    tested directly, and the answer matters for any attempt to use dosage or
    second-hit rate as a prognostic variable in patients.
  proposed_experiments:
  - experiment_id: hmo_heterozygote_second_hit_rate
    name: Measure spontaneous second-hit frequency in heterozygous mouse and human growth plates
    description: >-
      Use lineage-traced reporter alleles at the Ext locus in Ext1+/- mice,
      and deep sequencing of microdissected physeal cartilage from
      heterozygous patients undergoing surgery, to estimate the rate of
      spontaneous loss of the wild-type allele per cell per unit of growth in
      each species, and test whether the difference in rate accounts for the
      difference in lesion penetrance.
- discussion_id: hmo_malignant_transformation_determinants
  prompt: >-
    What determines which cartilage cap transforms to secondary peripheral
    chondrosarcoma, and is the EXT1 excess of sarcomas real?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Malignant Transformation of the Cartilage Cap
  rationale: >-
    Transformation is a few per cent over a lifetime, mostly low grade,
    mostly pelvic and mostly adult, and the risk factors are unresolved: one
    prospective genotype-phenotype study found seven sarcomas in EXT1 carriers
    against one in EXT2, while a larger 529-patient series found no
    association with genotype, sex, severity or lesion count. Nothing in the
    mouse models transforms, so there is no experimental system for the step.
    The molecular events downstream of the heparan-sulfate-deficient cap that
    convert it are curated in the Chondrosarcoma entry
    (Chondrosarcoma:pathophysiology#Secondary Peripheral Malignant
    Transformation); this discussion records the gap on the HMO side, which
    is the absence of any predictor better than cap thickness and post-maturity
    growth.
  proposed_experiments:
  - experiment_id: hmo_registry_transformation_risk_model
    name: Registry-based genotype-stratified transformation risk model
    description: >-
      Use a large longitudinal registry with confirmed genotypes to estimate
      transformation incidence by gene, variant class, sex, lesion count and
      site with adequate power, and test whether cap thickness at skeletal
      maturity predicts later transformation, which would turn a warning sign
      into a surveillance criterion.
- discussion_id: hmo_ptpn11_overlap
  prompt: >-
    Are PTPN11 loss-of-function variants in osteochondroma-only probands
    evidence of a third HMO gene, or of misclassified metachondromatosis?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - genetic#
  rationale: >-
    A 2024 cohort of 244 unrelated probands found PTPN11 loss-of-function
    variants in five probands with osteochondromas and no enchondromas, and
    EXT1/EXT2 variants in two with enchondromas, and proposed a phenotypic
    and genetic overlap between HMO and metachondromatosis. This entry does
    not add PTPN11 as a causal gene: enchondromas can be missed on
    conventional imaging, metachondromatosis lesions regress and point toward
    joints, and five cases do not establish a locus. The finding does mean
    that an EXT-negative patient should have PTPN11 sequenced, and it is
    recorded here so that it is not re-nominated as new.
  evidence:
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Specifically, we identified five cases with OCs and no ECs as well as four cases with MC carrying LoF variants in the PTPN11 gene and two additional cases with ECs harboring variants in the EXT1/2 genes."
    explanation: The observation behind the open question.
  - reference: PMID:40225915
    reference_title: "The Missing Piece of the Puzzle: Unveiling the Role of PTPN11 Gene in Multiple Osteochondromas in a Large Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is essential to determine whether MO and MC represent distinct diseases or if they encompass a broader clinical spectrum."
    explanation: The authors themselves leave the question open.
- discussion_id: hmo_palovarotene_translation
  prompt: >-
    Why did a drug that prevents 91% of osteochondromas in Ext1-deficient
    mice show no efficacy signal in children, and is the question closed?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Loss of Perichondrial Border Function and Ectopic Chondrogenesis
  - treatments#Palovarotene (investigational; MO-Ped trial terminated)
  rationale: >-
    Palovarotene is the only mechanism-directed drug to reach a randomised
    trial in HMO, and the trial was negative on the truncated data. The mouse
    result is robust and mechanistically coherent, so the discrepancy is
    informative: possibilities include that the mouse model's stochastic
    Cre-driven lesions are more retinoid-sensitive than second-hit human
    lesions, that the human dose was limited by physeal toxicity to below the
    effective range, and that twelve months in 30 children is simply too
    little to see an effect on annualised lesion rate. The trial's own
    authors say interpretation was limited by reduced treatment duration and
    a smaller than expected cohort, so the question is not closed, but any
    successor must first solve the growth-plate safety problem that stopped
    this one.
  evidence:
  - reference: PMID:41188357
    reference_title: "Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No significant differences in the annualized rate of new OCs, or change from baseline in volume of OCs or OC cartilage, were observed between treatment groups."
    explanation: The null efficacy result.
  - reference: PMID:29120519
    reference_title: Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Four-week daily treatment with PVO starting at postnatal day (P) 14 reduced the number of osteochondromas that develop in these mice by up to 91% in a dose-dependent manner."
    explanation: The preclinical result the trial failed to reproduce.

📚

References & Deep Research

References

3

PMID:20301413

Hereditary Multiple Osteochondromas.

No top-level findings curated for this source.

PMID:18271966

Multiple osteochondromas.

No top-level findings curated for this source.

PMID:19810120

Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb).

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Scope and lump/split. This entry is the disease-level concept MONDO:0005508 and carries the two OMIM-defined genetic types as `has_subtypes`: EXT1-related (MONDO:0007585, exostoses, multiple, type 1) and EXT2-related (MONDO:0007586, type 2). The two are curated together because the mechanism is identical at every node, the genes encode the two halves of one enzyme complex, and the phenotypes differ only in degree. The historical "EXT3" locus on 19p (MONDO:0010846, exostoses, multiple, type III) was mapped by linkage and never resolved to a gene; it is mentioned here and not entered as a subtype. The Langer-Giedion syndrome (trichorhinophalangeal syndrome type II), a contiguous-gene deletion of 8q24 removing EXT1 together with TRPS1, produces multiple osteochondromas as one feature of a broader syndrome and is a separate entry, not a subtype of this one. Metachondromatosis (PTPN11) is a differential diagnosis rather than a subtype; the 2024 cohort finding of PTPN11 loss-of-function variants in a few osteochondroma-only probands is recorded as an open question, not as a third causal gene. Module conformance deliberately not declared. The obvious candidate, `hedgehog_pathway_activation`, scopes itself to ligand-independent, constitutive SMO-GLI activation in neoplasms driven by PTCH1/PTCH2/SUFU loss or SMO gain, and defines the SMO-inhibitor mechanism of action. HMO is a different kind of hedgehog disturbance: the ligand is still Indian hedgehog, the receptor machinery is intact, and what changes is the diffusion range of the ligand because heparan sulfate no longer holds it near its source. The Ext2-heterozygous mouse in fact showed cartilage changes that were not attributable to a hedgehog defect at all, and BMP and FGF handling are disturbed in the same lesions. Conforming to a constitutive-SMO module would therefore assert a mechanism the entry does not claim and would wrongly suggest SMO antagonism as the drug pattern. The malignant branch is likewise not conformed to the Chondrosarcoma entry's nodes: that entry already carries an "EXT1/EXT2 Heparan Sulfate Polymerization Failure" node and a "Secondary Peripheral Malignant Transformation" node, so this entry stops at the transformation threshold and points across in prose and in a discussion rather than re-modelling chondrosarcoma biology. Evidence-source conventions. GeneReviews sentences are graded OTHER. Bovée's 2008 Orphanet review is graded HUMAN_CLINICAL where the quoted sentence reports a human clinical or epidemiological fact and OTHER where it states a management recommendation. The Sgariglia 2013 perichondrium paper mixes conditional-knockout mouse work with explant and micromass culture, so its sentences are graded individually: the conditional-ablation and summary sentences MODEL_ORGANISM, the BMP2-binding sentence IN_VITRO. The Hameetman 2007 homozygous-deletion finding concerns sporadic, nonhereditary osteochondromas and is cited with directness INDIRECT for the second-hit node. The gene-level `genetic` blocks do not repeat the inheritance object; the disease-level `inheritance` block is the single source for mode of inheritance, penetrance and de novo rate. The surveillance treatment is bound to NCIT Cancer Screening because the generic Surveillance, Patient Observation, Follow-Up and Patient Monitoring terms are not clinical interventions under NCIT:C25218 and fail the TreatmentActionTerm enum. Provenance. Built from an Edison Falcon deep-research report (research/Hereditary_Multiple_Osteochondromas-deep-research-falcon.md; reference validation 18/18 resolved, no unresolved terms, one obsolete NCIT term which is not used). The report cites by DOI and author-year key; every source used here was resolved to its PubMed record by title search and fetched by PMID, and all snippets are verified against the cached abstracts. Several of the report's suggested CURIEs were wrong on inspection and were not used: HP:0000934 is chondrocalcinosis, not multiple exostoses (HP:0002762 is); HP:0002970 is genu varum, not valgum (HP:0002857); CHEBI:177944 is a flavanone, not palovarotene (CHEBI:188559); and the proposed NCIT procedure codes named unrelated procedures. The classic primary papers (Ahn 1995, Stickens 1996, Wuyts 1998, McCormick 1998 and 2000, Lind 1998, Koziel 2004, Hameetman 2007, Jones 2010, Matsumoto 2010, Zak 2011, Sgariglia 2013, Schmale 1994, Wicklund 1995, Porter 2004, Pedrini 2011, Jennes 2009) were located directly on PubMed.

Address review: diagnosis section · 2026-09-19T20:51:30Z · View source

Addressed the automated review's blocking finding that the entry had no diagnosis section. Added diagnosis with four items: (1) clinical and radiographic diagnosis on the two-or-more-osteochondromas criterion, bound to NCIT:C137876 Bone Radiography and quoting the GeneReviews (PMID:20301413) statement of how the diagnosis is established plus the Bovee 2008 (PMID:18271966) two-lesion criterion and the Borovikov 2024 (PMID:40225915) restatement; (2) cross-sectional imaging (CT for complex sites, MRI for the cartilage cap, ultrasound for superficial caps) bound to NCIT:C16809 MRI, quoting the Bovee T2-weighted MRI cap-measurement sentence and the GeneReviews screening spine MRI dispute, with the ladder itself attributed to the Falcon deep-research report in the description; (3) evaluation of suspected malignant transformation, quoting Gnoli 2024 (PMID:38351015) for the 1.5-2 cm and WHO 2020 greater-than-2 cm cap thresholds and Bovee 2008 for the 1 cm lower bound, with the report's 3 cm paediatric threshold stated as unquoted; (4) EXT1/EXT2 sequencing then deletion/duplication (MLPA) analysis bound to NCIT:C15709 Genetic Testing, quoting GeneReviews, Borovikov (CNV analysis as gold standard, PTPN11 expansion), Gnoli (sequencing-then-MLPA order) and Bovee (MLPA reducing the mutation-negative fraction to under 15 percent). Added biochemical: blood heparan sulfate to chondroitin sulfate ratio (presence DECREASED) bound to NCIT:C540 Heparan Sulfate per the composite-index convention, quoting PMID:23514715, with a READOUT_OF readout link (direction NEGATIVE, endpoint_context DIAGNOSTIC) to the Systemic Heparan Sulfate Insufficiency node. Added differential_diagnoses: solitary osteochondroma (PMID:17341731; no MONDO term exists for the sporadic lesion), metachondromatosis MONDO:0007979, dysplasia epiphysealis hemimelica MONDO:0007489, Ollier disease MONDO:0008145, Maffucci syndrome MONDO:0013808, Langer-Giedion syndrome MONDO:0007874 (new reference PMID:35290978 fetched via just fetch-reference). All NCIT diagnosis terms verified via OLS and present in the TreatmentActionTerm enum cache; MONDO terms verified via OLS and added to the term and enum caches by validate-terms. Validation: just validate passed; count-verified-snippets 164/164; validate-terms passed; normalize-cache clean; check-entity-refs, check-causal-targets, check-enum-values OK; check_snippet_length, check-snippet-grading and check-title-snippets report no new findings; validate-disorders passed.

Create: Hereditary Multiple Osteochondromas (MONDO:0005508) · 2026-09-18T14:28:15Z · View source

New entry curated from the Edison Falcon deep-research report research/Hereditary_Multiple_Osteochondromas-deep-research-falcon.md with report DOIs resolved to PMIDs through PubMed and all snippets quoted from cached abstracts; the GeneReviews chapter PMID:20301413 is tagged and its clinical characteristics are covered. Ten-node pathograph: germline heterozygous loss-of-function in EXT1 or EXT2, reduced EXT1-EXT2 heparan sulfate copolymerase activity, systemic heparan sulfate insufficiency, somatic second hit in growth-plate chondrocytes, disrupted heparan-sulfate-dependent morphogen signalling (Indian hedgehog range, BMP and FGF handling), loss of perichondrial border function with ectopic chondrogenesis, osteochondroma formation by ectopic endochondral ossification, growth-plate tethering with disturbed longitudinal growth, mechanical impingement, and malignant transformation of the cartilage cap. Lump/split: the disease-level term MONDO:0005508 carries EXT1 (MONDO:0007585, the claim and stub key) and EXT2 (MONDO:0007586) as has_subtypes because the mechanism is identical at every node and the genes encode the two halves of one enzyme; the historical EXT3 locus is mentioned only; Langer-Giedion syndrome is a separate entry; metachondromatosis (PTPN11) is a differential and the 2024 PTPN11 finding in osteochondroma-only probands is recorded as an open question. Module conformance deliberately not declared: hedgehog_pathway_activation scopes itself to ligand-independent SMO-GLI activation in neoplasms, whereas HMO is a ligand-diffusion-range defect with intact receptor machinery. Secondary peripheral chondrosarcoma is recorded as the malignant complication with a link to the existing Chondrosarcoma entry rather than re-modelled. The palovarotene MO-Ped trial is recorded honestly as stopped. Validated: just validate passed; count-verified-snippets 127/127; validate-terms, check-entity-refs, check-causal-targets, check-enum-values and check-duplicate-keys passed; pytest -k Hereditary_Multiple_Osteochondromas passed. A first attempt at this curation was cut off by a session limit before writing; this record describes the completed second pass.

Falcon ▸

Hereditary Multiple Osteochondromas: Disease Characteristics Research Report

Edison Scientific Literature 44 citations 2026-09-04T23:39:29.499948

Hereditary Multiple Osteochondromas: Disease Characteristics Research Report

Scope. This report synthesizes disease-level resources, human cohorts, molecular studies, clinical-trial records, and model-organism evidence. Evidence is aggregated rather than derived from an individual electronic health record, except where a cited study explicitly analyzed clinical records. Literature was prioritized through 2024; a 2025 imaging review is used only where it clarifies current diagnostic practice.

Executive summary

Hereditary multiple osteochondromas (HMO), historically called hereditary multiple exostoses (HME), is a highly penetrant autosomal-dominant skeletal tumor-predisposition disorder. Multiple cartilage-capped osteochondromas arise near growth plates during childhood, enlarge during skeletal growth, and usually become quiescent after physeal closure. Heterozygous loss-of-function variants in EXT1 or EXT2, encoding the Golgi heparan-sulfate polymerase complex, explain approximately 70–95% of clinically diagnosed cases. A local somatic second hit and severe focal heparan-sulfate deficiency are strongly supported as the initiating events in many osteochondromas. Clinical morbidity includes deformity, impaired growth, restricted motion, neurovascular compression, pain, fatigue, repeated surgery, and a small but important risk of secondary peripheral chondrosarcoma. There is no approved disease-modifying treatment; management remains surveillance, symptom-directed surgery, pain care, and rehabilitation. Recent 2024 work expanded the detectable variant spectrum, implicated mosaic structural variants and possible PTPN11 overlap, quantified major adult pain/fatigue burden, and demonstrated palovarotene activity against established lesions in mice—but not established clinical benefit in HMO. (borovikov2024themissingpiece pages 1-2, gnoli2024secondaryperipheralchondrosarcoma pages 1-2, amajjar2024painandfatigue pages 1-2, garcia2024analysisofthe pages 1-2)

The following table provides a compact knowledge-base summary.

Domain	Curated fact	Quantitative evidence	Suggested ontology IDs	Strongest source/date
Disease identity	Hereditary multiple osteochondromas (HMO), also called multiple osteochondromas, hereditary multiple exostoses, diaphyseal aclasis, and multiple cartilaginous exostoses, is a Mendelian skeletal disorder producing multiple cartilage-capped, corticomedullary-continuous bone outgrowths.	Diagnostic definition commonly requires ≥2 osteochondromas.	MONDO:0005508; Orphanet:321; OMIM:133700 and 133701	Open Targets (OpenTargets Search: hereditary multiple osteochondromas-EXT1,EXT2); D’Arienzo et al., 20-Dec-2019, DOI:10.2147/ORR.S183979 (darienzo2019hereditarymultipleexostoses pages 1-2)
Causal genes	Heterozygous loss-of-function variants in EXT1 or EXT2 are the principal causes; their Golgi-resident glycosyltransferase complex polymerizes heparan sulfate.	EXT1/EXT2 variants explain approximately 70–95% of cases; earlier studies reported EXT1 in 28–65% and EXT2 in 21–61%.	HGNC:3512 (EXT1); HGNC:3513 (EXT2); GO:0000139, Golgi membrane; GO:0015012, heparan sulfate proteoglycan biosynthetic process	Open Targets (OpenTargets Search: hereditary multiple osteochondromas-EXT1,EXT2); PMID:10639137; PMID:11391482 (pacifici2018hereditarymultipleexostoses pages 7-9, pacifici2017hereditarymultipleexostoses pages 12-13)
Inheritance and prevalence	HMO is autosomal dominant with variable expressivity and nearly complete, partly sex-dependent penetrance.	Prevalence approximately 1:50,000 in Western populations; reported penetrance approximately 100% in males and 96% in females; recurrence risk for an affected heterozygous parent is 50% per pregnancy.	HP:0000006, autosomal dominant inheritance; HP:0003829, incomplete penetrance	D’Arienzo et al., 2019, DOI:10.2147/ORR.S183979 (darienzo2019hereditarymultipleexostoses pages 1-2)
Onset and course	Lesions are rarely apparent at birth, emerge in early childhood, enlarge while physes are open, and generally stop growing at skeletal maturity.	Median diagnosis approximately 3 years; visible lesion in 50% by age 5 and 80% by age 10; >80% present during the first decade.	HP:0011463, childhood onset; HP:0003674, onset in infancy	Tepelenis et al., Jan-2021, DOI:10.21873/invivo.12308 (tepelenis2021osteochondromasanupdated pages 1-2, tepelenis2021osteochondromasanupdated pages 2-3)
Core phenotype	Multiple sessile or pedunculated cartilage-capped osteochondromas arise mainly near growth plates and on surfaces of flat bones.	Mean reported burden approximately six lesions; common sites include distal femur 30%, proximal tibia 15–20%, and humerus 10–20%.	HP:0000934, multiple exostoses; HP:0030434, osteochondroma	Tepelenis et al., 2021, DOI:10.21873/invivo.12308 (tepelenis2021osteochondromasanupdated pages 1-2, tepelenis2021osteochondromasanupdated pages 2-3)
Musculoskeletal morbidity	Common consequences include short or disproportionate stature, limb bowing, forearm deformity, genu or ankle valgum, limb-length inequality, restricted joint motion, bursitis, and premature osteoarthritis.	In 158 children, 80.4% developed new lesions, 57.6% new deformities, and 23.4% new functional limitations; 46.2% showed progression.	HP:0004322, short stature; HP:0002970, genu valgum; HP:0001376, limitation of joint mobility; HP:0002814, abnormality of the lower limb	Mordenti et al., Oct-2020, DOI:10.1016/j.bone.2020.115499 (mordenti2020thenaturalhistory pages 1-6)
Pain, fatigue, and quality of life	Chronic mechanical pain and fatigue substantially impair physical, psychosocial, occupational, and social functioning in adults.	Among 353 adults, pain affected 87.8% (NRS 3.19±2.6) and fatigue 90.4% (NRS 4.1±2.6); CIS fatigue was 84.1±15.3 and exceeded healthy and rheumatoid-arthritis references (p<0.001).	HP:0012531, pain; HP:0012378, fatigue	Amajjar et al., 17-Jul-2024, DOI:10.1371/journal.pone.0305640 (amajjar2024painandfatigue pages 1-2)
Pathogenesis	Germline EXT haploinsufficiency lowers systemic heparan sulfate; a local somatic second hit can create EXT-null growth-plate or perichondrial cells, disrupting morphogen distribution and promoting ectopic chondrogenesis.	Human blood shows an approximately 50% reduction in the heparan-sulfate:chondroitin-sulfate ratio; loss of heterozygosity was found in 6 of 8 analyzed osteochondromas in one series.	GO:0030201, heparan sulfate proteoglycan metabolic process; GO:0061035, regulation of cartilage development; CL:0000138, chondrocyte	PMID:23514715; PMIDs:10441575, 17341731, 20813973 (pacifici2017hereditarymultipleexostoses pages 12-13, pacifici2017hereditarymultipleexostoses pages 10-12, pacifici2018hereditarymultipleexostoses pages 7-9)
Signaling consequences	Heparan-sulfate deficiency alters BMP, Indian hedgehog/PTHrP, FGF–MEK–ERK, and WNT/β-catenin signaling; increased pro-chondrogenic BMP/hedgehog activity and reduced anti-chondrogenic FGF signaling are chiefly supported by model systems.	No validated clinical pathway biomarker or disease-specific omics diagnostic is available.	GO:0030509, BMP signaling pathway; GO:0007224, smoothened signaling pathway; GO:0008543, fibroblast growth factor receptor signaling pathway; GO:0016055, Wnt signaling pathway	Pacifici, Jun-2018, DOI:10.1080/21678707.2018.1483232; PMID:23458899 (pacifici2018hereditarymultipleexostoses pages 12-13, pacifici2018hereditarymultipleexostoses pages 7-9)
Diagnosis	Diagnosis is clinical-radiographic: multiple lesions with continuity of lesion cortex and medulla with the parent bone. Radiography is first line; CT defines complex anatomy, and MRI evaluates cartilage caps, neurovascular or spinal complications, and malignancy.	Suspicious findings include new pain or growth after maturity and cartilage-cap thickness >2 cm in adults or >3 cm in children.	HP:0000934; NCIT:C38101, radiography; NCIT:C16809, magnetic resonance imaging; NCIT:C17204, computed tomography	Tepelenis et al., 2021, DOI:10.21873/invivo.12308 (tepelenis2021osteochondromasanupdated pages 1-2, tepelenis2021osteochondromasanupdated pages 7-8)
Genetic testing	Recommended testing begins with sequencing of EXT1 and EXT2, followed by deletion/duplication analysis; unresolved cases may require genome or RNA analysis for mosaic, deep-intronic, or structural variants. PTPN11 analysis is relevant when metachondromatosis or an overlapping phenotype is suspected.	Conventional EXT testing yields approximately 78–95%; 10–20% can remain unresolved after coding-region and copy-number analysis.	NCIT:C101293, genetic testing; NCIT:C18477, molecular diagnostic testing	Borovikov et al., Feb-2024, DOI:10.1155/2024/8849348 (borovikov2024themissingpiece pages 1-2)
Malignant transformation	The principal life-threatening complication is secondary peripheral chondrosarcoma arising from an osteochondroma cartilage cap; estimates vary by ascertainment, so specialist-center percentages should not be generalized.	Population-oriented estimates are approximately 0.5–5% or up to 3.9%. In 105 affected cases, median diagnosis was 34 years; pelvis accounted for 44%, and grade 2/3 disease or partial resection predicted worse disease-free survival.	NCIT:C121924, secondary peripheral chondrosarcoma; HP:0002664, neoplasm	Gnoli et al., Feb-2024, DOI:10.1186/s13023-023-03006-8 (gnoli2024secondaryperipheralchondrosarcoma pages 1-2)
Management	No approved disease-modifying therapy exists for HMO. Asymptomatic lesions are observed; surgery is used for pain, deformity, functional or neurovascular compromise, fracture, or suspected malignancy. Procedures include complete excision, corrective osteotomy, hemiepiphysiodesis, and limb lengthening.	Complete excision has reported recurrence below 2%; postoperative complications approximately 11.6–12.5%. Evidence that forearm reconstruction improves long-term function or quality of life remains weak.	NCIT:C15329, surgical procedure; NCIT:C52003, excision; NCIT:C51932, osteotomy; NCIT:C15214, rehabilitation	Tepelenis et al., 2021, DOI:10.21873/invivo.12308 (tepelenis2021osteochondromasanupdated pages 7-8); Beltrami et al., May-2016, DOI:10.11138/ccmbm/2016.13.2.110 (beltrami2016hereditarymultipleexostoses pages 7-8)
Recent genetics	A 2024 cohort expanded the recognized genetic overlap with metachondromatosis and showed that restricting testing to EXT1/EXT2 may miss relevant diagnoses.	Among 244 unrelated probands, 177 unique variants were detected across three genes—80 known and 97 novel; five osteochondroma-only cases carried PTPN11 loss-of-function variants.	HGNC:9644 (PTPN11); MONDO:0008162, metachondromatosis	Borovikov et al., Feb-2024, DOI:10.1155/2024/8849348 (borovikov2024themissingpiece pages 1-2)
Experimental therapy	The RARγ agonist palovarotene suppresses osteochondroma growth in mice but is not approved for HMO; pediatric safety concern centers on premature physeal closure.	In mice, treated tumors remained 0.31±0.049 mm³ versus 0.27±0.031 mm³ initially (p=0.66), while controls reached 1.03±0.23 mm³; phase 2 HMO trial NCT03442985 was terminated.	CHEBI:177944, palovarotene; NCIT:C96038, retinoic acid receptor gamma agonist	Garcia et al., 11-Jul-2024, DOI:10.3390/ijms25147610 (garcia2024analysisofthe pages 1-2); ClinicalTrials.gov NCT03442985 (NCT03442985 chunk 2)
Models	Conditional or clonal chondrocyte Ext1 loss, compound Ext1/Ext2 deficiency, and ext2-null zebrafish reproduce aspects of abnormal endochondral ossification and osteochondroma biology. Models strongly support the second-hit/low-heparan-sulfate mechanism but do not capture the full variable human phenotype.	Single heterozygous mice are largely normal; conditional biallelic or compound deficiency produces multiple lesions.	NCBI Taxon:10090, Mus musculus; NCBI Taxon:7955, Danio rerio; CL:0000138, chondrocyte	PMIDs:20080592, 20534475, 21310272, 16236767 (pacifici2017hereditarymultipleexostoses pages 12-13, pacifici2018hereditarymultipleexostoses pages 7-9, pacifici2017hereditarymultipleexostoses pages 1-2)
Research infrastructure	Longitudinal registries integrate clinical, imaging, genetic, surgical, biospecimen, and quality-of-life data to define natural history and genotype–phenotype associations.	Italian REM registry NCT04133285 plans enrollment of 10,000 and follow-up through 2032.	NCIT:C61393, patient registry; NCIT:C15273, longitudinal study	ClinicalTrials.gov NCT04133285, updated Nov-2025 (NCT04133285 chunk 1)

Table: Compact evidence table summarizing the identity, genetics, natural history, clinical burden, diagnosis, management, recent findings, and experimental models of hereditary multiple osteochondromas. Quantitative findings and ontology suggestions are paired with the strongest available cited sources.

1. Disease information

Definition and identifiers

HMO is defined by multiple benign, cartilage-capped bony outgrowths with cortical and medullary continuity with the parent bone. A commonly used clinical/radiologic threshold is at least two juxta-epiphyseal osteochondromas. The lesions are developmental skeletal neoplasms rather than inflammatory “exostoses.” (mordenti2020thenaturalhistory pages 1-6, tepelenis2021osteochondromasanupdated pages 1-2, ruedadeeusebio2025hereditarymultipleexostoses pages 1-2)

MONDO: MONDO:0005508, hereditary multiple osteochondromas.
Orphanet: ORPHA:321, multiple osteochondromas.
OMIM phenotypes: 133700, exostoses, multiple, type 1; 133701, type 2.
MeSH: Multiple Hereditary Exostoses.
ICD: ICD-10-CM commonly uses D16.9 (benign neoplasm of bone and articular cartilage, unspecified) or site-specific D16 codes; Q78.6 is used in some national modifications for multiple congenital exostoses. Coding therefore depends on jurisdiction and should not be treated as a globally uniform disease identifier.
Synonyms: hereditary multiple exostoses, multiple hereditary exostoses, multiple osteochondromas, hereditary multiple osteochondromas, osteochondromatosis, diaphyseal aclasis, hereditary deforming dyschondroplasia, and multiple cartilaginous exostoses. (OpenTargets Search: hereditary multiple osteochondromas-EXT1,EXT2, darienzo2019hereditarymultipleexostoses pages 1-2)

A concise abstract statement is: “Hereditary multiple exostoses (HME), also called hereditary multiple osteochondromas, is a rare genetic disorder characterized by multiple osteochondromas that grow near the growth plates.” (D’Arienzo et al., published 20 December 2019; DOI: https://doi.org/10.2147/ORR.S183979). (darienzo2019hereditarymultipleexostoses pages 1-2)

2. Etiology, risk, and protective factors

Causal and genetic factors

The primary cause is a germline heterozygous loss-of-function variant in EXT1 or EXT2. Both are strongly supported disease targets in Open Targets; EXT1 is ENSG00000182197 and EXT2 is ENSG00000151348. In individual lesions, loss of the remaining functional allele or another somatic event can create an EXT-null clone. Human tumor series have documented loss of heterozygosity, although lesion heterogeneity can obscure it. (OpenTargets Search: hereditary multiple osteochondromas-EXT1,EXT2, pacifici2017hereditarymultipleexostoses pages 12-13, pacifici2017hereditarymultipleexostoses pages 10-12, pacifici2017hereditarymultipleexostoses pages 1-2)

Risk of having HMO is determined principally by carrying a pathogenic germline allele or having an affected parent. EXT1 disease is generally associated with a greater lesion burden, more severe deformity, and possibly greater malignancy risk than EXT2, but marked intra- and interfamilial variability limits individual prediction. Age and skeletal immaturity increase the probability of new lesion formation because lesions arise during active endochondral growth; these are modifiers of expression, not independent causes. (mordenti2020thenaturalhistory pages 1-6, tepelenis2021osteochondromasanupdated pages 2-3, pacifici2017hereditarymultipleexostoses pages 6-7)

Environmental, lifestyle, infectious, and protective factors

No toxin, infection, diet, smoking behavior, occupational exposure, or lifestyle factor is established as a cause of this Mendelian disorder. No validated environmental or genetic protective allele prevents HMO in a pathogenic-variant carrier. Avoiding mechanical irritation may reduce lesion-related symptoms, but it does not prevent osteochondroma initiation. Evidence for clinically important gene–environment interactions is insufficient.

A human biochemical study found a modest effect of EXT1 heterozygosity on postprandial lipid clearance (PMID: 25568062), but this is not evidence that diet causes or protects against HMO. Likewise, the approximately halved heparan-sulfate:chondroitin-sulfate ratio in blood is a consequence of EXT dysfunction, not an exposure biomarker (PMID: 23514715). (pacifici2018hereditarymultipleexostoses pages 7-9, pacifici2017hereditarymultipleexostoses pages 12-13)

3. Phenotypes

Core and associated manifestations

Phenotype and type	Typical characteristics	Frequency/effect	Suggested HPO term
Multiple osteochondromas; physical sign	Rarely evident at birth; childhood onset; increase until skeletal maturity	Defining feature; mean reported burden about six lesions	HP:0000934 Multiple exostoses; HP:0030434 Osteochondroma
Palpable bony masses; sign	Usually painless initially; metaphyseal/juxtaphyseal	50% visible by age 5; 80% by age 10	HP:0000924 Abnormality of the skeletal system
Short/disproportionate stature; sign	Variable; reflects disturbed physeal growth	Qualitatively common	HP:0004322 Short stature; HP:0003508 Proportionate short stature where appropriate
Limb bowing/valgus and length inequality; sign	Progressive during growth; forearm, knee, and ankle prominent	New deformity in 57.6% of one pediatric cohort	HP:0002970 Genu valgum; HP:0003027 Mesomelia; HP:0002814 Abnormality of lower limb
Restricted range of motion; sign/function	Mechanical impingement or deformity; variable	New functional limitations in 23.4% of 158 children	HP:0001376 Limitation of joint mobility
Pain; symptom	Mechanical pressure, bursitis, fracture, osteoarthritis, nerve compression, or malignancy	87.8% of 353 adults; NRS 3.19±2.6	HP:0012531 Pain
Fatigue; symptom	Chronic and strongly associated with psychological factors and pain	90.4%; NRS 4.1±2.6; CIS 84.1±15.3	HP:0012378 Fatigue
Neurovascular compression; complication	Focal neuropathy, vessel displacement, pseudoaneurysm, or rare cord compression	Uncommon but potentially severe	HP:0003477 Peripheral axonal neuropathy or site-specific term; HP:0002176 Spinal cord compression
Scoliosis/axial deformity; sign	Usually growth-associated	Variable	HP:0002650 Scoliosis
Bursitis/fracture/early osteoarthritis; complication	Mechanical sequelae	Variable	HP:0003045 Abnormality of the synovium; HP:0002757 Recurrent fractures if applicable; HP:0002758 Osteoarthritis
Secondary peripheral chondrosarcoma; neoplasm	Usually adult, but pediatric cases occur	Estimated approximately 0.5–5%; ascertainment-dependent	HP:0002664 Neoplasm

In the 158-child natural-history cohort, 80.4% developed new lesions, 57.6% new deformities, 23.4% new functional limitations, and 46.2% met criteria for progression; new lesions appeared in 28.5%, 39.9%, and 50% by 12, 24, and 36 months, respectively. (Mordenti et al., October 2020; DOI: https://doi.org/10.1016/j.bone.2020.115499). (mordenti2020thenaturalhistory pages 1-6)

Quality of life

The strongest recent quantitative evidence is the 2024 Dutch study of 353 adults. Its abstract reports: “Pain was reported by 87.8% … and fatigue by 90.4%.” Fatigue exceeded reference values for both healthy people and rheumatoid-arthritis patients (p<0.001). Fear-avoidance beliefs and fatigue were most strongly associated with pain; anxiety and depression were the strongest correlates in fatigue models. These data favor multidisciplinary management rather than a surgery-only model. (Amajjar et al., published 17 July 2024; DOI: https://doi.org/10.1371/journal.pone.0305640). (amajjar2024painandfatigue pages 1-2)

4. Genetic and molecular information

Genes and proteins

EXT1: chromosome 8q24.11–q24.13; HGNC:3512; OMIM gene 608177.
EXT2: chromosome 11p11–p12; HGNC:3513; OMIM gene 608210.

EXT1 and EXT2 form a Golgi-resident hetero-oligomeric glycosyltransferase complex that alternately adds glucuronic acid and N-acetylglucosamine to elongate heparan-sulfate chains. Functional polymerase activity is supported by PMID 11391482; Golgi complex localization/function by PMID 10639137. (pacifici2018hereditarymultipleexostoses pages 7-9, pacifici2017hereditarymultipleexostoses pages 12-13)

Pathogenic variants and diagnostic yield

The disease mechanism is loss of function/haploinsufficiency followed, in many lesions, by focal biallelic deficiency. Reported variant classes include nonsense, frameshift, canonical splice, missense with proven functional effect, exon or multiexon deletion, whole-gene deletion, and other structural rearrangements. Pathogenic missense calls require caution because loss of function is the established mechanism and some historical missense classifications may be incorrect. Combined EXT1/EXT2 detection ranges from roughly 70–95%; individual historical ranges were 28–65% for EXT1 and 21–61% for EXT2. Causal alleles are rare or absent from population databases as expected for a highly penetrant rare disorder; variant-specific gnomAD frequency must be documented rather than assigning a single disease-wide frequency. (darienzo2019hereditarymultipleexostoses pages 1-2, mordenti2020thenaturalhistory pages 1-6, beltrami2016hereditarymultipleexostoses pages 1-2, pacifici2017hereditarymultipleexostoses pages 6-7)

Important 2024 developments include:

A study of 244 unrelated probands found 177 unique single-nucleotide/copy-number variants across EXT1, EXT2, and PTPN11—80 known and 97 novel. Five patients with osteochondromas but no enchondromas carried PTPN11 loss-of-function variants, suggesting overlap with metachondromatosis rather than proving that PTPN11 is a routine third HMO gene. The abstract states that prior EXT1/EXT2 DNA diagnostic yields were “78 to 95%.” (Borovikov et al., February 2024; DOI: https://doi.org/10.1155/2024/8849348). (borovikov2024themissingpiece pages 1-2)
Mosaic EXT1 deletions involving exons 8–11 and 2–11 were identified by genome/RNA-based investigation after standard tests were negative, supporting low-level mosaicism as one explanation for unresolved disease.
A novel tandem intragenic duplication involving EXT1 exon 4, c.(1128_1202)_(1284+29_1344)dup, demonstrated why dosage testing should accompany sequence analysis. The published abstract notes: “Our finding expands the spectrum of MO-causing variants … underlying the importance of quantitative analysis in patients with negative sequencing.” (Bartolotti et al., September 2024; DOI: https://doi.org/10.3390/genes15091169).

Variants in constitutional blood are germline; lesion-specific second hits are somatic. Constitutional mosaicism can produce milder or asymmetric expression and changes recurrence counseling. Large chromosomal deletions encompassing EXT genes can produce contiguous-gene phenotypes; routine karyotyping is otherwise low yield.

Modifiers and epigenetics

No modifier gene or protective allele has sufficient replicated evidence for clinical use. EXT1 versus EXT2 genotype, sex, lesion location, and genetic background correlate imperfectly with severity. Evidence for disease-defining DNA methylation, histone modification, or chromatin signatures is insufficient; epigenomic assays are not diagnostic. (pacifici2017hereditarymultipleexostoses pages 13-14, pacifici2017hereditarymultipleexostoses pages 6-7)

5. Environmental information

HMO is not infectious, transmissible, toxicant-induced, or lifestyle-caused. No vaccination, antimicrobial therapy, dietary intervention, or exposure avoidance prevents the initiating lesion. Mechanical load and trauma may make an existing osteochondroma symptomatic or cause fracture/bursal inflammation but are not established causes. Smoking and alcohol may affect general surgical or cancer health but have no demonstrated disease-specific etiologic role.

6. Mechanism and pathophysiology

Ordered causal chain

A germline heterozygous pathogenic EXT1 or EXT2 variant leads to reduced EXT1–EXT2 glycosyltransferase activity and systemic heparan-sulfate insufficiency.
A focal somatic second hit in a growth-plate/perichondrial progenitor or chondrocyte results in biallelic EXT dysfunction and a severely heparan-sulfate-deficient clone; this step is demonstrated in subsets of human tumors and strongly supported by mouse models. (pacifici2017hereditarymultipleexostoses pages 12-13, pacifici2017hereditarymultipleexostoses pages 10-12, pacifici2017hereditarymultipleexostoses pages 1-2)
Reduced cell-surface/extracellular-matrix heparan sulfate leads to abnormal distribution, stability, and receptor presentation of morphogens.
This altered morphogen handling results in increased pro-chondrogenic BMP/hedgehog activity and reduced anti-chondrogenic FGF–MEK–ERK restraint and Noggin/Gremlin expression; detailed directionality is primarily model-organism/in-vitro evidence. WNT/β-catenin disturbance is implicated but less completely resolved. (pacifici2018hereditarymultipleexostoses pages 12-13, beltrami2016hereditarymultipleexostoses pages 1-2, garcia2021osteochondromapathogenesismouse pages 1-2)
Abnormal signaling at the growth-plate/perichondrial border leads to failure of normal border function, ectopic chondrocyte differentiation, and recruitment of adjacent wild-type cells into a heterogeneous cartilage cap.
Ectopic cartilage undergoes endochondral ossification resulting in a cortex- and marrow-continuous osteochondroma that grows while the physis is open.
Multiple lesions near active growth plates lead to physeal tethering, asymmetric growth, bowing, limb-length inequality, restricted motion, and short stature.
Branch A: Lesion mass effect results in pain, bursitis, tendon irritation, fracture, neurovascular compression, and—rarely—spinal-cord compromise.
Branch B: Additional neoplastic evolution in a cartilage cap can lead to secondary peripheral chondrosarcoma; this is uncommon and incompletely predictable.

Human biochemical evidence includes approximately 50% reduction in the blood heparan-sulfate:chondroitin-sulfate ratio (PMID 23514715). Human lesion studies found LOH in 6/8 analyzed osteochondromas in one series. Mouse work provides causal evidence from clonal/chondrocyte-specific Ext1 loss (PMIDs 20080592, 20534475) and compound Ext1/Ext2 deficiency (PMID 21310272). (pacifici2018hereditarymultipleexostoses pages 7-9, pacifici2017hereditarymultipleexostoses pages 12-13, pacifici2017hereditarymultipleexostoses pages 10-12)

Suggested GO terms: GO:0015012 heparan sulfate proteoglycan biosynthetic process; GO:0030201 heparan sulfate proteoglycan metabolic process; GO:0030509 BMP signaling; GO:0007224 Smoothened signaling; GO:0008543 FGFR signaling; GO:0016055 Wnt signaling; GO:0051216 cartilage development; GO:0001503 ossification; GO:0001958 endochondral ossification. Cell Ontology: CL:0000138 chondrocyte; CL:0000062 osteoblast; CL:0000134 mesenchymal stem cell, with growth-plate/perichondrial progenitor annotations where available.

Profiling and advanced technologies

No validated transcriptomic, proteomic, metabolomic, lipidomic, liquid-biopsy, single-cell, spatial, or epigenomic diagnostic signature currently exists. In a 2024 mouse/cell study, palovarotene activated an osteoarthritis-like transcriptional program, upregulated matrix-catabolic genes, downregulated matrix-anabolic genes, and activated STAT3 but not STAT1/2. These are mechanistic/preclinical observations, not patient biomarkers. (garcia2024analysisofthe pages 1-2)

7. Anatomical structures affected

Primary sites are metaphyseal/metadiaphyseal regions of bones formed by endochondral ossification—especially distal femur, proximal tibia/fibula, proximal humerus, forearm, pelvis, scapula, ribs, and vertebrae. Nearly half of lesions occur around the knee; approximate site estimates include distal femur 30%, proximal tibia 15–20%, and humerus 10–20%. Hand/foot lesions occur but are less prominent. Craniofacial bones formed predominantly by intramembranous ossification are generally spared, although cranial-base lesions have been reported. Lesions may be bilateral and multiple but are often asymmetric. (darienzo2019hereditarymultipleexostoses pages 1-2, tepelenis2021osteochondromasanupdated pages 1-2, tepelenis2021osteochondromasanupdated pages 2-3, pacifici2018hereditarymultipleexostoses pages 7-9)

At tissue level, the cartilage cap, perichondrium, growth plate, adjacent cortical/trabecular bone, marrow, tendon/bursa, and nearby nerves/vessels are relevant. At cellular level, chondrocytes and perichondrial/skeletogenic progenitors are central, with osteoblast-lineage cells participating in endochondral conversion. The key subcellular compartment is the Golgi apparatus/Golgi membrane, where EXT1–EXT2 synthesizes heparan sulfate; downstream abnormalities occur at the plasma membrane and extracellular matrix.

Suggested anatomy: UBERON:0000981 femur; UBERON:0000979 tibia; UBERON:0001424 humerus; UBERON:0000976 radius; UBERON:0001423 ulna; UBERON:0001270 pelvis; UBERON:0001132 parietal pleura/rib-region annotations should be refined to the exact lesion; UBERON:0002412 vertebral column. GO cellular components: GO:0005794 Golgi apparatus; GO:0000139 Golgi membrane; GO:0005576 extracellular region; GO:0005886 plasma membrane.

8. Temporal development

HMO is genetically present from conception but usually clinically silent at birth. Lesions can appear by age 2; median diagnosis is approximately 3 years, 50% have a visible lesion by age 5, and 80% by age 10. Growth is chronic and insidious, with the highest lesion-accrual risk during rapid skeletal growth. Lesions generally stop enlarging at skeletal maturity; new growth or pain thereafter warrants investigation for complications or malignant transformation. (mordenti2020thenaturalhistory pages 1-6, tepelenis2021osteochondromasanupdated pages 2-3, ruedadeeusebio2025hereditarymultipleexostoses pages 2-5)

There is no standard stage system. A practical course is: early palpable lesions; accumulating lesions and deformity during childhood; functional restriction and corrective surgery during later growth; stable residual lesions after maturity; and adult complications such as osteoarthritis, chronic pain, fatigue, or rare chondrosarcoma. Spontaneous true remission is not expected, although some lesions regress and symptoms may improve after surgery. The critical monitoring window is childhood/adolescence for growth disturbance and adulthood for new pain or lesion enlargement. (beltrami2016hereditarymultipleexostoses pages 7-8, mordenti2020thenaturalhistory pages 1-6)

9. Inheritance and population

Inheritance is autosomal dominant. An affected heterozygous individual has a 50% transmission probability per pregnancy. Penetrance is near complete and has historically been estimated at approximately 100% in males and 96% in females, although ascertainment and modern imaging may alter this difference. Expressivity is highly variable, including within families. Anticipation is not established. De novo disease and constitutional/germline mosaicism occur; therefore, an apparently negative family history does not exclude HMO. Consanguinity has no special etiologic role in this dominant disorder. (darienzo2019hereditarymultipleexostoses pages 1-2, mangualgarcia2015multipleskeletaldeformities pages 1-2)

Reported prevalence is approximately 1:50,000 in Western populations; incidence estimates extend to 1:100,000 in some sources. Historical male:female ratios of about 1.5:1 probably reflect reduced clinical ascertainment in mildly affected females rather than true sex-linked inheritance. No consistently high-risk ethnicity is established, although founder variants may occur in individual families or isolates. Population carrier frequency cannot be reliably inferred from gnomAD because pathogenic alleles are heterogeneous, very rare, and incompletely captured. (darienzo2019hereditarymultipleexostoses pages 1-2, ruedadeeusebio2025hereditarymultipleexostoses pages 1-2)

10. Diagnostics

Clinical and imaging diagnosis

Diagnosis is based on physical examination, family history, and imaging showing at least two osteochondromas with cortical and medullary continuity. Plain radiography is first line. CT is valuable for complex pelvic, scapular, costal, or spinal anatomy. MRI best depicts the hyaline-cartilage cap, marrow, soft tissue, neurovascular structures, and suspected spinal or malignant complications. Ultrasound can measure a superficial cartilage cap. (tepelenis2021osteochondromasanupdated pages 1-2, ruedadeeusebio2025hereditarymultipleexostoses pages 1-2, tepelenis2021osteochondromasanupdated pages 7-8)

Red flags for secondary chondrosarcoma include new or increasing pain, growth after skeletal maturity, an irregular/lobulated surface, internal lysis or irregular calcification, erosion of adjacent bone, a soft-tissue mass, and a thick cartilage cap. Common thresholds are >2 cm in adults and >3 cm in children, although some HMO literature uses 1.5–2 cm; thresholds must be interpreted with age and imaging quality. Histology shows a perichondrial/fibrous covering, hyaline-cartilage cap, and endochondral bone. Suspected malignancy requires expert musculoskeletal radiology and pathology, with biopsy planned by the treating sarcoma team. (gnoli2024secondaryperipheralchondrosarcoma pages 1-2, tepelenis2021osteochondromasanupdated pages 7-8)

Genetic testing algorithm

Sequence EXT1 and EXT2 using a validated panel with full coding and splice-region coverage.
Perform exon-level deletion/duplication analysis—such as MLPA—if not already integrated.
Reassess phenotype and variant classification under ACMG/AMP criteria; do not assume every rare missense allele is causal.
If unresolved, consider high-depth genome sequencing, structural-variant analysis, and RNA studies; test another tissue when low-level mosaicism is suspected.
Add PTPN11 when enchondromas, lesions directed toward joints, spontaneous regression, or other features suggest metachondromatosis/overlap.
Use parental testing for segregation, de novo confirmation, and recurrence counseling.

WES can identify coding variants but may miss mosaic or structural lesions; WGS is more useful for noncoding and structural variants. CMA is appropriate for a syndromic phenotype suggesting a large deletion; karyotype/FISH are not routine first-line tests. Mitochondrial and repeat-expansion assays are not relevant. No omics-based clinical diagnostic is validated. (borovikov2024themissingpiece pages 1-2, pacifici2017hereditarymultipleexostoses pages 10-12, pacifici2017hereditarymultipleexostoses pages 6-7)

Differential diagnosis and screening

Differentials include solitary osteochondroma; metachondromatosis (PTPN11, osteochondromas plus enchondromas, often joint-directed); Ollier disease and Maffucci syndrome (enchondromas, with vascular anomalies in Maffucci); dysplasia epiphysealis hemimelica/Trevor disease (epiphyseal osteochondral overgrowth); Langer–Giedion syndrome/TRPS II (contiguous deletion including EXT1); and secondary peripheral chondrosarcoma. (borovikov2024themissingpiece pages 13-13, borovikov2024themissingpiece pages 1-2)

There is no newborn biochemical screen. Cascade clinical and molecular testing is appropriate for relatives. Prenatal or preimplantation genetic testing is possible after the familial variant is known. Routine indiscriminate repeated whole-body ionizing imaging is undesirable; surveillance should be individualized.

11. Outcome and prognosis

Life expectancy is usually near normal unless malignant or severe neurovascular complications occur. Disease burden is chiefly chronic morbidity rather than mortality. Pain, fatigue, mobility restriction, deformity, early osteoarthritis, work/sport limitations, and repeated operations can substantially impair quality of life. (amajjar2024painandfatigue pages 1-2, mordenti2020thenaturalhistory pages 1-6)

Malignant transformation estimates vary from approximately 0.5–5% in population-oriented literature, with higher figures in referral centers reflecting ascertainment bias. In the 2024 Rizzoli series of 105 HMO-associated secondary peripheral chondrosarcomas, age at diagnosis ranged from 13–63 years (median 34); pelvis was the commonest site (46/105, 44%), followed by lower limbs (35). Of 103 graded tumors, 59 were grade 1, 40 grade 2, and 4 grade 3. Grade 2/3 histology and partial resection predicted worse disease-free survival. The abstract concludes that malignant transformation “can occur also in younger patient[s]” and therefore age alone should not negate suspicious findings. (Gnoli et al., February 2024; DOI: https://doi.org/10.1186/s13023-023-03006-8). (gnoli2024secondaryperipheralchondrosarcoma pages 1-2)

For secondary peripheral chondrosarcoma, complete surgical margins and grade are major prognostic factors. Historical estimates include approximately 90% five-year survival overall and ten-year survival of 83% for grade I versus 29% for grade III disease, but these figures are not HMO-specific in every source and should not be used as an individualized calculator. (beltrami2016hereditarymultipleexostoses pages 7-8, tepelenis2021osteochondromasanupdated pages 7-8)

12. Treatment

Current standard care

No pharmacologic therapy prevents or reverses HMO. Asymptomatic lesions are observed. Indications for surgery include persistent pain, functional restriction, tendon or joint impingement, progressive deformity, fracture, neurovascular compromise, spinal-cord compression, and suspected malignancy. Procedures include complete marginal excision with removal of cartilage cap/perichondrium, corrective osteotomy, hemiepiphysiodesis, limb or ulnar lengthening, and sarcoma-wide resection. Incomplete cap/perichondrium removal increases recurrence. Reported recurrence after complete excision is below 2%, while postoperative complication estimates are approximately 11.6–12.5%. (beltrami2016hereditarymultipleexostoses pages 7-8, tepelenis2021osteochondromasanupdated pages 7-8)

Forearm surgery illustrates the evidence limitations: among 315 forearms in a systematic review, 66.7% underwent ulnar lengthening with or without associated procedures and 20.6% isolated excision, but evidence that reconstruction improves long-term function or quality of life was poor. Treatment must therefore be individualized rather than triggered by radiographic appearance alone.

Supportive care includes age-appropriate analgesia, physical and occupational therapy, maintenance of strength and safe range of motion, gait or orthotic assessment, workplace/school accommodation, and psychological treatment for fear avoidance, anxiety, or depression. Refractory pain occasionally prompts neuromodulation or intrathecal analgesia, but evidence is limited to case reports. (amajjar2024painandfatigue pages 1-2)

Suggested NCIT intervention terms: NCIT:C15329 Surgical Procedure; NCIT:C52003 Excision; NCIT:C51932 Osteotomy; NCIT:C15214 Rehabilitation; NCIT:C16809 MRI; NCIT:C101293 Genetic Testing.

Experimental and targeted therapy

Palovarotene is a retinoic-acid receptor-γ agonist (CHEBI:177944) investigated in phase 2 pediatric HMO trial NCT03442985. The study enrolled genetically confirmed, symptomatic children aged 2–14 but was terminated/held amid concern about premature growth-plate closure, a particularly serious risk in a pediatric skeletal-growth disorder. No approved HMO indication or established response rate exists. (NCT03442985 chunk 2, garcia2024analysisofthe pages 1-2)

In a 2024 mouse study, escalating systemic palovarotene held pre-existing tumor volume near baseline—0.31±0.049 mm³ versus 0.27±0.031 initially (p=0.66)—while controls grew to 1.03±0.23 mm³ (p=0.023 versus treated). Local nanoparticle delivery also reduced growth (0.26±0.10 versus 0.52±0.11 mm³; p=0.008). The abstract states: “These findings suggest that palovarotene treatment is effective against pre-existing osteochondromas and that the Stat3 pathway is involved.” This is preclinical evidence and does not overcome human safety/efficacy uncertainty. (Garcia et al., published 11 July 2024; DOI: https://doi.org/10.3390/ijms25147610). (garcia2024analysisofthe pages 1-2)

BMP antagonism, heparanase inhibition, hedgehog/IHH inhibition, and restoration of FGF restraint have reduced chondrogenesis or lesion formation in models. They remain experimental, with no validated HMO gene therapy, CRISPR therapy, RNA therapy, cell therapy, immunotherapy, or pharmacogenomic treatment algorithm. (pacifici2018hereditarymultipleexostoses pages 12-13, beltrami2016hereditarymultipleexostoses pages 8-8, pacifici2017hereditarymultipleexostoses pages 10-12, pacifici2018hereditarymultipleexostoses pages 7-9)

13. Prevention

Primary prevention through lifestyle change or immunization is not possible. Reproductive options after molecular confirmation include genetic counseling, prenatal diagnosis, and IVF with preimplantation genetic testing. Counseling should address 50% transmission risk, variable expressivity, mosaicism, and the inability to predict severity precisely from genotype.

Secondary prevention consists of cascade testing and early clinical recognition in at-risk children, allowing monitoring of growth, limb alignment, motion, spinal/neurologic signs, and symptomatic lesions. Tertiary prevention includes timely correction of progressive deformity, complete excision when indicated, rehabilitation, pain management, and prompt MRI/sarcoma referral for adult lesion growth or new persistent pain. There is no accepted population screening program or prophylactic medication. Suggested follow-up intervals in older reviews—6–12 months in growing children and 12–24 months in adults—are expert-practice recommendations rather than high-level trial evidence and should be individualized. (beltrami2016hereditarymultipleexostoses pages 7-8)

14. Other species and natural disease

A well-characterized, naturally occurring veterinary counterpart attributable to orthologous EXT1/EXT2 variants is not established strongly enough in the retrieved evidence for a curated natural-disease assertion. Osteochondromas occur in domestic animals, but sporadic veterinary lesions should not automatically be labeled orthologous HMO. There is no zoonotic potential or cross-species transmission.

Relevant taxa for experimental comparative biology are Mus musculus (NCBI Taxon:10090) and Danio rerio (Taxon:7955). EXT heparan-sulfate biosynthesis and endochondral ossification are evolutionarily conserved, explaining why engineered models reproduce key mechanisms.

15. Model organisms

Mouse

Ext1- or Ext2-single-heterozygous mice are often largely normal, limiting their utility as simple haploinsufficiency models. Compound Ext1+/−;Ext2+/− mice, chondrocyte-specific conditional Ext1-null mice, and mosaic/clonal Ext1 inactivation models develop multiple osteochondroma-like lesions. These models strongly support severe focal heparan-sulfate deficiency and a second-hit mechanism and are used to test BMP antagonists, heparanase inhibitors, and RARγ agonists. Key studies include PMIDs 16236767, 20080592, 20534475, and 21310272. Limitations include engineered timing/cell specificity, more uniform genetic backgrounds, and incomplete reproduction of variable human pain, deformity, and malignancy. (beltrami2016hereditarymultipleexostoses pages 8-8, pacifici2017hereditarymultipleexostoses pages 12-13, pacifici2018hereditarymultipleexostoses pages 7-9, pacifici2017hereditarymultipleexostoses pages 1-2)

Zebrafish

The dackel/ext2 mutant reproduces abnormal cartilage and bone patterning. Homozygous ext2-null fish show failed terminal chondrocyte differentiation, impaired osteoblast differentiation, altered bone–fat lineage balance, misshapen bones, and muscle abnormalities. These models are powerful for developmental imaging and pathway screening but do not anatomically reproduce every human osteochondroma. Dental abnormalities observed in ext2 mutants generated a hypothesis of underrecognized dental manifestations in patients, illustrating both comparative utility and the need for human validation.

Cellular systems

Primary chondrocytes, lesion-derived cells, and cultured skeletal progenitors permit assays of heparan-sulfate production, BMP/FGF/hedgehog/WNT signaling, matrix synthesis, and retinoid response. No validated human HMO organoid, iPSC assay, or CRISPR screen currently functions as a clinical diagnostic or treatment-selection platform.

Current research infrastructure and evidence gaps

The Italian Registry of Multiple Osteochondromas, NCT04133285, is a recruiting retrospective/prospective cohort designed for up to 10,000 participants through 2032. It integrates clinical, genetic, genealogic, imaging, surgery, quality-of-life, tissue, and longitudinal malignancy data. Such registries are essential because rarity, variable expressivity, and referral bias undermine precise prevalence, malignancy-risk, and treatment-effect estimates. (NCT04133285 chunk 1)

Major gaps are: validated age- and genotype-specific surveillance schedules; prospective surgical comparative studies; robust malignant-transformation biomarkers; replicated modifier genes; longitudinal patient-reported outcomes; human single-cell/spatial maps of lesion initiation; and a safe disease-modifying therapy. The current expert interpretation is therefore conservative: molecular diagnosis and multidisciplinary longitudinal care are clinically actionable, whereas pathway-targeted treatment remains investigational.

References

(borovikov2024themissingpiece pages 1-2): Artem Borovikov, Nailya Galeeva, Andrey Marakhonov, Aysylu Murtazina, Varvara Kadnikova, Kseniya Davydenko, Anna Orlova, Peter Sparber, Tatiana Markova, Maria Orlova, Darya Osipova, Tatyana Nagornova, Natalia Semenova, Olga Levchenko, Alexandra Filatova, Margarita Sharova, Peter Vasiluev, Ilya Kanivets, Denis Pyankov, Artem Sharkov, Vasilisa Udalova, Vladimir Kenis, Natalia Nikitina, Maria Sumina, Konstantin Zherdev, Aleksandr Petel'guzov, Oleg Chelpachenko, Pavel Zubkov, Ivan Dan, Andrey Snetkov, Alexandra Akinshina, Yury Buklemishev, Oxana Ryzhkova, Vyacheslav Tabakov, Ekaterina Zakharova, Sergey Korostelev, Rena Zinchenko, Mikhail Skoblov, Alexander Polyakov, Elena Dadali, Sergey Kutsev, and Olga Shchagina. The missing piece of the puzzle: unveiling the role of ptpn11 gene in multiple osteochondromas in a large cohort study. Human Mutation, 2024:1-13, Feb 2024. URL: https://doi.org/10.1155/2024/8849348, doi:10.1155/2024/8849348. This article has 6 citations and is from a domain leading peer-reviewed journal.
(gnoli2024secondaryperipheralchondrosarcoma pages 1-2): Maria Gnoli, Marco Gambarotti, Alberto Righi, Eric Lodewijk Staals, Andrea Evangelista, Morena Tremosini, Evelise Brizola, Marina Mordenti, Manila Boarini, Manuela Locatelli, Elena Pedrini, and Luca Sangiorgi. Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-023-03006-8, doi:10.1186/s13023-023-03006-8. This article has 12 citations and is from a peer-reviewed journal.
(amajjar2024painandfatigue pages 1-2): Ihsane Amajjar, Kuni Vergauwen, Nienke W. Willigenburg, S. John Ham, and Rob J. E. M. Smeets. Pain and fatigue in adult patients with multiple osteochondromas: the netherlands. PLOS ONE, 19:e0305640, Jul 2024. URL: https://doi.org/10.1371/journal.pone.0305640, doi:10.1371/journal.pone.0305640. This article has 6 citations and is from a peer-reviewed journal.
(garcia2024analysisofthe pages 1-2): Sonia A. Garcia, Kimberly Wilson, Ningfeng Tang, Hongying Tian, Takeshi Oichi, Aruni T. Gunawardena, Michael Chorny, Ivan S. Alferiev, John E. Herzenberg, Vincent Y. Ng, Masahiro Iwamoto, and Motomi Enomoto-Iwamoto. Analysis of the actions of rarγ agonists on growing osteochondromas in a mouse model. Jul 2024. URL: https://doi.org/10.3390/ijms25147610, doi:10.3390/ijms25147610. This article has 4 citations.
(OpenTargets Search: hereditary multiple osteochondromas-EXT1,EXT2): Open Targets Query (hereditary multiple osteochondromas-EXT1,EXT2, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(darienzo2019hereditarymultipleexostoses pages 1-2): Antonio D'Arienzo, Lorenzo Andreani, Federico Sacchetti, Simone Colangeli, and Rodolfo Capanna. Hereditary multiple exostoses: current insights. Orthopedic Research and Reviews, 11:199-211, Dec 2019. URL: https://doi.org/10.2147/orr.s183979, doi:10.2147/orr.s183979. This article has 138 citations and is from a peer-reviewed journal.
(pacifici2018hereditarymultipleexostoses pages 7-9): Maurizio Pacifici. Hereditary multiple exostoses: are there new plausible treatment strategies? Expert Opinion on Orphan Drugs, 6:385-391, Jun 2018. URL: https://doi.org/10.1080/21678707.2018.1483232, doi:10.1080/21678707.2018.1483232. This article has 18 citations.
(pacifici2017hereditarymultipleexostoses pages 12-13): Maurizio Pacifici. Hereditary multiple exostoses: new insights into pathogenesis, clinical complications, and potential treatments. Current Osteoporosis Reports, 15:142-152, May 2017. URL: https://doi.org/10.1007/s11914-017-0355-2, doi:10.1007/s11914-017-0355-2. This article has 159 citations and is from a peer-reviewed journal.
(tepelenis2021osteochondromasanupdated pages 1-2): KOSTAS TEPELENIS, GEORGIOS PAPATHANAKOS, AIKATERINI KITSOULI, THEODOROS TROUPIS, ALEXANDRA BARBOUTI, KONSTANTINOS VLACHOS, PANAGIOTIS KANAVAROS, and PANAGIOTIS KITSOULIS. Osteochondromas: an updated review of epidemiology, pathogenesis, clinical presentation, radiological features and treatment options. In Vivo, 35:681-691, Jan 2021. URL: https://doi.org/10.21873/invivo.12308, doi:10.21873/invivo.12308. This article has 247 citations and is from a peer-reviewed journal.
(tepelenis2021osteochondromasanupdated pages 2-3): KOSTAS TEPELENIS, GEORGIOS PAPATHANAKOS, AIKATERINI KITSOULI, THEODOROS TROUPIS, ALEXANDRA BARBOUTI, KONSTANTINOS VLACHOS, PANAGIOTIS KANAVAROS, and PANAGIOTIS KITSOULIS. Osteochondromas: an updated review of epidemiology, pathogenesis, clinical presentation, radiological features and treatment options. In Vivo, 35:681-691, Jan 2021. URL: https://doi.org/10.21873/invivo.12308, doi:10.21873/invivo.12308. This article has 247 citations and is from a peer-reviewed journal.
(mordenti2020thenaturalhistory pages 1-6): Marina Mordenti, Fei Shih, Manila Boarini, Elena Pedrini, Maria Gnoli, Diego Antonioli, Morena Tremosini, and Luca Sangiorgi. The natural history of multiple osteochondromas in a large italian cohort of pediatric patients. Oct 2020. URL: https://doi.org/10.1016/j.bone.2020.115499, doi:10.1016/j.bone.2020.115499. This article has 32 citations and is from a domain leading peer-reviewed journal.
(pacifici2017hereditarymultipleexostoses pages 10-12): Maurizio Pacifici. Hereditary multiple exostoses: new insights into pathogenesis, clinical complications, and potential treatments. Current Osteoporosis Reports, 15:142-152, May 2017. URL: https://doi.org/10.1007/s11914-017-0355-2, doi:10.1007/s11914-017-0355-2. This article has 159 citations and is from a peer-reviewed journal.
(pacifici2018hereditarymultipleexostoses pages 12-13): Maurizio Pacifici. Hereditary multiple exostoses: are there new plausible treatment strategies? Expert Opinion on Orphan Drugs, 6:385-391, Jun 2018. URL: https://doi.org/10.1080/21678707.2018.1483232, doi:10.1080/21678707.2018.1483232. This article has 18 citations.
(tepelenis2021osteochondromasanupdated pages 7-8): KOSTAS TEPELENIS, GEORGIOS PAPATHANAKOS, AIKATERINI KITSOULI, THEODOROS TROUPIS, ALEXANDRA BARBOUTI, KONSTANTINOS VLACHOS, PANAGIOTIS KANAVAROS, and PANAGIOTIS KITSOULIS. Osteochondromas: an updated review of epidemiology, pathogenesis, clinical presentation, radiological features and treatment options. In Vivo, 35:681-691, Jan 2021. URL: https://doi.org/10.21873/invivo.12308, doi:10.21873/invivo.12308. This article has 247 citations and is from a peer-reviewed journal.
(beltrami2016hereditarymultipleexostoses pages 7-8): G. Beltrami, G. Ristori, G. Scoccianti, A. Tamburini, and R. Capanna. Hereditary multiple exostoses: a review of clinical appearance and metabolic pattern. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 13 2:110-118, May 2016. URL: https://doi.org/10.11138/ccmbm/2016.13.2.110, doi:10.11138/ccmbm/2016.13.2.110. This article has 120 citations.
(NCT03442985 chunk 2): An Efficacy and Safety Study of Palovarotene for the Treatment of MO. Clementia Pharmaceuticals Inc.. 2018. ClinicalTrials.gov Identifier: NCT03442985
(pacifici2017hereditarymultipleexostoses pages 1-2): Maurizio Pacifici. Hereditary multiple exostoses: new insights into pathogenesis, clinical complications, and potential treatments. Current Osteoporosis Reports, 15:142-152, May 2017. URL: https://doi.org/10.1007/s11914-017-0355-2, doi:10.1007/s11914-017-0355-2. This article has 159 citations and is from a peer-reviewed journal.
(NCT04133285 chunk 1): Luca Sangiorgi. Registry of Multiple Osteochondromas. Luca Sangiorgi. 2013. ClinicalTrials.gov Identifier: NCT04133285
(ruedadeeusebio2025hereditarymultipleexostoses pages 1-2): Alvaro Rueda-de-Eusebio, Sara Gomez-Pena, María José Moreno-Casado, Gloria Marquina, Juan Arrazola, and Ana María Crespo-Rodríguez. Hereditary multiple exostoses: an educational review. Insights into Imaging, Feb 2025. URL: https://doi.org/10.1186/s13244-025-01899-6, doi:10.1186/s13244-025-01899-6. This article has 28 citations and is from a peer-reviewed journal.
(pacifici2017hereditarymultipleexostoses pages 6-7): Maurizio Pacifici. Hereditary multiple exostoses: new insights into pathogenesis, clinical complications, and potential treatments. Current Osteoporosis Reports, 15:142-152, May 2017. URL: https://doi.org/10.1007/s11914-017-0355-2, doi:10.1007/s11914-017-0355-2. This article has 159 citations and is from a peer-reviewed journal.
(beltrami2016hereditarymultipleexostoses pages 1-2): G. Beltrami, G. Ristori, G. Scoccianti, A. Tamburini, and R. Capanna. Hereditary multiple exostoses: a review of clinical appearance and metabolic pattern. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 13 2:110-118, May 2016. URL: https://doi.org/10.11138/ccmbm/2016.13.2.110, doi:10.11138/ccmbm/2016.13.2.110. This article has 120 citations.
(pacifici2017hereditarymultipleexostoses pages 13-14): Maurizio Pacifici. Hereditary multiple exostoses: new insights into pathogenesis, clinical complications, and potential treatments. Current Osteoporosis Reports, 15:142-152, May 2017. URL: https://doi.org/10.1007/s11914-017-0355-2, doi:10.1007/s11914-017-0355-2. This article has 159 citations and is from a peer-reviewed journal.
(garcia2021osteochondromapathogenesismouse pages 1-2): Sonia Arely Garcia, Vincent Y. Ng, Masahiro Iwamoto, and Motomi Enomoto-Iwamoto. Osteochondroma pathogenesis: mouse models and mechanistic insights into interactions with retinoid signaling. The American journal of pathology, 191 12:2042-2051, Dec 2021. URL: https://doi.org/10.1016/j.ajpath.2021.08.003, doi:10.1016/j.ajpath.2021.08.003. This article has 20 citations.
(ruedadeeusebio2025hereditarymultipleexostoses pages 2-5): Alvaro Rueda-de-Eusebio, Sara Gomez-Pena, María José Moreno-Casado, Gloria Marquina, Juan Arrazola, and Ana María Crespo-Rodríguez. Hereditary multiple exostoses: an educational review. Insights into Imaging, Feb 2025. URL: https://doi.org/10.1186/s13244-025-01899-6, doi:10.1186/s13244-025-01899-6. This article has 28 citations and is from a peer-reviewed journal.
(mangualgarcia2015multipleskeletaldeformities pages 1-2): M Mangual-García and A Sánchez-Cruz. Multiple skeletal deformities in a middle-aged man. Unknown journal, 2015.
(borovikov2024themissingpiece pages 13-13): Artem Borovikov, Nailya Galeeva, Andrey Marakhonov, Aysylu Murtazina, Varvara Kadnikova, Kseniya Davydenko, Anna Orlova, Peter Sparber, Tatiana Markova, Maria Orlova, Darya Osipova, Tatyana Nagornova, Natalia Semenova, Olga Levchenko, Alexandra Filatova, Margarita Sharova, Peter Vasiluev, Ilya Kanivets, Denis Pyankov, Artem Sharkov, Vasilisa Udalova, Vladimir Kenis, Natalia Nikitina, Maria Sumina, Konstantin Zherdev, Aleksandr Petel'guzov, Oleg Chelpachenko, Pavel Zubkov, Ivan Dan, Andrey Snetkov, Alexandra Akinshina, Yury Buklemishev, Oxana Ryzhkova, Vyacheslav Tabakov, Ekaterina Zakharova, Sergey Korostelev, Rena Zinchenko, Mikhail Skoblov, Alexander Polyakov, Elena Dadali, Sergey Kutsev, and Olga Shchagina. The missing piece of the puzzle: unveiling the role of ptpn11 gene in multiple osteochondromas in a large cohort study. Human Mutation, 2024:1-13, Feb 2024. URL: https://doi.org/10.1155/2024/8849348, doi:10.1155/2024/8849348. This article has 6 citations and is from a domain leading peer-reviewed journal.
(beltrami2016hereditarymultipleexostoses pages 8-8): G. Beltrami, G. Ristori, G. Scoccianti, A. Tamburini, and R. Capanna. Hereditary multiple exostoses: a review of clinical appearance and metabolic pattern. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 13 2:110-118, May 2016. URL: https://doi.org/10.11138/ccmbm/2016.13.2.110, doi:10.11138/ccmbm/2016.13.2.110. This article has 120 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	18
Resolved	18
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	18
On topic	6
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	73
Resolved	62
Unresolved (possible confabulation)	0
Obsolete	1
Unverifiable	10

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

NCIT:C121924 (Enostosis) (1 mention)

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Orphanet, OMIM, PMIDs, Taxon, ORPHA.

62 of 73 terms resolved to a current term; the rest could not be looked up either way.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Prevalence

Differential Diagnoses

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Hereditary Multiple Osteochondromas: Disease Characteristics Research Report

Executive summary

1. Disease information

Definition and identifiers

2. Etiology, risk, and protective factors

Causal and genetic factors

Environmental, lifestyle, infectious, and protective factors

3. Phenotypes

Core and associated manifestations

Quality of life

4. Genetic and molecular information

Genes and proteins

Pathogenic variants and diagnostic yield

Modifiers and epigenetics

5. Environmental information

6. Mechanism and pathophysiology

Ordered causal chain

Profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical and imaging diagnosis

Genetic testing algorithm

Differential diagnosis and screening

11. Outcome and prognosis

12. Treatment

Current standard care

Experimental and targeted therapy

13. Prevention

14. Other species and natural disease

15. Model organisms

Mouse

Zebrafish

Cellular systems

Current research infrastructure and evidence gaps

Artifacts

Reference Validation

Term Validation

Obsolete terms

Prefixes with no resolver